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Chapter 1
General introduction    





Various types of giant cell-rich tumors exist, which are all distinct clinico-
pathological and genetic entities (Table 1). This thesis focusses exclusively on 
giant cell tumor of bone and tenosynovial tissue.
Table 1 WHO classification of primary giant cell-rich tumors of bone and soft tissue
Tumor Synonym Site Epidemiology Diagnostics Histopathology Behavior Treatment 
Osteoclastic giant cell-rich tumors




<5% small bones 






CT: cortical thinning, 
pathologic fracture
MRI: intra-osseous spread, 
soft tissue and joint 
involvement, Dynamic 






primary or secondary after 





































Tenosynovial giant cell tumor, 
localized type
Giant cell tumor 













cells, foamy macrophages, 
siderophages, stroma.











75% knee; 15% 










Few or absent osteoclastic 
giant cells. Mononuclear 
cells: small histiocyte-like 
cells, rounded cells with 
haemosiderin granules.
Malignancy (very rare): 














Giant cell tumor of soft tissue 
(GCT-ST)
Osteoclastoma 
of soft tissue, 
giant cell tumor 
of low malignant 
potential
70% extremities; 
20% trunk; 7% 
head and neck
Age 40-50, no 
difference in 
gender
MRI Multinodular (85%), 
haemosiderin-laden 
macrophages, round to 












*Abbreviations as used in this thesis
MRI = magnetic resonance imaging
CT = computed tomography
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Giant cell tumor of bone
Giant cell tumor of bone (GCTB) is described histopathologically as an 
admixture of rounded mononuclear histiocytic or macrophage-like osteoclast 
precursor cells and spindle-shaped mononuclear neoplastic stromal cells and 
large reactive multinucleated osteoclast-like giant cells [1]. Overexpression of 
receptor activator factor kappa-B ligand (RANKL) by mononuclear neoplastic 
stromal cells promotes recruitment of reactive multinucleated giant cells, 
capable of lacunar bone resorption [1]. 
Radiologically, GCTB is an eccentric, lytic lesion with a non-sclerotic and sharply 
defined geographic border, located in the metaphysis of long bones and 
extending to the epiphysis of the subarticular region [2,3]. MR imaging typically 
shows low to intermediate intensity on T1-weighted images and intermediate 
to high signal intensity on T2-weighted images. 
Clinically, GCTB behaves as a benign but often aggressive lesion with a typical 
tendency towards recurrence [4]. GCTB accounts for around 5% of all primary 
bone tumors and around 20% of all benign bone tumors, the incidence is higher 
in Asian populations compared to Caucasians. GCTB occurs mostly between 
the ages of 30-50 years, with a slight predominance for female patients.
GCTB was first described in 1818 by Cooper and Travers and was known as giant-
cell sarcoma or osteoclastoma; it was considered malignant until the beginning 
of the 20th century [5,6]. In 1912, Bloodgood was the first to introduce the term 
giant-cell tumor; he emphasized the probably benign nature and recognized the 
importance of radiographs in the diagnosis [7]. By 1925, the benign nature of 
GCTB was confirmed and the term giant-cell sarcoma was officially abandoned 
[6]. In 1940, Jaffe et al. were the first to identify GCTB as distinct clinical, 
radiological and pathological entity, separate from other giant cell containing 
lesions including brown tumor of hyperparathyroidism, giant cell reparative 
granuloma, chondroblastoma, non-ossifying granuloma and osteoblastoma 
[8]. This definition of GCTB as one separate entity was based on only fourteen 
cases, and the histological grading was later proven of little clinical predictive 
value [6,9]. From the second half of the 20th century, publication of larger series 
of GCTB increased knowledge on its pathology and clinical behavior [10-12]. 
Already in 1912, Bloodgood had proposed a surgical approach for GCTB 
that is in part still valid today [7]. At the time, amputation was common, but 
Bloodgood advocated curettage, application of carbolic acid (i.e. phenol), 




alcohol and bone grafting as first choice treatment for all GCTB, instead of 
primary resection [7,13]. From the 1950s, the use of local chemical adjuvants 
other than phenol also became widespread. In 1965, cryosurgery was 
introduced, consisting of curettage followed by the use of liquid nitrogen [14]. 
From the 1970s, polymethylmethacrylate (PMMA) was increasingly used to fill 
the cavity after curettage and it soon started replacing bone grafting [15]. Over 
the past four decades, surgical treatment options for GCTB remained rather 
static and there is still no consensus on standard treatment for more extended 
cases of GCTB [16]. 
The clinical challenge in the treatment of giant cell tumor of bone is to extend 
indications for intralesional surgery, while providing optimal oncological, 
functional and quality of life results. This may be aided by promising results of 
systemic therapy such as receptor activator of nuclear factor kappa-B ligand 
(RANKL) inhibitors and bisphosphonates, which may enable less invasive forms 
of surgery [17-20].
Figure 1 Painting of a giant cell tumor of bone located in the distal radius by Dr. Harvey Cushing. 
(In: Bloodgood JC. Ann Surg 1912; 56:210-239. Reprinted with permission of the Annals of Surgery and 
Yale University, Harvey Cushin/John Hay Whitney Medical Library.
Giant cell tumor of tenosynovial tissue
Giant cell tumors arising from synovium and tendon sheath are 
histopathologically described as an admixture of synovial lining cells containing 
hemosiderin, extracellular hemosiderin deposits, siderophages, lipid-laden 
foamy macrophages and multinucleated osteoclast-like giant cells [21,22]. 
Overexpression of macrophage colony-stimulating factor 1 (M-CSF) and its 
receptor (M-CSFR) by synovial fibroblasts promotes formation of a tumor-like 
mass [23]. 
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On MR images, hemosiderin depositions cause local changes in susceptibility, 
resulting in the characteristic low signal intensity appearance of tenosynovial 
giant cell tumors on T1- and T2-weighted spin echo sequences [24]. 
Clinically, a distinction is made between localized and diffuse types of 
tenosynovial giant cell tumor, with the latter being more aggressive and with 
a higher risk for recurrence. The incidence is approximated at two per million 
people per year, mostly under the age of 40 and with an equal distribution 
between the sexes. 
The first cases of localized type tenosynovial giant cell tumor were described 
in 1852 by Chassaignac and the first cases of diffuse type tenosynovial giant 
cell tumor early in the 20th century [25-27]. At the time, it was considered a 
malignant condition, but nomenclature was confusing including fibrous 
xanthoma, myeloxanthoma, villous arthritis and benign synovioma [26]. In 
1912, Dowd was the first to question the malignant character of the lesion 
[27]. In 1941, pigmented villonodular synovitis (PVNS) or nodular synovitis was 
recognized as a distinct clinical, radiological and pathological entity by Jaffe et 
al. [28]. As the authors observed similar histological features in local and diffuse 
lesions and a benign course of disease, they concluded that it must have been 
a reactive or inflammatory condition instead of a malignancy. This definition of 
PVNS as one separate entity was based on only twenty cases. In 1984, the lesions 
were again suggested to be neoplastic rather than reactive or inflammatory 
[29]. This was confirmed by chromosomal aberrations found in both local 
and diffuse forms [30-32]. Nowadays, the localized subtype characterized by 
solitary pedunculated lesions in synovium or tendon sheath is called giant 
cell tumor of tendon sheath (GCT-TS), also described as tenosynovial giant cell 
tumor, localized type [21]. The diffuse subtype involving the entire synovium 
of predominantly large joints is called diffuse-type giant cell tumor (Dt-GCT), 
also described as tenosynovial giant cell tumor, diffuse type [22]. Nevertheless, 
to date the disease remains best known under the term PVNS among most 
treating physicians.
From the 1940s, surgical treatment for localized and diffuse disease consisted 
of partial or complete open synovectomy, respectively. From the 1950s, 
radiation therapy was introduced in order to address the high recurrence 
rates after synovectomy. However, as high rates of joint stiffness were feared 
and satisfactory results were obtained even after irradical removal, the role 
of radiation therapy soon became questioned [26]. With the development 




of arthroscopy in the 1980s, this was introduced in the surgical treatment of 
tenosynovial giant cell tumor. However, recurrence rates were generally higher 
after arthroscopy when compared to open synovectomy and consensus on 
standard treatment currently remains under debate. 
The clinical challenge in the treatment of tenosynovial giant cell tumor is to 
improve oncological results and maintain a functional joint and quality of life. 
To that aim, adjuvant radioactive colloids and external beam radiation therapy 
and neoadjuvant systemic targeted therapy with M-CSFR-targeted tyrosine 
kinase inhibitors have been introduced, but not yet validated. 
Aim of thesis  
Given the above, enhanced and up-to-date decision making is required to 
optimize treatment for giant cell tumors of bone and tenosynovial tissue. 
Therefore, the aims of this thesis are to improve patient selection for different 
types of surgery by identifying risk factors for recurrences and complications, 
to define indications for systemic targeted therapy and to evaluate clinical 
outcome after treatment for both types of disease by providing for a 
clinical decision analysis based on outcome data. More specifically, surgical 
management of different clinical presentations is evaluated and integrated 
in multidisciplinary treatment recommendations for both giant cell tumors of 
bone and tenosynovial tissue.
Thesis outline 
Giant cell tumor of bone
A multidisciplinary evaluating system of giant cell tumor of bone including 
radiological, histopathological and clinical features is required as basis of an 
optimal treatment protocol [16]. 
Chapter 2 addresses most relevant issues concerning diagnosis and 
multidisciplinary treatment of GCTB. Local adjuvants phenol, liquid nitrogen 
and PMMA decrease recurrence rates after curettage, but relative effectiveness 
of these local adjuvants has never been compared. Chapter 3 presents a 
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retrospective cohort study on relative eff ectiveness of diff erent standard 
treatments in two tertiary referral centers; the aim is to determine recurrences, 
complications and functional outcome after curettage with phenol and PMMA; 
liquid nitrogen and PMMA; or liquid nitrogen and bone grafts.Approximately 
one in fi ve patients with GCTB presents with a pathologic fracture, which may 
impede adequate intralesional surgery [33-35]. Recurrence rates after en bloc 
or intralesional resection diff er substantially and it is unclear when curettage 
is reasonable after a pathologic fracture. Chapter 4 addresses recurrence rates, 
complications and functional outcome after curettage with adjuvants or en 
bloc resection for GCTB with a pathologic fracture in a multicenter retrospective 
cohort study.
GCTB in the small bones of hands and feet accounts for only 2-5% of all GCTB 
[36-41]. Chapter 5 contains a systematic literature review and a retrospective 
multicenter study evaluating recurrence rates, complications and functional 
outcome after diff erent surgical approaches for GCTB of the small bones of the 
hands and feet.
The sacrum is the most aff ected bone within the axial skeleton, representing 
about 2-8% of all GCTB [42-44]. Surgical management of sacral GCTB is 
challenging because of its often large size due to late discovery, involvement 
of sacral nerve roots and spinal instability. 
Figure 2 Resection specimen of a benign giant cell tumor of bone originating from the distal femur. 
Photograph from the collection of the Anatomical Museum of the Leiden University Medical Center, 
Leiden, the Netherlands (estimated date between 1770 and 1818).




Figure 3 Resection specimen of a giant cell tumor of bone located in the distal femur of a 36-year old 
male. Photograph from the collection of the Anatomical Museum of the Leiden University Medical Cen-
ter, Leiden, the Netherlands (1966).
Chapter 6 evaluates oncological, surgical and functional results after 
intralesional excision with diff erent adjuvant treatments for sacral GCTB in a 
retrospective nationwide study.In clinical practice, the choice for type of surgery 
depends on the feasibility of curettage with local adjuvants versus en bloc 
resection, and on the expected risk of local recurrence in individual patients. 
Cortex destruction, soft tissue extension, pathologic fracture, young age and 
localization in distal radius have been proposed as risk factors for recurrence 
[45-51], but this was not confi rmed in other studies [52-54]. Chapter 7 aims at 
identifying individual risk factors for recurrence exclusively after curettage with 
adjuvants in a retrospective single center study.
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Hyperthermic reaction from PMMA polymerization in combination with 
subchondral bone involvement by GCTB in close relation with articular cartilage 
may result in secondary osteoarthritis [55-60]. Chapter 8 is a radiological study 
to determine prevalence, risk factors and clinical relevance of radiological 
osteoarthritis after curettage and PMMA for GCTB around the knee.
Giant cell tumor of tenosynovial tissue
A multidisciplinary evaluating system of tenosynovial giant cell tumor including 
radiological, histopathological and clinical features is required for optimal 
surgical and systemic treatment decisions. Chapter 9 addresses most relevant 
issues concerning diagnosis and multidisciplinary treatment of tenosynovial 
giant cell tumor.
Chapter 10 outlines a framework for diagnosis and management of localized 
and diffuse types of tenosynovial giant cell tumor. Results from a systematic 
review including all cases available from the literature treated with arthroscopic 
or open synovectomy, radiation therapy or synoviorthesis are combined with 
experience from two tertiary referral centers and integrated in multidisciplinary 
treatment recommendations for Dt-GCT and GCT-TS.
The majority of studies on treatment of Dt-GCT about the knee only reported 
oncological outcomes after arthroscopic or open synovectomy. Only few 
studies described functional results, and quality of life results have never been 
published. Chapter 11 describes functional outcome and quality of life after 
multiple surgical interventions including arthroscopic and open synovectomy for 
Dt-GCT in the knee. 
Finally, a summary of this thesis is provided in Chapter 12 and conclusions, 
clinical implications and future perspectives for the subjects of this thesis are 
discussed in Chapter 13.
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Abstract 
We provide an overview of imaging, histopathology, genetics and 
multidisciplinary treatment of giant cell tumor of bone (GCTB), an intermediate, 
locally aggressive but rarely metastasizing tumor. Overexpression of receptor 
activator of nuclear factor kappa-B ligand (RANKL) by mononuclear neoplastic 
stromal cells promotes recruitment of numerous reactive multinucleated giant 
cells. Conventional radiographs show a typical eccentric lytic lesion, mostly 
located in meta-epiphyseal area of long bones. GCTB may also arise in axial 
skeleton and very occasionally in small bones of the hands and feet. Magnetic 
resonance imaging is necessary to evaluate the extent of GCTB within bone 
and surrounding soft tissues to plan a surgical approach. Curettage with 
local adjuvants is the preferred treatment. Recurrence rates after curettage 
with phenol and polymethylmethacrylate (PMMA; 8-27%) or cryosurgery and 
PMMA (0-20%) are comparable. Resection is indicated when joint salvage is not 
feasible (e.g. intra-articular fracture with soft tissue component). Denosumab 
(RANKL-inhibitor) blocks and bisphosphonates inhibit GCTB-derived osteoclast 
resorption. With bisphosphonates, stabilization of local and metastatic disease 
has been reported, although level of evidence was low. Denosumab has been 
studied to a larger extent and seems to be effective in facilitating intralesional 
surgery after therapy. Denosumab was recently registered for unresectable 
disease. Moderate dose radiotherapy (40-55Gy) is restricted to rare cases in 
which surgery would lead to unacceptable morbidity and RANKL-inhibitors are 
contraindicated or unavailable.




Giant cell tumor of bone (GCTB) is an intermediate, locally aggressive but rarely 
metastasizing tumor (International Classification of Diseases for Oncology 
(ICD-O) code 9250/1), representing 5% of primary bone tumors and 20% of 
benign bone tumors [1]. It occurs mostly between the ages of 30-50 years 
and rarely arises in the immature skeleton. There is a slight predominance for 
female patients [1,2]. At presentation, 15-20% of patients have a pathologic 
fracture due to substantial cortical destruction followed by relatively minor 
trauma. GCTB is typically seen solitary, mostly located in the metaepiphyseal 
region of long bones (85%), but may also occur in the axial skeleton (10%) or 
occasionally in the small bones of hands and feet (5%) [2,3]. At the latter location, 
so-called giant cell lesion of the small bones—a different entity—should 
be considered [4]. Approximately 1-4% of otherwise conventional patients 
develop pulmonary metastases [3,5-9]. These metastases often have a relatively 
indolent behavior. Multifocal GCTB is rare, appearing either simultaneously or 
metachronously. In these presentations, so-called brown tumor associated 
with hyperparathyroidism should be ruled out by blood biochemistry as they 
are histologically barely distinguishable from GCTB. Malignant transformation 
has been described in less than 1% of all GCTB and may be either primary (i.e. 
sarcomatous progression) or more commonly secondary (mostly radiation-
induced) [1].
The main problem in the management of GCTB is local recurrence after 
surgical treatment: 27-65% after isolated curettage [2,3]; 12-27% after 
curettage with adjuvants such as high-speed burr, phenol, liquid nitrogen or 
polymethylmethacrylate (PMMA) [2,10-12]; and 0-12% after en bloc resection 
[2,13]. In clinical practice, the choice of surgical treatment depends mostly on 
the feasibility of curettage and local adjuvants versus resection, but also in part 
on the expected risk for local recurrence in each individual patient. Soft tissue 
extension, for example, is commonly present and increases the risk for local 
recurrence [14,15]. Pathologic fractures are also common, and although this 
does not in itself increase recurrence risk, it may render curettage technically 
more difficult. In general, the aim for joint preservation is justified, considering 
the benign but locally aggressive nature, young patient population and 
significant complications including need for revision surgery after resection 
and reconstruction with tumor prostheses [16-19].
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The clinical challenge in GCTB treatment is to improve local control and 
broaden indications for intralesional surgery, providing optimal functional 
and oncological results. This may be aided by the promising results of 
systemic targeted therapy with receptor activator of nuclear factor kappa-B 
ligand (RANKL)-inhibitors or bisphosphonates [20-23]. Consequently, a 
multidisciplinary evaluating system including radiological, histopathological 
and clinical features is required as basis of an optimal treatment protocol. 
This review addresses most relevant issues concerning diagnosis and 
multidisciplinary treatment of GCTB and future perspectives.
Imaging
Conventional radiographs and contrast-enhanced magnetic resonance 
imaging (MRI) are the most important imaging modalities in diagnosing GCTB, 
local staging, evaluating response to systemic treatment and detecting local 
recurrence [24,25]. 
Figure 1 (A, B) Radiographs demonstrating an eccentric, sharply demarcated lytic lesion in the distal 
femur metaphysis extending to the epiphysis without tumor mineralization. Radiographic features are 
consistent with giant cell tumor of bone.
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Figure 2 (A, B) Radiographs of a large expansile completely osteolytic lesion in the proximal radius 
demonstrating a permeative destruction pattern with cortical destruction, consistent with giant cell 
tumor of bone. (C, D) Radiographs demonstrate new bone formation with reconstitution of cortical 
bone after five months of treatment with denosumab.
The radiographic appearance of GCTB is rather characteristic. GCTB appears as 
an eccentric, lytic lesion with a non-sclerotic and sharply defined geographic 
border (narrow zone of transition), located in the metaphysis of long bones and 
extending to the epiphysis in subarticular region [26,27]. The periosteum may 
be elevated with expansion of the cortex (Figure 1). In more aggressive lesions, 
however, the zone of transition can be wide, with cortical breakthrough and 
extension into surrounding soft tissues (Figure 2). Matrix mineralization is 
absent. In short tubular bones of the hands and feet, radiographic features 
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are similar to those in long bones and indistinguishable from the so-called 
giant cell lesion of the small bones, which is considered another entity [4]. 
In addition, giant cell tumor of tendon sheath (GCT-TS) may mimic osseous 
lesions on radiographs as they are capable of invading bone [28]. The sacrum 
is the most frequently affected bone within the axial skeleton, but GCTB 
may also appear in vertebral bodies with extension to pedicles and possibly 
compression fractures [29]. 
GCTB was generally categorized radiologically following the system of 
Campanacci et al. [3] or Enneking et al. [30]; both were purely based on 
radiographs and are now considered less useful. MRI is more useful for staging 
and predicting clinical behavior of GCTB [26,31]. Computed tomography (CT) 
can be used to assess cortical thinning, pathologic fractures and to monitor 
fracture consolidation. On MRI, GCTB typically shows low to intermediate signal 
intensity on T1-weighted sequences and intermediate to high signal intensity 
on T2-weighted sequences. Areas of low signal intensity can be seen due to 
haemosiderin deposition, causing local changes in susceptibility especially on 
gradient echo sequences (Figure 3) [32]. A cystic appearance with fluid-fluid 
levels from secondary cyst formation or aneurysmal bone cyst-like changes 
is present in 10-14% of GCTB [1,26,27]. Dynamic contrast-enhanced MRI with 
intravenous gadolinium administration shows early and rapidly progressive 
enhancement followed by contrast washout (Figure 4) [24,25,33]. 
Figure 3 (A) T1-weighted MRI demonstrates an eccentric lesion with mild expansion with intermediate 
signal intensity. (B) T2-weighted MRI shows low signal intensity through haemosiderin depositions and 
high signal intensity through secondary cystic changes. (C) T1-weighted MRI with fat suppression after 
intravenous Gadolinium administration demonstrates marked relatively homogeneous enhancement. 
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Figure 4 (A) Plain radiograph shows a lytic lesion with extensive cortical destruction and a pathologic 
fracture in the distal radius. (B-D) T1- and T2-weighted MRI shows inhomogeneous low to high signal 
intensity and marked enhancement after Gadolinium administration. (E-H) Dynamic contrast-enhanced 
MRI (DCE-MRI) shows homogeneous enhancement within 6 seconds after Gadolinium administration. 
DCE-MRI can provide functional information on tumor angiogenesis and permeability but will not be 
part of standard imaging protocols in many centers. 
Clinical and radiographic characteristics usually allow a correct diagnosis. 
The differential diagnosis includes chondroblastoma, intraosseous ganglion 
or subchondral cyst. Chondroblastoma typically occurs in the immature 
skeleton and may contain calcifications. Brown tumor of hyperparathyroidism, 
plasmacytoma, osteolytic metastasis, aneurysmal bone cyst, giant cell lesion 
of the small bones and teleangiectatic osteosarcoma are included in the 
differential diagnosis and are sometimes less easy to rule out.
Detection of local recurrence can be difficult because of granulation tissue at 
the site of curettage followed by bone grafting or reconstruction with PMMA. 
Increased focal osteolysis around the area of treatment on serial conventional 
radiographs with high signal intensity on T2-weighted MR images with early 
dynamic enhancement followed by wash-out are highly suggestive for local 
recurrence.
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Histopathology
With appropriate radiographic findings, the diagnosis GCTB can often be 
made before surgery. However, core needle biopsy or intra-operative frozen 
section is advised to establish the final diagnosis before or during surgery, 
given the aggressive nature of the tumor and its rare tendency to malignant 
transformation [34,35]. Macroscopically, GCTB is well vascularized and contains 
broad bands of cellular or collagenous fibrous tissue. Areas of hemorrhage, 
haemosiderin deposition and foamy macrophages can be noted and necrosis 
and hemorrhage are especially common in large sized GCTBs. In addition, 
primary GCTB associated with lung nodules commonly shows large areas 
of hemorrhage and thrombus formation, that is not seen in primary GCTB 
without local or distant recurrence [36]. Reactive bone formation is common 
after pathologic fracture or open biopsy. Secondary aneurysmatic bone cysts 
are seen in 10-14% of GCTB [1,26,27]. 
Microscopically, GCTB is composed of neoplastic and reactive cell populations 
(Figure 5). The neoplastic cell population includes rounded mononuclear 
histiocytic or marcophage-like osteoclast precursor cells and spindle-shaped 
mononuclear neoplastic “stromal” cells [1,37]. The stromal cells have poorly 
defined cytoplasm and spindle-shaped nuclei and show variable degrees 
of mitotic activity (up to 20 per 10 high power fields). Mononuclear stromal 
cells also express smooth muscle actin, which may be useful in the differential 
diagnosis of giant cell-rich lesions of bone, as its expression differs between 
several primary bone tumors [38]. 
Figure 5 (A) Biopsy with numerous uniformly spaced multinucleated giant cells and mononuclear 
stromal cells. (B) Surgical specimen after denosumab shows stromal cells, scattered mononuclear 
spindle cells without evident atypia and diffuse foamy macrophages; no multinucleated giant cells are 
seen. (C) Mechanism of action of RANKL-inhibitors and bisphosphonates.
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The reactive cell population includes numerous large reactive multinucleated 
osteoclast-like giant cells causing lacunar bone resorption [1,37]. Osteoclast-
like giant cells have eosinophilic cytoplasm and vesicular nuclei (up to 20 to 50) 
with prominent nucleoli, and are often larger than normal osteoclasts.
Regarding the functional molecular biology of GCTB, RANKL is highly 
expressed by neoplastic mononuclear stromal cells [39-41]. RANK-RANKL 
interaction and macrophage colony-stimulating factor (M-CSF) play important 
roles in osteoclastogenesis by stimulating recruitment of osteoclastic cells 
from blood-born mononuclear osteoclast precursor cells that differentiate 
into multinucleated osteoclast-like giant cells [37,42-45]. This is supported by 
the fact that giant cells in GCTB have an osteoclast-like phenotype (CD45+, 
CD68+, CD33+, CD14-, CD51+, CD163-, HLA-DR-) [44,45]. CD33+, which is 
characteristic for GCTB, may constitute a novel therapeutic target, analogous 
to the treatment of acute myeloid leukemia with gemtuzumab, an anti-CD33 
antibody [44]. Epidermal growth factor receptor signaling (EGFR), a tyrosine 
kinase expressed by neoplastic mononuclear stromal cells, supports stromal 
cell proliferation and promotes osteoclastogenesis in the presence of M-CSF 
[46]. EGFR expression was more frequent in recurrent and metastatic disease, 
suggesting that it may be related with disease progression [46].
There are also several RANKL-independent mechanisms of osteoclastogenesis 
expressed by GCTB; known RANKL-substitutes are tumor necrosis factor-α 
(TNF-α), interleukin-6 (IL-6) and tumor growth factor-β (TGF-β) [37]. Recently, 
other cytokines and growth factors including a proliferation-inducing ligand, 
B cell-activating factor, nerve growth factor, insulin-like growth factors (IGF)-I 
and IGF-II, demonstrated osteoclastogenesis and formation of multinucleated 
giant cells capable of lacunar bone resorption [37]. Although less potent than 
RANKL, these substitutes may form alternative therapeutic targets for GCTB.
Cathepsin K is the principal protease exclusively expressed in osteoclast-like 
giant cells that actively absorb bone, resulting in the osteolysis associated with 
GCTB [47]. This could be triggered by overexpression of transcription factor 
CCAAT/enhancer binding protein beta, but exact etiology remains unclear [48].
Recently, an in vivo model for growing GCTB cell lines on chick chorio-allantoic 
membranes was developed, which may offer new perspectives to test 
therapeutical agents and monitor their effects [49]. 
Cytogenetically, telomeric associations—a chromosomal end-to-end fusion 
seen in 50-70% of GCTBs—are the most common chromosomal aberrations 
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[50,51]. Telomere length maintenance is an important key factor in the 
pathogenesis of GCTB, probably through a structural telomere protective-
capping mechanism [52]. GCTB expresses telomerase maintenance markers 
(human telomerase reverse transcriptase and promyelocytic leukemia body-
related antigens) in mononuclear rounded osteoclast precursor cells and 
spindle-shaped mononuclear neoplastic stromal cells [52]. There is a moderate 
reduction in telomere length [52,53]; however, telomere dysfunction is not the 
only factor responsible for genetic instability [53,54]. Recently, a driver mutation 
has been identified in H3F3A in 92% of GCTB; these alterations were seen 
exclusively found in stromal cells and not in precursor or mature osteoclasts 
[55]. In addition, it has been hypothesized that chromosomal instability may be 
caused by centrosome abnormalities, through erroneous mitotic segregation 
during cell-cycle progression [56]. Centrosome amplification and aneuploidy 
were reportedly higher in recurrent and metastatic GCTB, suggesting a relation 
with clinical behavior [57,58]. Allelic losses of 1p, 9q and 19q are common in 
primary, recurrent and metastatic GCTB [50]. Mutations of TP53 and HRAS 
are seen in secondary malignant GCTB and may thus play a role in malignant 
progression [59,60]. However, even if nuclear TP53 expression may indicate 
potential suppressor gene damage, there might be TP53 abnormalities that do 
not result in tumor formation, implicating other causes of genomic instability 
[57].
Primary malignancy in GCTB is seen at initial diagnosis as an area of high-grade 
sarcoma within an otherwise conventional GCTB. In secondary malignant 
GCTB, a high-grade sarcoma arises subsequent to previous radiation or surgical 
treatment, and the pre-existing GCTB is not always evident anymore. Atypical 
mitotic figures are suggestive of malignancy. 
In view of the current treatment modalities, histopathological features of 
GCTB have not yet been clearly predictive for clinical behaviour, including 
risk for recurrent or metastatic disease [61]; however, the abovementioned 
novelties may offer new approaches for predicting clinical behavior based on 
histopathological, genetic and functional findings.




The most important challenge in surgical management of GCTB of the long 
and small bones is the relatively high recurrence rate after curettage, mostly 
diagnosed within two years after index surgery [11]. Although recurrence 
rates are lowest after en bloc resection (0-16%), curettage with local 
adjuvants is preferred as it presents less morbidity and functional impairment 
[2,10,11,13,14,62-66]. When local adjuvants are not utilized, the mean 
recurrence rate is ~42% (21-65%) [2,10,11,14,67-70]. The most established 
standard treatment with acceptable recurrence rates is curettage with local 
adjuvant application of phenol and PMMA (3-33%) [2,10,13-15,63-65,67,71,72] 
or PMMA alone (0-29%) [2,10,11,14,15,62-65,67,70,71,73]. Centers specialized 
in cryosurgery apply liquid nitrogen with bone grafts or PMMA resulting in 
recurrence rates of 8-42% [62,64,67,74-78] and 0-20% [62,79-81] respectively 
(Table 1). 
With extensive curettage, a large oval window is made in the cortex, creating 
sufficient exposure of the tumor cavity and taking the fracture risk into account. 
GCTB is then carefully curetted with curettes of different sizes, followed by high-
speed burring of cavity walls. When using phenol, cavity walls are phenolized 
with protection of surrounding soft tissues, followed by rinsing with alcohol 
and neutralizing with repeated (high-speed pulse) lavage. This is repeated two 
to three times. Although phenol is effective on GCTB in vitro, infiltration depth 
in vivo is unknown [82], and beneficial effects of phenol when used combined 
with PMMA are currently under debate [11,14,15]. Complications resulting 
from phenol use include chemical burns, and caution is warranted in vicinity 
of neurovascular structures and soft tissues [83,84]. With cryosurgery, a liquid 
nitrogen spray is used, allowing for more equal freezing of cavity walls and 
better penetration in bone compared with pouring liquid nitrogen directly 
into the cavity. Thermocouples placed in the tumor cavity and surrounding soft 
tissues are advisable to monitor freezing [85]. Soft tissues should be irrigated 
with warm fluids to protect from thermal injury. Three cycles of rapid freezing 
(-50ºC) and slow thawing (20ºC) are performed to increase margins up to 
2cm, comparable with marginal resection [77,86]. Complication rates of 12-
50% have been reported after use of liquid nitrogen, including postoperative 
fracture, skin necrosis, (transient) nerve palsy and infection [74,78,86]. Whereas 
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postoperative fractures were the most important concern after cryosurgery 
in the past, adequate monitoring of freezing temperatures and prophylactic 
osteosynthesis in selected cases have decreased fracture rates dramatically 
(from 25-50% [77,78] to 0-7% [62,74]). Several options exist for filling the 
cavity, which can be left empty awaiting new bone formation during partial 
immobilization [70,87,88], or may be filled with cancellous bone grafts 
[64,83,89]. 
However, reported recurrence rates are high after both options, and this may 
only be adequate after use of a potent local adjuvant such as cryosurgery. The 
most commonly used technique is filling with PMMA, which hypothetically 
lowers recurrence risk through its hyperthermic properties. Furthermore, it 
provides immediate mechanical support and facilitates early detection of 
local recurrences [2,10,11]. Complication rates of 13-25% have been reported 
after use of PMMA, including cement leakage into joints or surrounding soft 
tissues and osteoarthritic changes. PMMA is recommended as a filling and local 
adjuvant [2,10,11,13,14,90,91]. 
Local recurrence risk is strongly increased by soft tissue extension (20-25% 
of all GCTBs) [14,15]. Curettage with adjuvants is reasonable depending on 
the extent of the soft tissue component. If initially inoperable, neoadjuvant 
systemic targeted therapy may facilitate intralesional surgery at a later stage, 
avoiding more invasive surgery. Pathologic fractures are also common (15-20%) 
but do not appear to increase local recurrence risk [15], contrary to previous 
suggestions [71]. Recent studies confirmed both resection and curettage 
as viable treatment options for GCTB with a pathologic fracture [92]. If joint 
salvage is feasible, GCTB with a pathologic fracture can safely be curetted. With 
extra-articular fractures, consolidation may be awaited before surgery; with 
intra-articular fractures, immediate curettage should be performed. Resection 
should be considered for dislocated intra-articular fractures, fractures with 
soft tissue extension or when structural integrity cannot be regained [92-95]. 
Young age has also been suggested to increase risk for recurrence [11,14], but 
was not confirmed by others [15]. 
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Secondary osteoarthritis may result from curettage with PMMA in large 
subchondral GCTB [70,89,96]. This relatively low risk would be increased after 
repeated curettage for recurrence, with close proximity to articular cartilage 
[89,97], and with large subchondral defects [96,97].
Generally, curettage with PMMA can be repeated for recurrence as it presents 
acceptable re-recurrence rates of 14-22% [93,94]. Although 1-4% of patients 
have pulmonary metastases at primary presentation, a higher incidence was 
noted after multiple recurrences (10-15%), but this seemed independent from 
surgical treatment [93,94]. Location in distal radius was thought to have an 
increased risk for metastases [6], but this was not generally confirmed [7].
Considering the above-mentioned points, en bloc resection should be 
considered in case of multiple recurrent or unresectable GCTB, impossible joint 
salvage, extensive cortex destruction (i.e. insufficient cortex left to curette) 
and extensive soft tissue involvement. Defects can be reconstructed with 
endoprosthetic replacement, structural allografts, or a combination [98]. The 
most important disadvantages are higher complication risk, subsequent need 
for revision surgery and decreased function [16,19,99]. En bloc resection can 
also be performed in expendable bones (e.g. proximal fibula, distal ulna, iliac 
wing), in which a bony reconstruction is not required and functional outcome 
is not likely to be affected. 
Postoperative treatment after curettage consists of functional mobilization and 
immediate full weight bearing for most patients. With reduced bone integrity 
(i.e. pathologic fracture, large oval window or close relation to the joint), only 
partial weight bearing is allowed during the first 6-12 weeks. After resection 
and endoprosthetic reconstruction, immediate full weight bearing is allowed. 
Follow-up protocol, based on the National Comprehensive Cancer Network 
guidelines for GCTB and on the European Society for Medical Oncology 
guidelines for low grade sarcoma, consists of physical examination and 
radiographs, MRI and/or CT of the surgical site as clinically indicated to detect 
local recurrences and complications and chest imaging to detect pulmonary 
metastases every six months during the first two postoperative years and 
annually thereafter for at least ten years [34,35]. 
Surgical management of GCTB in axial skeleton and sacrum (2-8% of all GCTBs) 
is more challenging because of often late discovery, large size, spinal or pelvic 
instability and involvement of nerve roots [100-102]. Preoperative arterial 
embolization can be performed as primary treatment [100,103-105], or as 
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preoperative treatment reducing intraoperative hemorrhage [100,106,107]. 
Total spondylectomy for vertebral GCTB or en bloc resection for sacral GCTB 
may result in severe morbidity with bleeding, infection and neurological 
deficits, and total spondylectomy for sacral GCTB may result in bladder, rectal 
and sexual dysfunction; therefore, the procedure should not be considered 
as primary treatment [108-110]. Marginal resection is less mutilating and can 
be performed in small vertebral lesions and sacral GCTB distal from S3 [100]. 
Curettage is less invasive and advantages are salvage of nerve roots and visceral 
structures and maintenance of intrinsic spinal or pelvic support; however, it 
results in relatively high recurrence rates of 10-37%, because complete removal 
is difficult and adequate local adjuvants are absent [102,111,112]. Caution is 
warranted with application of local adjuvants such as phenol or liquid nitrogen 
in vicinity of neurovascular structures [75,113]. After curettage, spinal or 
pelvic stability should be assessed and stabilization performed if needed. If at 
least S1 is preserved after intralesional resection, reconstruction is generally 
unnecessary. If S1 is partially or completely resected, stabilization with ilio-
lumbar screw fixation is preferred. 
Systemic therapy 
In light of the current understanding of molecular biology of GCTB, systemic 
targeted therapy has been introduced, in addition to existing surgical treatment 
options with the aim of facilitating intralesional surgery at a later stage instead 
of performing more mutilating surgery for the most complex cases.
Bisphosphonates bind to bone mineral and are assumed to inhibit GCTB-
derived osteoclast formation, migration and osteolytic activity at sites of bone 
resorption and to promote apoptosis of osteoclasts (Figure 5). Over the past 
decade, there has been some experience with bisphosphonate zoledronic acid 
as systemic therapy for GCTB [22,114,115]. In most reported inoperable tumors, 
stabilization of local and metastatic disease was achieved. These were, however, 
small retrospective series with different other treatments; therefore, the level 
of evidence is low. Currently, a phase II randomized study with zoledronic acid 
is ongoing in high-risk GCTB patients after surgery (www.clinicaltrials.gov, 
NCT00889590).
Recently, denosumab has become a new treatment option for locally advanced 
GCTB. Denosumab is a RANKL-inhibitor that blocks osteoclast maturation and 
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therewith its osteolytic properties (Figure 5) [21,116]. Denosumab is a fully 
human monoclonal antibody [117] that is approved for osteoporosis treatment 
in postmenopausal women at risk for fracturing; to increase bone mass in 
patients with prostate or breast cancer at risk for fracture due to androgen 
deprivation therapy or aromatase inhibitor therapy, respectively; and for the 
prevention of skeletal-related events in patients with bone metastases from 
solid tumors. In addition, denosumab has been approved by the U.S. Food 
and Drug Administration for the treatment of adults and skeletally mature 
adolescents with GCTB that is unresectable or when surgical resection is likely to 
result in severe morbidity [23]; it is currently pending approval by the European 
Medicines Agency. A first open-label phase II study has shown clear clinical 
benefits in the treatment of GCTB [20]. In 86% of patients (30 of 35), there was 
an objective response to denosumab therapy, defined as >90% elimination 
of giant cells on histological evaluation or no radiographic progression of the 
lesion. Only a small minority of these patients underwent intralesional surgery 
after denosumab, and to date, it remains unknown whether local recurrence 
rate will be affected by denosumab treatment. Data with longer follow-up 
will follow and will provide more information on a possible lowering effect 
of denosumab on the recurrence rate. The interim analysis of a second and 
larger study (n=282) was recently published and confirmed the high efficacy 
of denosumab in GCTB [23]. Ninety-six percent of surgically unsalvageable 
patients had no disease progression after a median follow-up of 13 months. 
Seventy-four of 100 patients with tumors needing morbid surgery at study 
entry had no surgery and 16 of 26 patients underwent less morbid surgery 
after a median follow-up of 9.2 months. Long-term treatment may be required 
for long-term local tumor control.  Most important side effects are headache 
and bone pain (1-10%), osteonecrosis of the jaw (1-2%), hypocalcaemia and 
hypophosphatemia (<0.01%) [20,23,118,119]. 
In response to denosumab treatment, sclerosis and reconstitution of cortical 
bone is seen on conventional radiographs and CT (Figure 2) [27]. On dynamic 
contrast-enhanced MRI, later enhancement followed by slower washout 
compared to index MRI may indicate response to treatment. Furthermore, 
reduced uptake is seen on fluorodeoxyglucose-positron emission tomography 
(FDG-PET) after denosumab treatment, suggesting that FDG-PET may be a 
sensitive monitor for the response to denosumab [20]. Histopathologically, a 
strong decrease of reactive osteoclast-like giant cells (≥90%) and a reduced 
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number of neoplastic stromal cells was seen after denosumab treatment, in 
addition to new formation of non-proliferative dense fibrous tissue and woven 
bone [21]. 
Denosumab is clearly an active drug in GCTB treatment and has an acceptable 
toxicity profile. Consequently, It should be standard for unresectable disease to 
facilitate intralesional surgery at a later stage, avoiding more invasive surgery. 
Data on the use of denosumab for metastatic GCTB are scarce; it is hoped that 
final data of the open-label phase II trial will provide more knowledge about 
this matter.
Radiation therapy
Curettage with local adjuvants is the mainstay of treatment for GCTB. With 
the advent of neoadjuvant systemic targeted therapy using RANKL-inhibitors, 
promising short-term phase II results with regard to local control have been 
obtained. However, even after neoadjuvant systemic treatment, extensive 
soft tissue involvement and axial localization (e.g. sacral lesions) can offer 
challenges for a satisfactory surgical approach.
In the past, moderate-dose radiotherapy (40-55Gy) has shown to be effective 
as primary treatment in unresectable GCTB or in cases of residual or recurrent 
disease when surgery would result in unacceptable morbidity. Most studies 
were retrospective and included only limited numbers of patients over a 
considerable time span. In this setting, reported 5-year local control was 
approximately 80% and ranged between 62-90% [120-131]. Risk factors for 
local recurrence or residual disease after radiotherapy are large size (>8.5cm) 
and recurrent disease [128]. 
Radiotherapy may induce (secondary) malignant transformation, which is 
of concern especially because most patients are relative young (presenting 
between 30-50 years of age). The reported risk of malignant transformation 
varies between 0% and 5% [120,123,125,127,129].
In the era of RANKL-inhibitors, the role of radiotherapy in the treatment of GCTB 
needs to be redefined. Currently, there is no data on the use of radiotherapy in 
combination with RANKL-inhibitors for the treatment of primary unresectable 
or recurrent GCTB. However, given the promising short-term results of phase II 
studies with RANKL-inhibitors so far, use of radiotherapy should be restricted to 
those rare cases of unresectable, residual or recurrent GCTB in which treatment 
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with RANKL-inhibitors is not possible or has been proven to be ineffective, and 
when surgery would lead to unacceptable morbidity (often in axial location).
Conclusion 
GCTB is an intermediate, locally aggressive but rarely metastasizing tumor [1]. 
Treatment decisions should be made by a multidisciplinary team consisting of 
dedicated experts in the field of musculoskeletal oncology and should include 
radiography, dedicated MRI, histopathological assessment and planned 
surgery, supplemented with systemic targeted therapy if indicated (Figure 6).
Ideally, all patients should be treated with intralesional excision with local 
adjuvant treatment (e.g. phenol, liquid nitrogen, PMMA), achieving joint 
salvage and optimal functional outcome. Concurrently, recurrence risk should 
be minimized to rates similar to those reported after en bloc resection. In this 
regard, curettage with local adjuvants is safe in patients with GCTB confined 
to bone or with a pathologic fracture in which joint salvage is feasible. For soft 
tissue extension, the feasibility of intralesional surgery depends on the extent 
of the soft tissue component. For GCTB in the axial skeleton, feasibility of 
intralesional surgery depends on the involvement of neurovascular structures 
and soft tissue extension. 
In patients with high-risk GCTB (e.g. large cortical defects; large soft tissue 
components; localization in vertebrae, sacrum or pelvis; and multiple recurrent 
GCTB), acceptable recurrence rates are not achievable with intralesional 
surgery alone, and these patients are ideally suited for systemic targeted 
therapy with RANKL-inhibitors or bisphosphonates. Denosumab was 
associated with tumor responses and reduced the need for morbid surgery; 
further data on possible delay or avoidance of recurrent disease and further 
investigation on the duration and dose of denosumab as a therapy for GCTB 
is warranted.  Consequently, neoadjuvant therapy with denosumab should be 
standard treatment for unresectable disease to facilitate intralesional surgery 
at a later stage, avoiding more invasive surgery. Long-term effects as well as 
optimal therapy duration still warrant further study. For patients who require 
immediate surgery due to intra-articular pathologic fracture or spinal cord 
compression, adjuvant systemic targeted therapy might reduce recurrence 
risk, but this is still unknown and is currently under study. 
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Figure 6 Multidisciplinary treatment recommendations for GCTB *With extra-articular pathologic 
fractures, preoperative fracture healing may be awaited, while immediate surgery is required with intra-
articular pathologic fractures. **Caution is warranted with local adjuvants (e.g. phenol, alcohol, liquid 
nitrogen) in case of involvement of soft tissues or neurovascular structures as it may induce (severe) 
necrosis. 
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Use of moderate-dose radiotherapy (40-55Gy) should be limited to rare cases 
of unresectable, residual or recurrent GCTB in which denosumab is not 
available, is contraindicated or is not effective and when surgery would lead to 
unacceptable morbidity.
In conclusion, we propose multidisciplinary integrated recommendations 
for the management of GCTB, including radiological, histopathological and 
surgical aspects. Especially for patients with high-risk GCTB, multidisciplinary 
treatment should be optimized with respect to immediate local control and 
optimal functional outcome. The role for systemic targeted therapy needs to 
be further explored.
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Abstract
Background The rate of recurrence of giant cell tumor of bone (GCTB) is 
decreased by use of adjuvant treatments such as phenol, liquid nitrogen, or 
polymethylmethacrylate (PMMA) during curettage. We assessed recurrence 
and complication rates and functional outcome after curettage with use of 
phenol and PMMA, liquid nitrogen and PMMA, and liquid nitrogen and bone 
grafts.
Methods We retrospectively compared the relative effectiveness of treatment 
of GCTB at two tertiary centers with a regional function from 1990 to 2010. The 
132 (of 201) patients who met the inclusion criteria had a mean age of 33 years 
(range 11-69 years). Treatment assignment depended purely on the center, 
with primary treatment consisting of curettage with use of phenol and PMMA 
(n=82) at one center and with use of either liquid nitrogen and PMMA (n=26) 
or liquid nitrogen and bone grafts (n=24) at the other center. Recurrence and 
complication rates were determined, and functional outcome was assessed on 
the basis of the Musculoskeletal Tumor Society (MSTS) score.
Results The mean duration of follow-up was 8 years (range 2-22 years). 
Recurrence rates were comparable among the groups (28% for phenol and 
PMMA, 31% for liquid nitrogen and PMMA, and 38% for liquid nitrogen and 
bone grafts; p=0.52). Soft-tissue extension increased the recurrence risk 
(hazard ratio [HR]=2.1, 95% confidence interval [CI]=1.1-4.0, p=0.024). The 
complication rate was 33% after use of liquid nitrogen and bone grafts, 27% 
after liquid nitrogen and PMMA, and 11% after phenol and PMMA (p=0.019); 
complications included osteoarthritis, infection, postoperative fracture, 
nonunion, transient nerve palsy, and PMMA leakage. The complication risk was 
increased by the presence of a pathologic fracture (HR=4.1, 95%CI=1.7-9.5, 
p=0.001) and use of liquid nitrogen (HR=3.9, 95%CI=1.5-10, p=0.006 for liquid 
nitrogen and bone grafts; HR=3.1, 95%CI=1.1-8.6, p=0.028 for liquid nitrogen 
and PMMA). The mean MSTS score was 26 (range 8-30) and was comparable 
among all three cohorts (p=0.52).
Conclusions Recurrence rates were comparable for treatment with phenol 
and PMMA, liquid nitrogen and PMMA, and liquid nitrogen and bone grafts. 
Complications rates were higher after use of liquid nitrogen. The functional 
outcome was excellent in all three cohorts. 




The main difficulty in management of giant cell tumors of bone (GCTB) is the 
relatively high recurrence rate after curettage, with most recurrences occurring 
within the first two postoperative years [1]. Although recurrence rates are lower 
(0 to 12%) after en bloc resection, curettage with local adjuvants is preferable as 
it results in less morbidity and superior functional outcome [2-5]. Without any 
local adjuvant, reported recurrence rates range from 21% to 65% [6,7]. The most 
widely accepted treatment today is curettage combined with phenolization 
and use of polymethylmethacrylate (PMMA) [7-11]. 
Phenol is a chemical agent that induces tumor necrosis and coagulation of 
proteins at the borders of the cavity [12,13]. The cytotoxic effect of phenol 
has been studied in vitro on monolayer cultures of cells from GCTB, and the 
infiltration-depth has been estimated at 0.2 mm [14]; the in vivo infiltration-
depth in bone remains unknown [15]. Reported recurrence rates range from 
9% to 34% after curettage with phenol [5,10,16,17] and 8% to 27% after 
curettage with phenol and PMMA [7-11]; the additional effect of phenol during 
curettage with use of PMMA remains unclear [1,10,11]. Complications resulting 
from phenol use include chemical burns, and caution is warranted in vicinity of 
neurovascular structures and soft tissues [18,19].
Cryosurgery is used at some centers for aggressive benign bone tumors (e.g. 
GCTB, aneurysmal bone cyst, chondroblastoma) and low-grade malignant 
bone tumors (e.g. chondrosarcoma grade I) [20,21]. Liquid nitrogen induces 
tissue necrosis by causing the formation of intracellular ice crystals and 
membrane disruption [22]. Repetitive cycles of rapid freezing and slow thawing 
increase surgical margins by up to 2 cm, comparable with marginal resection 
[21,23]. Use of liquid nitrogen after curettage has been reported to result in 
recurrence rates of 8% to 42% when used with bone grafts [13,24-26] or 0% to 
20% when used with PMMA [13,27,28]. Complication rates of 12% to 50% have 
been reported, with the complications including postoperative fracture, skin 
necrosis, (transient) nerve palsy, and infection [23,24,29].
PMMA is a thermal adjuvant that increases surgical margins by up to 1.5 to 
2 mm in cancellous and 0.5 mm in cortical bone [30,31]. When applied after 
curettage, PMMA has been reported to lower the recurrence risk to 7% to 
29%, hypothetically through its hyperthermic reaction [1,7,9,11,32-35]. PMMA 
provides immediate mechanical support and facilitates early radiographic 
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detection of recurrences. Complication rates of 13% to 25% have been reported, 
with the complications including cement leakage into joints or surrounding 
soft tissues and osteoarthritic changes. The latter may occur after curettage 
with PMMA if a large giant cell tumor is close to the articular cartilage [36-39].
Various combinations of local adjuvants have been used in the past, but the 
effectiveness of phenol has never been compared with that of liquid nitrogen 
in a comparative cohort study involving various standard treatments. We 
therefore assessed recurrences, non-oncological complications, and functional 
outcome after curettage with use of phenol and PMMA, liquid nitrogen and 
PMMA, and liquid nitrogen and bone grafts.
Patients and methods
After approval by the local ethics committee, we retrospectively evaluated 201 
consecutive patients treated for giant cell tumor of a long bone at two tertiary 
centers from 1990 to 2010. Sixty-nine patients did not meet the inclusion 
criteria (Figure 1). Sixty of these patients underwent a primary treatment other 
than the standard treatment because of soft-tissue extension, an intra-articular 
pathologic fracture, or a difficult anatomic location. (Thirty-two underwent 
resection, sixteen underwent isolated curettage, eight underwent curettage 
with use of PMMA, and four underwent curettage with phenol.) Two patients 
had giant cell tumors at multiple sites. Seven patients were lost to follow-up 
within two years (4-17 months) after the primary surgery; two of these had had 
a recurrence (after two and 11 months). 
The remaining 132 patients (63 female) were included in the analysis. These 
patients had a mean follow-up of 93 months (range 24-266 months) and a mean 
age of 33 years (range 11-69 years). All included patients had a histologically 
verified GCTB. Two patients developed pulmonary metastases (after 11 and 12 
months). Four patients died of a cause unrelated to the tumor after four to nine 
years; no recurrent or metastatic disease was noted at the time of death. No 
patients were recalled specifically for this study; all data were obtained from 
medical records and imaging studies used in the follow-up. 
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Figure 1 Surgical treatment for giant cell tumor of bone at two tertiary referral centers for orthopaedic 
oncology with different standard treatment protocols approximating randomization for phenol and 
liquid nitrogen use, and resulted in three cohorts for this retrospective comparative cohort study. *The 
primary treatment in forty-three patients was not the typical method described, and six were lost to 
follow-up. **The primary treatment in 17 patients was not the typical method described, two had giant 
cell tumors in multiple locations, and one was lost to follow-up. P-PMMA = phenol and PMMA, LN-
PMMA = liquid nitrogen and PMMA, LN-BG = liquid nitrogen and bone grafts.
Patients were treated at two tertiary referral centers for musculoskeletal 
oncology. All surgeons were fellowship-trained orthopaedic oncologists; 
surgical expertise was comparable at the two centers, and each center 
specialized in its standard technique. Confounding by indication was minimal 
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as both centers apply similar indications for curettage, with both including 
patients with a pathologic fracture or soft-tissue extension—primary en bloc 
resection was rarely considered. Center 1 is situated in a more densely populated 
area, resulting in a greater number of patients. However, both centers have a 
regional function, as patients are referred on the basis of their residence, and 
this minimized the differences between the study populations at the two 
centers. All patient and tumor characteristics except anatomic location were 
similar among the three treatment cohorts (Table 1). 















Age at diagnosis (yr) 33 (11-69) 32 (13-61) 37 (16-69) 32 (11-63) 0.29
Time to recurrence (mo) 29 (4-156) 32 (4-156) 18 (7-29) 31 (8-72) 0.71
Time to complication (mo) 45 (1-203) 40 (6-115) 35 (1-85) 59 (3-203) 0.87
Follow-up (mo) 93 (24-266) 100 (24-266) 72 (28-151) 92 (24-228) 0.21
Sex 0.27
Male 69 52% 46 56% 14 54% 9 38% -
Female 63 48% 36 44% 12 46% 15 62% -
Age <30 years 64 48% 44 54% 10 38% 10 42% 0.31
Location 0.004
Distal femur 63 48% 47 57% 9 34.5% 7 29% -
Proximal tibia 25 20% 14 17% 9 34.5% 2 8% -
Distal radius 15 11% 9 11% 2 8% 4 17% -
Distal tibia 8 6% 5 6% 2 8% 1 4% -
Proximal humerus 7 5% 3 4% 1 4% 3 13% -
Proximal femur 7 5% 2 2.5% 3 11% 2 8% -
Fibula 5 4% 2 2.5% - - 3 13% -
Distal ulna 2 1% - - - - 2 8% -
Tumor characteristics
Soft-tissue extension 34 27% 22 27% 6 23% 6 25% 0.90
Pathologic fracture 28 22% 17 21% 7 27% 4 17% 0.68
     Intra-articular 9 - 6 - 2 - 1 - -
     Complex 8 - 4 - 1 - 3 - -
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Reconstruction with bone grafts was sometimes preferred in non-weight-
bearing bones, whereas PMMA was used more often in weight-bearing bones 
to facilitate immediate weight-bearing. 
The standard primary treatment at Center 1 consisted of curettage with use of 
phenol and PMMA (n=82). Three cycles of phenolization of the cavity walls were 
performed, followed by application of 70% ethanol. Surrounding soft tissues 
were carefully protected. After treatment, the cavity was rinsed extensively by 
means of high-speed pulsatile lavage with saline solution. When <10 mm of 
subchondral bone remained after curettage, bone grafts were used to increase 
the health of the articular cartilage (n=42). The cavity was filled with PMMA in 
all 82 patients. One patient also underwent osteosynthesis.
The standard treatment at Center 2 consisted of curettage and high-
speed burring followed by cryosurgery involving a liquid nitrogen spray. 
Thermocouples were used to monitor freezing of the cavity walls [40], and 
surrounding soft tissues were continuously irrigated with warm fluids to 
protect against thermal injury. Three cycles of rapid freezing (to ≤-50 ºC) and 
slow thawing (to 20 ºC) were performed. In 26 patients, PMMA was used to fill 
the cavity. As at Center 1, subchondral bone grafts were used when <10 mm of 
subchondral bone remained (n=17). In 24 patients, the cavity was entirely filled 
with bone grafts, with no PMMA used. Prophylactic osteosynthesis was used to 
prevent postoperative fracture in 17 patients treated with liquid nitrogen and 
PMMA and in eight patients treated with liquid nitrogen and bone grafts. The 
choices regarding cavity filling with either bone grafts or PMMA and regarding 
prophylactic osteosynthesis were made intraoperatively and depended on 
tumor location, cortical stability, and anticipated fracture risk. PMMA was used 
as often as bone grafts after cryosurgery, and both types of filling material are 
still used at Center 2.
Postoperative treatment after use of phenol and PMMA consisted of functional 
mobilization with immediate full weight-bearing. Postoperative treatment after 
use of liquid nitrogen and either bone grafts or PMMA consisted of functional 
mobilization with partial weight-bearing for at least six weeks. Weight-bearing 
was increased when radiographs indicated sufficient incorporation and 
excluded postoperative fracture. High-impact activities were avoided during 
the first six months, with no subsequent activity restrictions.
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Follow-up protocols were similar at the two centers. Potential bias resulting 
from patient-requested visits between the administratively scheduled regular 
follow-up appointments would have been similar for both centers and unlikely 
to influence the outcomes of this study. Follow-up consisted of radiographs at 
1.5, 3, 6, 12, 18, and 24 months postoperatively followed by yearly radiographs for 
the next 10 years. Magnetic resonance (MR) imaging was performed at two and 
five years postoperatively and if recurrence was suspected. Thoracic computed 
tomography (CT) scans or chest radiographs were made at presentation and 
with every proven recurrence to detect pulmonary metastases. 
Medical records were reviewed to determine age, sex, tumor location, presence 
of soft-tissue extension, presence of a pathologic fracture, type of surgery 
and reconstruction, development of local recurrences, development of non-
oncological complications, functional outcome, and duration of follow-up 
(Table 1). 
The local recurrences were confirmed by imaging studies and histopathology 
during the follow-up, and the recurrence rate in each of the three treatment 
cohorts was confirmed by review of the medical records. Non-oncological 
complications were recorded and were evaluated in each treatment cohort 
and according to the use of PMMA or bone grafts for reconstruction. In all 
patients in whom the location of the tumor was about the knee, preoperative 
and postoperative radiographs (if available) were reviewed to assess knee 
osteoarthritis with use of the Kellgren-Lawrence scale [41]. Complete 
radiographic data were available for 77 (88%) of these 88 patients, and 
the presence of osteoarthritis of the knee on radiographs was defined as a 
Kellgren-Lawrence grade 3 or 4 [41]. The functional outcome was evaluated 
in each treatment cohort and according to the use of PMMA or bone grafts 
for reconstruction with use of the Musculoskeletal Tumor Society (MSTS) score. 
Functional results were available for 113 (86%) of the patients at the time of the 
latest follow-up (mean 8 years [range 2-22 years]); the remaining 19 patients 
could not be reached.
Statistical analysis
Baseline differences among the cohorts were assessed with use of chi-square 
and Mann-Whitney U tests. Recurrence-free survival was assessed with use of 
Kaplan-Meier survival analysis and compared among cohorts with use of log-
27935_Heijden.indd   65 25-06-14   11:32
Chapter 3
66
rank tests. Univariate and multivariate Cox regression analyses were performed 
to determine risk factors for recurrence and complications. MSTS scores were 
compared with use of Mann-Whitney U tests.
Results
The recurrence rate after curettage was 28% (23 of 82) in the patients treated 
with phenol and PMMA, 31% (8 of 26) in those treated with liquid nitrogen and 
PMMA, and 38% in those treated with liquid nitrogen and bone grafts (Figure 
2). 
Figure 2 Kaplan-Meier recurrence-free survival for giant cell tumor of bone treated with curettage with 
use of phenol and PMMA (black line), liquid nitrogen and PMMA (dark grey line), and liquid nitrogen and 
bone grafts (light grey line) (p = 0.52). 
Recurrence-free survival at five years was estimated to be 0.76 after use 
of phenol and PMMA, 0.69 after use of liquid nitrogen and PMMA, and 0.63 
after use of liquid nitrogen and bone grafts (p=0.52). In the 40 patients with 
recurrence, the median time to recurrence was 20 months (range 4-156 
months). Seven recurrences occurred later than three years postoperatively. 
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Recurrences were confined to bone in 27 patients and had soft-tissue extension 
in 13. In the multivariate Cox regression analysis, soft-tissue extension at initial 
presentation increased the risk for recurrence (hazard ratio [HR]=2.3, 95% 
confidence interval [CI]=1.2-4.5, p=0.0012). Fifteen (44%) of the 34 patients 
with soft-tissue extension at presentation developed recurrence. An age of 
less than 30 years, sex, the presence of a pathologic fracture, and the choice of 
local adjuvant treatment did not influence the risk for recurrence (Table 2). In 
the patients treated with phenol and PMMA, the recurrence rate did not differ 
between those who underwent reconstruction with and without subchondral 
bone grafting (31% [13 of 42] compared with 25% [10 of 40], p=0.36). Likewise, 
in the patients treated with liquid nitrogen, it did not differ between the 
patients who did and did not receive bone grafts (18% [4 of 22] compared with 
7% [2 of 28], p = 0.23). Local control was achieved with use of one or multiple 
intralesional procedures in 119 (89%) of the 132 patients. Thirty of the 40 first 
recurrences were treated with curettage with use of phenol and PMMA (n=17), 
liquid nitrogen and PMMA (n=7), liquid nitrogen and bone grafts (n=4), PMMA 
(n=1), or phenol (n=1); seven were treated with resection; and the remaining 
three were still awaiting surgery. Ten patients developed a second recurrence; 
five were treated with curettage with use of phenol and PMMA (n=1), PMMA 
(n=2), or liquid nitrogen and bone grafting (n=2); four were treated with 
resection; and the remaining patient was still awaiting surgery. Two patients 
developed a third recurrence; one was treated with curettage with use of liquid 
nitrogen and PMMA, and the other was treated with excision of the soft-tissue 
recurrence.  
Non-oncological complication rates were significantly higher (p=0.019) after 
curettage with use of liquid nitrogen and bone grafts (33%; 8 of 24) or liquid 
nitrogen and PMMA (27%; 7 of 26) compared with phenol and PMMA (11%; 9 
of 82) (Table 3).
The rate of complications was also significantly higher (p=0.038) after 
reconstruction with bone grafts (33%; 8 of 24) compared with PMMA (15%; 16 
of 108). The median time to development of a complication was 31 months 
(range 1-203 months). Non-oncological complications included osteoarthritis, 
infection, postoperative fracture or femoral condyle collapse, nonunion, 
nerve palsy, and PMMA leakage (Table 3). In the multivariate Cox regression 
analysis, the complication risk was increased by the presence of a preoperative 
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pathologic fracture (HR=4.1, 95%CI=1.7-9.5, p=0.001) and by use of liquid 
nitrogen (HR=3.9, 95%CI=1.5-10, p=0.006 for use of liquid nitrogen and bone 
grafts; HR=3.1, 95%CI=1.1-8.6, p=0.028 for use of liquid nitrogen and PMMA). 
Table 2 Cox regression analysis of risk factors for recurrence and complications after curettage with 
adjuvants for giant cell tumor of bone






Soft-tissue extension 34 15 44% 2.1 1.1-4.0 0.024
Age <30 years 64 22 34% 1.5 0.78-2.7 0.24
Pathologic fracture 28 6 21% 0.64 0.27-1.5 0.31
Sex (female) 63 18 29% 0.80 0.43-1.5 0.48
Local adjuvants
    Phenol and PMMA 82 23 28% - - 0.52
    Liquid nitrogen and PMMA 26 8 31% 1.3 0.56-2.8 0.58
    Liquid nitrogen and bone grafts 24 9 38% 1.6 0.56-3.4 0.27
Multivariate analysis
Soft-tissue extension 34 15 44% 2.3 1.2-4.5 0.012
Age <30 years 64 22 34% 1.6 0.81-3.0 0.18
Local adjuvants
    Phenol and PMMA 82 23 28% - - 0.32
    Liquid nitrogen and PMMA 26 8 31% 1.4 0.62-3.2 0.41
    Liquid nitrogen and bone grafts 24 9 38% 1.8 0.82-4.0 0.14






Pathologic fracture 28 11 39% 3.6 1.6-8.2 0.002
Soft-tissue extension 34 7 21% 1.1 0.45-2.6 0.87
Sex (female) 63 10 16% 0.94 0.42-2.1 0.87
Age <30 years 64 6 9% 0.42 0.17-1.0 0.054
Local adjuvants
    Phenol and PMMA 82 9 11% - - 0.016
    Liquid nitrogen and PMMA 26 9 35% 3.3 1.2-9.1 0.019
    Liquid nitrogen and bone grafts 24 6 25% 3.4 1.3-8.9 0.011
Multivariate analysis
Pathologic fracture 28 11 39% 4.1 1.7-9.5 0.001
Soft-tissue extension 34 7 21% 1.4 0.55-3.4 0.49
Local adjuvants
    Phenol and PMMA 82 9 11% - - 0.012
    Liquid nitrogen and PMMA 26 9 35% 3.1 1.1-8.6 0.028
    Liquid nitrogen and bone grafts 24 6 25% 3.9 1.5-10 0.006
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Eleven (39%) of the 88 patients with a pathologic fracture developed 
complications (osteoarthritis in six, infection in two, postoperative fracture in 
two, and nonunion in one). An age of less than 30 years, sex, and soft-tissue 
extension did not influence the complication risk (Table 2). Knee osteoarthritis 
(a Kellgren-Lawrence grade of 3 or 4) was found on radiographs made at a 
median of 34 months (range 3-116 months) postoperatively in 12% (6 of 50) 
patients treated with phenol and PMMA, 17% (3 of 18) treated with liquid 
nitrogen and PMMA, and 22% (2 of 9) treated with liquid nitrogen and bone 
grafts. None of these patients had had Kellgren-Lawrence grade 3 or 4 knee 
osteoarthritis preoperatively. In addition, two patients treated with liquid 
nitrogen developed carporadial osteoarthritis. Among the patients treated 
with phenol and PMMA, 24% (4 of 17) who received subchondral bone grafts 
and 44% (4 of 9) treated without bone grafts developed osteoarthritis (p=0.26) 
Among the patients treated with liquid nitrogen and PMMA, one of eleven 
who received subchondral bone grafts and two of five patients treated without 
bone grafts developed osteoarthritis (p=0.21). The osteoarthritis in ten of the 
patients did not require surgery, two underwent total knee arthroplasty, and 
one underwent wrist arthrodesis. 
Other complications included osteomyelitis (n = 2) and wound infection (n 
= 2), which resolved after intravenous antibiotics. One of these patients also 
underwent PMMA replacement with cancellous bone grafts. Two patients 
had femoral condyle collapse (after 3 and 35 months); the first had Kellgren-
Lawrence grade 4 osteoarthritis and underwent total knee arthroplasty, and 
the second was not treated because of palliative care for a comorbidity. One 
patient had a postoperative fracture that healed after PMMA replacement. 
Nonunion occurred in two patients; both underwent PMMA replacement with 
cancellous bone grafts, with reduction of the fracture with external fixator in 
one of the patients. Transient peroneal nerve palsy occurred in one patient. 
One patient had intra-articular leakage of PMMA; the PMMA that leaked was 
surgically removed two weeks after the initial surgery. 
Functional outcome was measured on the basis of the MSTS score at the time 
of the latest follow-up was comparable among the three cohorts (p=0.52). The 
mean MSTS score was 26 (range 11-30) in 67 patients treated with phenol and 
PMMA, 26 (range 8-30) in 22 patients treated with liquid nitrogen and PMMA, 
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and 27 (range 13-30) in 24 patients treated with liquid nitrogen and bone grafts. 
There was also no clinically relevant difference between the two reconstruction 
methods with respect to the MSTS score, which averaged 27 (range 13-30) in 
24 patients who received bone grafts and 26 (range 8-30) in 89 patients who 
received PMMA (p=0.039).
Discussion 
Most retrospective case series involving treatment of GCTB by curettage 
followed by use of a local adjuvant have focused on only a single adjuvant. 
Comparisons among these series may be misleading as the centers may have 
had different study populations and different indications for selection of 
curettage with adjuvants or resection. To our knowledge, the effectiveness of 
phenol has never been compared directly with that of liquid nitrogen.  
Recurrence rates did not differ significantly among the three treatment cohorts 
in the present study, but they were at the higher end of the ranges reported 
in the literature (Table 4). These high recurrence rates may be explained by 
the relatively broad indications for intralesional curettage applied at both 
centers, including patients with a pathologic fracture or soft-tissue extension. 
This is in accordance with extended indications for curettage in 80% to 88% 
of patients as described previously by some authors [7,9,10,42]. In contrast, 
other authors appear to prefer primary resection (in 32% to 55% of patients) 
for more complicated cases [1,5,6,12,43]. At the time of the latest follow-up in 
the present study, local control had been achieved with use of one or multiple 
intralesional procedures in 89% of the patients, indicating that repeated 
curettage with adjuvants is a safe alternative to resection. En bloc resection was 
rarely considered as the primary treatment at either center, and it was used 
in only eleven patients with (first or later) recurrences, as expected functional 
results are inferior [2-5]. The recurrence rate data indicate that cryosurgery is 
a good alternative to the more commonly used combination of phenol and 
PMMA; however, it is preferably performed at centers experienced with this 
technique, as complications are more common. Whereas bone grafts and 
PMMA were used equally often at Center 2 for filling of the cavity during the 
time period described in this study, most giant cell tumors of bone are now 
treated with curettage and use of liquid nitrogen and PMMA at that center.
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Non-oncological complications were more common after use of liquid 
nitrogen and bone grafts (33%) or liquid nitrogen and PMMA (27%) compared 
with phenol and PMMA (11%). Non-oncological complications were more 
common after reconstruction with bone grafts (33%) compared with PMMA 
(mean 15% in two cohorts). However, as the difference in complication rates 
after cryosurgery (mean 30% in two cohorts) compared with phenolization 
(11%) was most striking, we conclude that this risk can be attributed to the use 
of liquid nitrogen and that it is especially elevated in combination with use of 
bone grafts for reconstruction. 
The most common complication in all cohorts was secondary osteoarthritis. 
It has been hypothesized that a large subchondral bone defect close to the 
joint in combination with the hyperthermic reaction of PMMA may increase 
the risk for secondary osteoarthritis [33,36-39]. To our knowledge, this is the 
first study to evaluate the prevalence of osteoarthritis after cancellous bone 
grafting or PMMA use in the treatment of giant cell tumor of bone about the 
knee. Osteoarthritis was observed more frequently after cryosurgical treatment, 
especially if bone grafts were used for reconstruction. In theory, subchondral 
bone grafts may protect articular cartilage from degeneration by increasing 
the distance between the cartilage and PMMA, thus creating a barrier against 
thermal effects [33,36,37]. In the present study, subchondral bone grafts were 
used in patients with little remaining subchondral bone stock (<10 mm), and 
we only found a modest decrease in the prevalence of osteoarthritis compared 
with that in patients in whom subchondral bone grafts were not used. However, 
the numbers available were too small to draw conclusions and we did not study 
the influence of patient, treatment, and tumor characteristics on osteoarthritis 
development. A previous detailed analysis of the amount of subchondral bone 
involvement and the distance between giant cell tumors of bone and articular 
cartilage demonstrated that these factors both strongly increase the risk for 
osteoarthritis—thus, in the present study, patients in whom subchondral bone 
grafts were placed would have been at an a priori increased risk for osteoarthritis 
[39]. Whereas postoperative fractures were the most important concern after 
cryosurgery in the past, adequate monitoring of freezing temperatures and 
prophylactic osteosynthesis in selected cases have decreased fracture rates 
dramatically (from 25%-50% [21,29] to 0%-7% [13,24,26,28]; Table 5). The 
postoperative fracture rate of 6% after cryosurgery in the present study confirms 
that the fracture risk with current cryosurgery techniques is relatively low. 
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In the present study, the functional outcome as assessed with the MSTS score 
was excellent for all adjuvants and reconstruction methods. However, even 
though joint salvage was achieved in all patients, different cavity fillings and 
complications might alter the functional outcome. For example, osteoarthritis 
was more common after cryosurgery, but this did not appear to negatively 
influence the mean functional outcome. The clinical impact of osteoarthritis 
appeared modest at intermediate-term follow-up, but longer follow-up is 
required as the study involved relatively young patients. One could hypothesize 
that the weight-bearing that is possible during the immediate postoperative 
period if PMMA is used for reconstruction would yield functional results 
during this period that are superior to those for reconstruction with bone 
grafts. However, because of the retrospective nature of this study, we were 
unable to compare such interim functional results. Our functional results were 
comparable with those reported in the literature for all adjuvants. For example, 
mean MSTS scores of 25 (range 16-30) after use of phenol and PMMA, 26 (range 
14-30) after use of liquid nitrogen and PMMA, and 28 (range 21-30) after use of 
liquid nitrogen and bone grafts were reported in a previous study [13].
This study has several strengths: both centers had different but equally accepted 
standard treatments during the same period, applied identical criteria for the 
choice between intralesional and wide resection of the giant cell tumor, and 
had similar surgical expertise. Regional or inter-center differences in treatment 
have been used previously as instrumental variables [44]. 
In observational studies, analysis of instrumental  variables  can estimate the 
therapeutic effects of various standard treatments and deal with controlled 
and uncontrolled confounding [44-46]. Several assumptions should be met: 
an  instrumental  variable should directly affect the treatment decision, must 
not be related to patient prognosis, and may not affect the primary outcome 
measures other than through chance [44-46]. 
Our study has several limitations. First, it would have been interesting to 
analyze four cohorts (use of phenol and bone grafts, phenol and PMMA, liquid 
nitrogen and bone grafts, and liquid nitrogen and PMMA) to compare the 
unique effects of phenol and liquid nitrogen and the combined effects of these 
treatments with use or non-use of PMMA. However, as curettage followed by 
phenolization and bone grafting was performed in only four patients, this 
cohort was too small to include. In addition, this treatment was abandoned 
at Center 1 as the surgeons preferred using PMMA because of its advantages. 
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Second, the decisions for bone grafts, PMMA and osteosynthesis at Center 2 
were made intraoperatively and were based on the structural integrity of the 
remaining bone after curettage. These choices were not standardized and this 
may have resulted in confounding by indication. 
In conclusion, treatment of GCTB remains challenging as recurrence rates 
remain relatively high after curettage with local adjuvants. Recurrence rates 
in the present study were comparable for curettage with use of phenol and 
PMMA, liquid nitrogen and PMMA, and liquid nitrogen and bone grafts. The 
risk of complications, especially the development of osteoarthritis, was higher 
with cryosurgery. Functional outcome was excellent in all cohorts, making the 
relatively high recurrence rates (in comparison with the rate following en bloc 
resection and endoprosthetic reconstruction) acceptable.
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Abstract
Background Approximately one in five patients with giant cell tumor of bone 
(GCTB) presents with a pathologic fracture. However, recurrence rates after 
resection or curettage differ substantially in the literature and it is unclear 
when curettage is reasonable after fracture. We therefore determined: (1) 
local recurrence rates after curettage with adjuvants or en bloc resection; (2) 
complication rates after both surgical techniques and whether fracture healing 
occurred after curettage with adjuvants; and (3) function after both treatment 
modalities for GCTB with a pathologic fracture.
Patients and methods We retrospectively reviewed 48 patients with fracture 
from among 422 patients treated between 1981 and 2009. The primary 
treatment was resection in 25 and curettage with adjuvants in 23 patients. 
Minimum follow-up was 27 months (mean 101 months; range 27–293 months).
Results Recurrence rate was higher after curettage with adjuvants when 
compared with resection (30% vs. 0%). Recurrence risk appears higher with 
soft tissue extension. The complication rate was lower after curettage with 
adjuvants when compared with resection (4% vs. 16%) and included aseptic 
loosening of prosthesis, allograft failure, and pseudoarthrosis. Tumor and 
fracture characteristics did not increase complication risk. Fracture healing 
occurred in 24 of 25 patients. Mean Musculoskeletal Tumor Society score was 
higher after curettage and adjuvants (mean 28; range 23–30; n=18) when 
compared with resection (mean 25; range 13–30; n=25).
Conclusions Our observations suggest curettage with adjuvants is a reasonable 
option for GCTB with pathologic fractures. Resection should be considered with 
soft tissue extension, fracture through a local recurrence, or when structural 
integrity cannot be regained after reconstruction.




Giant cell tumor of bone (GCTB) is a primary benign bone tumor with a peak 
incidence between the third and fifth decades and a slight predominance for 
females [28]. It is most commonly found in the epimetaphyseal region of the 
long bones [28]. GCTB contains mononuclear histiocytic cells, multinucleated 
giant cells, and mononuclear stromal cells; the latter are believed to be 
neoplastic. Overexpression of receptor activator nuclear factor kappa-B ligand 
by mononuclear stromal cells promotes the recruitment of multinucleated 
giant cells [28]. Cathepsin K, exclusively expressed by these giant cells, 
is believed to be the principal protease in GCTB [18]. This indicates the 
osteoclast-like giant cells are responsible for the osteolysis seen in giant cell 
tumor of bone. Pathologic fractures occur at first presentation in 9% to 30% of 
all patients with GCTB [4–6, 19, 20, 27] and are often intra-articular as a result of 
the epimetaphyseal location. 
Curettage with adjuvants and en bloc resection are both considered treatment 
options for GCTB with a pathologic fracture. The use of curettage with adjuvants 
reportedly is associated with relatively high local recurrence rates (12%–34%) 
[2, 3, 16]. Most local recurrences occur within the first 2 postoperative years [15]. 
Although based on a relatively small series, O’Donnell et al. [20] suggested the 
presence of pathologic fractures would be associated with a higher recurrence 
risk after curettage through fracture contamination of surrounding soft tissues. 
However, more recent studies have suggested that this may not be the case 
[2, 3, 16]. The majority of GCTB with a pathologic fracture about the knee have 
reportedly been treated with resection and reconstruction with either allograft 
or tumor prosthesis [19]. Some authors consider resection and reconstruction 
the preferred treatment in patients with severe joint destruction or dislocated, 
comminuted, or intra-articular fractures [6]. Although the risk for local recurrence 
is generally low after en bloc resection (0%–12%) [2, 9, 15, 27], it is not necessarily 
the most favorable primary treatment. Considering the benign nature of the 
disease, the young patient population, the substantial complications, and the 
need for revision surgery, the aim for joint preservation is generally justified [12, 
13, 19, 22]. The preferred surgical treatment for primary GCTB with a pathologic 
fracture therefore remains controversial [7, 9, 11, 20, 21, 24]. 
Although presentation with a pathologic fracture is not uncommon for patients 
with GCTB, combining our collective experience is critical to the understanding 
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of this difficult to study subject. In the present study, we therefore reviewed 
our multicenter experience of patients with GCTB presenting with a pathologic 
fracture to determine if tumor and fracture characteristics led to universally 
better or worse outcomes. 
We therefore determined: (1) local recurrence rates after curettage with 
adjuvants or en bloc resection; (2) complication rates after both surgical 
techniques and whether fracture healing occurred after curettage with 
adjuvants; and (3) function after both treatment modalities for GCTB with a 
pathologic fracture.
Patients and methods
We retrospectively evaluated 63 patients treated for GCTB with a pathologic 
fracture (15%) from a total of 422 consecutive patients with GCTB treated in one 
of three tertiary referral centers specializing in the interdisciplinary treatment 
of bone and soft tissue tumors between 1981 and 2009. We excluded eight 
patients with less than 2-year follow-up, three patients who underwent primary 
treatment other than mentioned, two with axially located GCTB, and two with 
rapidly progressive (malignant) GCTB with recurrent and metastatic disease 
eventually resulting in death at 4 and 9 months after initial surgery (Figure 1). 
Both patients had eventually undergone resection (distal and proximal femur) 
for local recurrences and they developed pulmonary metastases (3%). From the 
eight patients with less than 2-year follow-up (1–19 months; five resections, 
three curettage with adjuvants), none developed a local recurrence so far. These 
15 exclusions left 48 patients with primary GCTB with a pathologic fracture for 
analysis in this tri-center retrospective study. Primary treatment consisted of en 
bloc resection (n=25) or curettage with adjuvants (n=23). Local adjuvants were 
combinations of phenol, hydrogen peroxide, and polymethylmethacrylate 
(PMMA). There were 27 male and 21 female patients. Mean age was 36 years 
(range 11–77 years). Most common locations of GCTB with a pathologic fracture 
were the distal femur (n=23; 48%), proximal humerus (n=9; 19%), and proximal 
tibia (n=6; 13%). Minimum follow-up of the living patients was 27 months (mean 
101 months; range 27–293 months). One patient died from an unrelated disease. 
No patients were recalled specifically for this study; all data were obtained from 
medical records. The study was approved by the local ethics committee. 
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Figure 1 Surgical treatment of a primary giant cell tumor of bone (GCTB) with a pathologic fracture and 
subsequent recurrences. *Patients with a follow-up of less than 2 years (n = 10), other primary treatment 
(n = 2), or axial location (n = 2) were excluded.
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Table 1 Patient demographics
Demographic Mean Range
Age at diagnosis (years) 39 11-77
Time to recurrence (months) 15 6-26
Follow-up (months) 101 27-293







Proximal humerus 9 19
Distal radius 4 8
Distal ulna 1 2
Proximal femur 4 8
Distal femur 23 48
Proximal tibia 6 13
Distal tibia 1 2
Tumor characteristics
Soft tissue extension 18 38
Complex fractures 13 27
Joint proximity (< 1 cm) 37 77
Intra-articular fractures 16 33
Surgical treatment
En bloc resection 25 52
Curettage with adjuvants 23 48
    PMMA 21 91
    Phenol 20 87
    Hydrogen peroxide 3 13
GCTB = giant cell tumor of bone; PMMA = polymethylmethacrylate.
We collected data from medical records and included patient demographics, 
imaging, histopathological evaluation, tumor localization, soft tissue extension, 
fracture characteristics, fracture healing, date and type of surgical intervention, 
method of reconstruction, local recurrences, complications, functional 
outcome, and follow-up (Table 1). All data were complete. Conventional 
radiographs were available for all patients; preoperative MRI for 42 patients; and 
preoperative CT for the other six patients. Soft tissue extension was assessed 
on preoperative MRI. We considered soft tissue involvement as an entity only 
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when this was a preexisting feature with cortex destruction and a tumor mass 
in the surrounding soft tissues; the fracture hematoma was not considered soft 
tissue extension. 
The presumptive diagnosis was based on radiographic characteristics (i.e. 
conventional radiographs and MRI) and clinical findings and history (e.g. pain, 
swelling, preceding trauma); this was later confirmed by either preoperative (45) 
or intraoperative (six) biopsy. None of the patients underwent surgery without a 
proper histopathologic diagnosis. All patients were surgically treated by one of 
six fellowship trained oncological orthopaedic surgeons (Center 1: PDSD, MAJS, 
AHMT; Center 2: DAC, RC; Center 3: CLMHG). Treatment of GCTB with a pathologic 
fracture differed (chi square: p<0.001) among the three centers. In one of three 
centers, curettage with adjuvants was preferred over resection in the presence 
of a pathologic fracture (Table 2). Complex fractures, intra-articular fractures, 
and subchondrally located GCTB (less than 1 cm from the articular cartilage), 
which were assessed on imaging and operative reports, occurred equally in 
the three centers; only the incidence of soft tissue extension differed slightly 
(Table 3). Patient, tumor, and fracture characteristics were equal within both 
treatment groups (Table 4). Surgical management of the pathologic fracture 
consisted of two steps, namely surgical resection of the GCTB and fractured 
bone or joint reconstruction. Resection was performed within 1 week after the 
pathologic fracture occurred. In these cases, the tumor, fractured or involved 
bone, and contaminated soft tissue were resected and reconstructed (Table 1). 
In case of intra-articular fractures, the resection was performed transarticularly. 
En bloc resection was always followed by reconstruction with either allograft 
or cemented modular tumor prosthesis. Surgical margins were reviewed in 
operation and pathology reports. We performed intralesional treatment using 
curettage with adjuvants either before or after fracture healing. In 15 patients, 
immediate curettage with adjuvants and fracture reconstruction with use of 
PMMA only was performed. In only two patients internal fixation was necessary 
to maintain structural integrity after curettage. In two patients we awaited 
fracture consolidation using an external fixation and in six patients with use of 
a plaster cast before performing intralesional resection of GCTB. In all patients 
who underwent curettage, we used local adjuvants to reduce the risk for local 
recurrence (Table 1). In two patients, cancellous bone graft was applied instead 
of PMMA because of considerable loss of cortical and subchondral bone stock. 
We used hydrogen peroxide in three patients as an alternative for phenol. 
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Curettage with adjuvants 23 18 78% 1 7% 4 40%
En bloc resection 25 5 22% 14 93% 6 60%
Table 3 Distribution of tumor and fracture characteristics among the three participating centers







Soft tissue extension 7 30% 2 13% 7 70% 0.012
Complex fractures 3 13% 6 40% 4 40% 0.088
Intraarticular fractures 8 35% 7 47% 3 30% 0.719
Joint proximity (< 1 cm) 16 69% 14 93% 7 70% 0.216
Table 4 Distribution of tumor and fracture characteristics between treatment modalities
Treatment modality Number Curettage  with




Soft tissue extension 16 7 30% 9 36% 0.307
Complex fractures 13 4 17% 9 36% 0.123
Intraarticular fractures 18 6 26% 12 48% 0.092
Joint proximity (< 1 cm) 37 16 69% 21 84% 0.133
Postoperative treatment after curettage consisted of functional mobilization 
with partial weightbearing for at least 6 to 12 weeks. Weightbearing was 
increased when pain and radiographic follow-up indicated stable fusion of the 
fracture. Five patients needed additional immobilization using a (removable) 
cast for 6 to 12 weeks based on postoperative radiographs and clinical 
examination. In case of prosthetic reconstruction, immediate weightbearing 
was allowed; for allograft reconstruction, this was dependent on union as 
assessed on radiographs. 
The follow-up protocol consisted of radiography at 1.5, 3, and 6 months 
postoperatively followed by half yearly radiographs until 2 years postoperatively 
and yearly radiographs in the next years to detect local recurrences or 
complications. We performed MRI at 1, 2, 5, and 10 years postoperatively. We 
recorded local recurrences, complication rates, fracture healing, and function 
for both curettage with adjuvants and en bloc resection. Musculoskeletal Tumor 
Society (MSTS) scores were obtained to evaluate functional outcome and pain 
in the affected extremity [8]. We took the questionnaire at latest follow-up 
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(mean 101 months). MSTS scores were available for 43 patients. Five patients 
did not return the questionnaire and could not be contacted by telephone. 
A distinction between major complications requiring surgical intervention 
and minor complications demanding nonsurgical treatment was made. The 
primary oncological end point was a radiological or histological-proven local 
recurrence and, for the complication rate, failure of the prosthesis or allograft 
requiring surgical revision. Radiological signs for loosening of prostheses 
were not evaluated. We evaluated several variables potentially increasing the 
recurrence and complication risk: complex or intra-articular fractures, soft 
tissue extension, and subchondral GCTB. 
Statistical analysis
Recurrence-free survival was assessed using Kaplan-Meier survival analysis and 
differences in survival between treatment groups were assessed using a log 
rank test. Local recurrence and complication rates were calculated. Univariate 
and multivariate (two variables) Cox regression analysis was performed to 
determine independent factors of influence on the recurrence and complication 
risk. Functional outcome (MSTS score) for both groups was compared with an 
unpaired t-test. We used SPSS 17.0 (SPSS Inc, Chicago, IL, USA) to perform all 
statistical analysis.
Results
No recurrences occurred in the resection group, whereas in the curettage 
group, the recurrence-free survival rates were 74% and 70% at 2 and 5 years 
postoperative, respectively (p=0.003) (Figure 2). The local recurrence rate was 
30% after curettage with adjuvants (seven of 23) and 0% after en bloc resection 
(zero of 25). Surgical margins were negative in 24 patients and marginal in 
one patient who underwent en bloc resection; no piecemeal resection was 
performed. All local recurrences were found at the site of the primary tumor 
and were confined to the bone in five patients and with an additional soft 
tissue component in two patients. No skip lesions or distant recurrences were 
reported. Because there were no recurrences in the resection cases, we only 
performed a risk analysis for local recurrence in the intralesional treatment 
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group. The only factor increasing (hazard ratio=4.8; p=0.046) recurrence risk 
after curettage with adjuvants in univariate analysis was preexisting tumor soft 
tissue extension (five recurrences in seven patients with soft tissue extension). 
Complex fractures (p=0.073), intra-articular fractures (p=0.76), or subchondral 
GCTB close to the articular cartilage (p=0.94) did not increase the recurrence risk 
(Table 5). For simple fractures without soft tissue extension, the recurrence rate 
after curettage with adjuvants was only 7% (one of 14). All but one recurrence 
occurred within the first 2 years postoperatively; mean time to local recurrence 
was 15 months (range 6–26 months; n=7). Surgical treatment of all first and 
second local recurrences is summarized in a flowchart (Figure 1). 
Figure 2 Recurrence-free survival (RFS) after curettage with adjuvants (with 95% confidence interval) 
and en bloc resection for giant cell tumor of bone with a pathologic fracture. After curettage with 
adjuvants, the RFS was lower than after resection (p = 0.003) and was estimated at 74% and 70% at 2 
and 5 years postoperatively, respectively. After resection, the RFS was 100%.
The major complication rate was 4% after curettage with adjuvants (one of 
23) and 16% after en bloc resection (four of 25). The one major complication in 
the intralesional treatment group was a pathologic fracture of the distal femur 
that did not heal after immediate curettage and cementation and developed 
a pseudarthrosis; this was successfully treated with cancellous bone graft and 
postoperative immobilization with a plaster cast. Minor complications after 
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Table 5 Factors of influence on recurrence and complication risk 





Influence on recurrence risk after curettage with adjuvants (n = 23)
Multivariate analysis
Soft tissue extension 7 5 4.6 1.0-21 0.053
Complex fracture 4 3 3.8 0.83-17 0.086
Univariate analysis
Soft tissue extension 7 5 4.8 1.0-22 0.046
Complex fracture 4 3 4.0 0.88-18 0.073
Intraarticular fracture 6 2 1.2 0.07-34 0.76
Joint proximity (< 1 cm 
from joint cartilage)
16 5 1.1 0.15-7.6 0.94
Influence on complication risk after en bloc resection (n = 25)
Univariate analysis
Soft tissue 9 0 1.8 0.25-13 0.55
Complex fracture 9 0 0.93 0.09-9.2 0.95
Intraarticular fracture 12 0 0.44 0.04-4.3 0.48
Joint proximity 21 0 0.27 0.04-1.9 0.19
curettage with adjuvants (three of 23; 13%) were chronic pain, superficial 
wound infection, and deep venous thrombosis; all were successfully treated 
nonsurgically. Fracture healing occurred in 22 of the 23 patients treated with 
curettage and adjuvants after a mean of 12 weeks (range 6–48 weeks) either 
after immediate curettage with adjuvants (n=14) or after treatment with external 
fixation (n=2) or a plaster cast (n=6) before surgery. Fracture healing was assessed 
by conventional radiographs and clinical examination. After resection, major 
complications were reported in four patients. Two patients had aseptic loosening 
of tumor prostheses (two of 25; 8%); both were successfully revised. In one 
patient, the allograft humeral head fragmented; this was successfully replaced by 
a shoulder hemiprosthesis. One patient developed subluxation of the wrist after 
distal radius reconstruction with an autologous vascularized fibula inlay graft 
and osteosynthesis. Surgical correction was performed resulting in decreased 
ROM and persistent pain. Minor complications after resection (four of 25; 16%) 
were reduced ROM (n=3) and joint effusion (n=1). Decreased ROM improved 
after physiotherapy in one patient and was persistent in two. Complication risk 
was not increased by soft tissue extension (p=0.55), complex fractures (p=0.95), 
intra-articular fractures (p=0.48), or joint proximity (p=0.19) in univariate analysis 
(Table 5). We performed risk analysis for major complications only after resection.
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Functional ability and pain as reported by patients at latest follow-up were 
superior (p=0.013) after curettage with adjuvants when compared with 
resection. Mean MSTS score after curettage was 28 (range 23–30; n=18). 
Fourteen patients had an MSTS score over 90%, two 80% to 89%, and two 60% 
to 79%. Mean MSTS score after resection was 25 (range 13–30; n=25). Eleven 
patients had an outcome score greater than 90%, seven between 80% and 
89%, five from 60% to 79%, and two less than 60%.
Discussion
Pathologic fracture is a relatively infrequent complication of GCTB, being 
a purely osteolytic primary skeletal lesion. It was commonly believed that 
pathologic fracture was associated with a higher recurrence risk as a result 
of the expected contamination of surrounding tissues [20]. En bloc resection 
reduces the recurrence risk dramatically and has therefore been preferred as 
the primary treatment [14]. However, more recent studies could not confirm 
pathologic fractures as a risk factor for local recurrence. Furthermore, articular 
resection may result in important morbidity and functional impairment. This 
created opportunities for further studies investigating the indication for and 
outcome of curettage with adjuvants for GCTB with a pathologic fracture [6, 
7, 14]. Deheshi et al. [6] compared recurrence-free survival and functional 
outcome after curettage for both patients with and without pathologic 
fracture; outcomes were comparable. Dreinhöfer et al. [7] analyzed 10 of 15 
patients with a pathologic fracture treated with curettage and PMMA and 
reported a recurrence rate of four of 10. Jeys et al. [14] evaluated treatment 
options for different types of fractures and concluded that curettage can be 
safe for cortical breach but that discrete fractures more often require resection. 
Thus, the appropriate treatment remains controversial. To address these 
controversies in the literature, we determined (1) local recurrence rates after 
curettage with adjuvants or en bloc resection; (2) complication rates after both 
surgical techniques and whether fracture healing occurred after curettage 
with adjuvants; and (3) functional outcome after both treatment modalities for 
GCTB with a pathologic fracture. 
Our study has several limitations. First, patients were treated in three centers 
where indications for surgical treatment differed, possibly resulting in selection 
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and treatment bias. This multicenter approach was needed to accrue sufficient 
numbers of cases of this relatively infrequent occurrence with its variable 
presentation. Indications for curettage were more extended in Center 1 than 
in the other centers; a majority of cases with soft tissue extension and/or intra-
articular or complex fractures in this center were treated with curettage and 
adjuvants. It is therefore probable that the high overall recurrence rate after 
curettage is a result of selection bias based on different indications for curettage 
or resection. Second, long-term clinical outcomes of GCTB with pathologic 
fracture were not compared with outcomes of GCTB without pathologic fracture. 
We can draw conclusions from our results as to which surgical treatment option 
would be most favorable in the presence of a pathologic fracture, but a relative 
interpretation of results on local recurrences, complications, and functional 
outcome is possible only considering available literature. Third, patients 
received different local adjuvants after curettage; the creation of subgroups 
for local adjuvants could have addressed this inconsistency. However, because 
treatment groups were small, statistics would not be reliable. Furthermore, only 
two patients did not receive PMMA as cavity fill-up and hydrogen peroxide was 
used as an alternative for phenol in only three patients. We therefore compared 
an en bloc approach with an intralesional approach with due consideration of 
small differences regarding local adjuvant treatment. 
In our study, the local recurrence rate for primary GCTB with a pathologic 
fracture was higher after curettage with adjuvants and lower after en bloc 
resection when compared with recent literature [2–4, 9, 15, 16]. However, we 
also treated difficult cases with curettage plus adjuvants; this probably resulted 
in the relatively high recurrence rate after curettage. If we consider only simple 
fractures without soft tissue extension, the recurrence rate was only 7%, 
which is even lower than recurrence rates reported in the literature (Table 6). 
The pulmonary metastasis rate was comparable to that previously reported 
in the literature (0%–4%) [16]. Therefore, we do not believe the relatively 
high recurrence rate affected the metastasis rate. Soft tissue extension is a 
known risk factor for local recurrence [2, 3, 21]; this was confirmed in our risk 
analysis. Regression analysis showed a higher recurrence risk only for patients 
with preexisting soft tissue extension (five of seven). Performing a thorough 
curettage is technically challenging in the presence of a pathologic fracture and 
soft tissue mass, because there is no adequate local adjuvant available that is 
applicable on soft tissues without inducing severe tissue necrosis. In principle, 
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each dislocated fracture can also induce contamination of surrounding soft 
tissues. Complex fractures indeed had a high recurrence rate after curettage 
with adjuvants (three of four) and intralesional treatment was insufficient 
to obtain immediate local control. In these cases, en bloc resection can be 
considered to improve local control. In the near future, systemic targeted 
neoadjuvant therapy with receptor activator of nuclear factor kappa-B ligand 
inhibitor denosumab may facilitate wider indications for curettage in these 
cases. Such treatments result in calcification in GCTB and affected soft tissues, 
facilitating surgical removal through curettage and application of adequate 
adjuvants (e.g. phenol, PMMA) [17, 25]. Intra-articular fractures did not 
demonstrate a higher recurrence rate after curettage with adjuvants (two of 
six). In the literature, intra-articular pathologic fractures were often resected as 
a result of technical difficulties in performing curettage and a presumed high 
risk for local recurrence [9, 16]. Likewise, in our series, 12 of 18 patients with an 
intra-articular fracture underwent primary resection. However, the recurrence 
risk was not influenced by the presence of an intra-articular fracture when 
treated with curettage plus adjuvants. Curettage can therefore be considered 
a feasible treatment option for intra-articular fractures. Subchondrally located 
GCTB had a similar acceptable recurrence rate after curettage with adjuvants 
(five of 16). Subchondral bone stock may be augmented by cancellous bone 
grafting before applying PMMA to prevent damage to the articular cartilage by 
the heat of the bone cement. Within our study population, this was performed 
only in case of an intra-articular fracture or complete loss of subchondral bone 
stock. A layer of approximately 1 cm is considered sufficient. Subsequent 
local recurrences were only reported in patients who underwent recurettage 
for a local recurrence, not for those who underwent resection (Figure 1). 
This indicated local recurrences after GCTB with a pathologic fracture can be 
successfully treated with en bloc resection. 
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The major complication rate was higher after resection when compared with 
curettage with adjuvants (16% versus 4%). In the literature, complications 
were even more frequent after resection and reconstruction with allograft or 
tumor prosthesis when compared with our results (e.g. allograft fracture 16%, 
nonunion 19%, aseptic loosening prosthesis 19%, periprosthetic infection 11%–
34%) [1, 12, 13, 16, 19, 22], but only few articles have reported on complications 
after surgical treatment for GCTB with a pathologic fracture in specific [6, 7, 14]. 
In one study, it has been postulated that the complication rate for GCTB with 
and without pathologic fractures is comparable [6]. As mentioned, we did not 
evaluate data on complications after treatment of GCTB without a pathologic 
fracture in this study. Multivariate regression analysis showed the complication 
risk after resection was independent of the complexity of fractures, soft tissue 
extension, intra-articular fractures, or joint proximity; the complication risk is 
thus inherent in the surgical treatment itself. 
As expected, higher MSTS scores were reported after curettage with adjuvants 
(range 23–30) when compared with resection (range 13–30). Functional 
outcome after both treatment modalities was comparable to outcomes 
described in the literature [7, 8, 26]. However, wide variations in function after 
resection possibly make this finding less clinically relevant. Outliers with a poor 
function were patients with multiple surgical interventions for recurrences 
and/or complications; the number of surgical interventions should therefore 
be minimized. 
The observations from our multicenter experience suggest a higher overall 
local recurrence rate after curettage with adjuvants for GCTB with a pathologic 
fracture when compared with resection. The local recurrence rate after 
curettage with adjuvants for simple fractures without soft tissue extension 
was not elevated. The risk for recurrence was only increased for coexistence 
of a pathologic fracture and soft tissue extension. Also, further recurrences 
only occurred after curettage with adjuvants. Fewer complications were 
reported after curettage when compared with resection. No tumor or fracture 
characteristics (including intra-articular fractures) influenced the risk for 
complications after surgery. Fracture healing was not impaired after curettage 
with adjuvants. Finally, functional outcome was better after curettage with 
adjuvants. Therefore, we believe that curettage can be considered in case 
of GCTB with a relatively simple pathologic fracture. In more complicated 
fractures, the higher recurrence risk but better functional results and lower 
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complication rates should be valued when performing intralesional treatment. 
En bloc resection should be considered in case of soft tissue extension, complex 
fractures, local recurrences, and when structural integrity cannot be regained 
after reconstruction.
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Abstract
Background Giant cell tumor of bone (GCTB) of the small bones of the hands 
and feet are rare. Small case series have been published but there is no 
consensus about ideal treatment. 
Patients and methods We performed a systematic review, initially screening 
775 titles, and included 12 papers comprising 91 patients with GCTB of the 
small bones. We then retrospectively analyzed 30 patients treated for GCTB 
of the small bones between 1987 and 2010 in five specialized centers. We 
evaluated the rate of complications and recurrence as well as the factors that 
influenced their functional outcome.
Results The rate of recurrence in literature was found to be 72% (18 of 25) after 
curettage, 13% (2 of 15) after curettage with adjuvants, 15% (6 of 41) after 
resection and 10% (1 of 10) after amputation. In this study, primary treatment 
was curettage in six, curettage with adjuvants (phenol or liquid nitrogen with 
or without polymethylmethacrylate (PMMA)) in 18 and resection in six. At a 
mean follow-up of 7.9 years (2 to 26) the rate of recurrence was 50% (n=3) 
after curettage, 22% (n=4) after curettage with adjuvants and 17% (n=1) after 
resection (p=0.404). The only complication was pain in one patient, which 
resolved after surgical removal of remnants of PMMA. We could not identify any 
individual factors associated with a higher rate of complications or recurrence. 
The mean postoperative Musculoskeletal Tumor Society scores were slightly 
higher after intralesional treatment including curettage and curettage with 
adjuvants (mean 29; range 20–30) compared with resection (mean 25; range 
15–30) (p=0.091). 
Conclusions Repeated curettage with adjuvants eventually resulted in the cure 
for all patients and is therefore a reasonable treatment for both primary and 
recurrent GCTB of the small bones of the hands and feet.




Giant cell tumor of bone (GCTB) is a relatively common benign lytic lesion that 
accounts for 4% to 5% of primary bone tumors and almost 20% of benign 
bone tumors [1]. It occurs mainly between the ages of 30 and 50 years and is 
slightly more common in women [2, 3]. The most common sites are the meta-
epiphyseal regions of the long bones (85%), with more than 50% located in 
the distal femur, proximal tibia and distal radius [4]. GCT of the axial skeleton 
accounts for a further 10% [2, 4]. It is rare in the small bones of the hands 
and feet (between 1.7% and 5% of all GCT) [5-11]. The differential diagnosis 
includes enchondroma, fibrous dysplasia, aneurysmal bone cyst, osteomyelitis 
and brown tumor from hyperparathyroidism. 
The standard treatment of lesions in the long bones is curettage, often 
with local adjuvants such as phenol, liquid nitrogen (cryosurgery) and/or 
polymethylmethacrylate (PMMA) to reduce the recurrence rate, which has 
been reported from 12% to 34% [12-16]. More aggressive lesions of the long 
bones with soft tissue extension, pathologic fracture or involvement of joints 
may be treated by en bloc resection [14, 16]. 
Only a few studies of GCTB of the small bones have been published. As most 
are single case reports there is no consensus about the preferred treatment, 
which ranges from curettage (with or without adjuvants) to en bloc resection 
and even amputation. Local recurrence rates anywhere between 0% and 100% 
have been reported after surgical treatment [6-8, 17]. 
Most recurrences occur within two years of surgery, and en bloc resection has been 
shown to result in a lower rate of recurrence (0% to 50%) [6-8, 18, 19]. However, 
reconstruction after resection may be difficult in cases of multicentric GCTB of 
the small bones, which has been reported in 7% to 18% of cases [5, 20]. Curettage 
without adjuvants may not afford complete tumor removal, resulting in a higher 
rate of recurrence (0% to 100%) [6, 8, 17, 21, 22]. Radiation-induced sarcoma 
has been reported in 5% to 10% of patients receiving radiotherapy as adjuvant 
treatment, and it is therefore not recommended for primary lesions [4, 8]. 
The aims of this multicenter study were first to perform a systematic literature 
review of the surgical treatment of GCTB of the small bones. Secondly, we aimed 
to evaluate the rates of complication and recurrence and attempt to define any 
association between patient and tumor characteristics and functional outcome 
after different surgical approaches.
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Patients and methods
We performed a systematic search of the literature on GCTB of the small bones 
published between 1 January 1990 and 17 January 2011. Search terms and 
MeSH headings used were ‘giant cell tumors’, ‘GCT’, ‘small bones’, ‘hand bones’, 
‘foot bones’, and all the individual small bones separately. We identified 775 
unique titles in PubMed, EMBASE, Web of Science and Academic Search 
Premier. All titles and abstracts were screened by two reviewers (VCO, LH). 
Inclusion criteria were case series only published after 1990 in English, Dutch, 
Portuguese, French, Italian or German; other languages were excluded. 
Furthermore, we excluded papers that focused purely on radiological and/or 
histopathological assessment of GCTB of the small bones, reviews without new 
clinical cases, and papers on GCTB of the long bones, giant cell tumor of soft 
tissue (GCT-ST), diffuse-type giant cell tumor (Dt-GCT) and giant cell tumor of 
the tendon sheath (GCT-TS). After review of the 775 titles, 42 abstracts were 
screened, of which 23 full-text articles were assessed. Full text assessment 
resulted in 11 further exclusions, leaving a total of 12 papers for systematic 
review (Figure 1) [6-9, 17-19, 21-25]. 
In addition we retrospectively reviewed 31 consecutive patients with primary 
GCTB of the small bones from a total of 570 consecutive patients with GCTB 
(5.4%) treated between 1987 and 2010 in the authors’ five tertiary referral 
centers for orthopedic oncology. One patient with a malignant GCTB after 
local recurrence was excluded. The 30 remaining patients had a mean follow-
up of 7.9 years (range 2–26; median 5.2). No patient was lost to follow-up. 
There were 17 men and 13 women with a mean age of 29.6 years (mean 
13–68) (Table 1). As primary treatment, six patients underwent curettage, 18 
curettage plus adjuvants (nine phenol, five liquid nitrogen, two phenol and 
PMMA, one liquid nitrogen and PMMA and one PMMA), and six resection (five 
en bloc and one marginal) (Table 2). Thorough curettage was followed by three 
cycles of phenolization and neutralization with ethanol, or by three cycles of 
liquid nitrogen, and subsequently by filling the cavity with either bone graft 
or PMMA. A high-speed burr was used in nine patients treated with curettage 
and adjuvants (Table 2). In the Leiden University Medical Center, Leiden, the 
Netherlands (center 1) and the Centro Hospitalar do Porto – Hospital Santo 
Antonio, Porto, Portugal (center 5) musculoskeletal pathologists graded the 
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GCTB histologically, but this did not influence the choice of surgical treatment. 
As extension of the tumor can be evaluated very accurately on MR imaging, 
the purely radiological grading system of Campanacci et al. [1] was not used. In 
practice, every GCTB is treated according to its tumor characteristics, such as 
site, the presence of a pathologic fracture and/or soft tissue extension, instead 
of according to a specific grading system.
Figure 1 Flowchart of systematic literature search
*Including but not limited to: GCTB of the long bones (mainly distal radius), GCTB of the axial skeleton, 
multifocal GCTB, malignant GCTB, other bone and soft tissue tumors (e.g. Dt-GCT, GCT-TS, chondroblas-
toma, chondrosarcoma, osteosarcoma), GCTB in animals etc.
**Excluded languages were Chinese and Turkish.
27935_Heijden.indd   110 25-06-14   11:32
5





   Male 17 57
   Female 13 43
Site
   Foot 18 60
   Hand 12 40
Treatment
   Curettage 6 20
   Curettage with adjuvants 18 60
   Wide or marginal resection 6 20
Tumor characteristics
   Soft tissue extension 7 23
   Pathologic fracture 6 20
Complications 1 3
Local recurrence
   1st recurrence 8 27
   2nd recurrence 2
   3rd recurrence 1
   4th recurrence 1
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Data including age, gender, tumor site, soft tissue extension, pathologic 
fracture, surgical treatment, local adjuvants, local recurrence, complications and 
further surgical treatment were collected. All data were complete. Functional 
outcome was assessed at final follow-up using the Musculoskeletal Tumor 
Society (MSTS) scoring system [26] and was available for 22 patients (73%). The 
remaining patients were discharged from follow-up (n=1), relocated (n=5) or 
had died (n=2), and therefore could not be reached by telephone and/or post.
Statistical analysis
Recurrence-free survival was calculated for the three different treatment 
groups using Kaplan-Meier survival analysis with 95% confidence intervals 
(CI), and differences between the groups were analyzed using the log rank 
test. Associations between different patient and tumor characteristics and the 
resulting recurrence rates were calculated using Pearson’s chi-squared test 
and Fisher’s exact test. Unpaired t-tests were used to compare MSTS scores 
between different treatment groups. The results were analyzed statistically 
with SPSS 20.0 (IBM SPSS Statistics, Chicago, Illinois) and a p-value < 0.05 was 
used to denote statistical significance.
Results
Data including number of cases, tumor localization, treatment, reconstruction, 
local recurrences and complications from the studies included in our 
systematic review are listed in Table 3. Within the 12 included studies, a total of 
25 patients were treated with curettage alone [6, 8, 17, 21, 22], 15 were treated 
with curettage and adjuvants [6, 8, 9, 25] and 41 were treated with resection 
[6-8, 18, 18, 22-24]. A further ten patients from the studies were treated with 
amputation [6-8, 17, 21, 22, 25]. Results from our systematic review showed 
that the highest mean rate of recurrence occurred after curettage alone (72%; 
range 0%–100%; n=18) followed by resection (15%; range 0%–50%; n=6) and 
curettage with adjuvants (13%; range 0%–50%; n=2). The lowest recurrence 
rates were reported after amputation (10%; range 0%–100%; n=1); however, 
this is associated with marked functional and aesthetic impairment and is only 
indicated rarely as a salvage procedure. 
27935_Heijden.indd   116 25-06-14   11:32
5









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































27935_Heijden.indd   118 25-06-14   11:32
5



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































27935_Heijden.indd   120 25-06-14   11:32
5


























































































































































































































































































































































































































































































































































































































































27935_Heijden.indd   121 25-06-14   11:32
Chapter 5
122
In our 30 patients the anatomical distribution of the 12 cases of GCTB in the 
bones of the hand was first, second and third metacarpal bones (two each), 
fourth and fifth metacarpal bones (one each), scaphoid (two), and middle and 
distal phalanges (one each). The anatomical distribution of the 18 GCTB in the 
bones of the foot was: talus (five), calcaneus (three), cuneiform (two), cuboid 
(one), first and fourth metatarsal bones (two each), and second, third and fifth 
metatarsal bones (one each). No patient had a multicentric GCTB. There was soft 
tissue involvement in seven patients (four in small bones of the hand and three 
in the foot) and a pathologic fracture in six (four in small bones of the foot and 
two in the hand; two patients had both soft tissue extension and a pathologic 
fracture): only one of these underwent resection. None of the patients had any 
intra-articular involvement and none had distant or pulmonary metastases. 
Two patients died respectively five and ten years after their index surgery, both 
from conditions unrelated to the GCTB. 
Overall, eight patients had a first local recurrence (three in metatarsal bones, 
three in metacarpal bones, one in a phalange and one in the talus), with a mean 
time to recurrence of 14 months (range 6–31) (Figure 2). The rate of recurrence 
was 50% (three of six) in patients treated with isolated curettage, 22% (four of 
18) after curettage in conjunction with local adjuvants and 17% (one of six) 
after resection (Table 2). The Kaplan-Meier five-year estimated recurrence-free 
survival was 50% (95% confidence interval (CI) 1.6–2.4) for curettage, 76% (95% 
CI 1.7–2.2) for curettage with adjuvants and 80% (95% CI 1.6–2.3) for resection 
(p=0.404; log rank test) (Figure 3). The five-year estimated recurrence-free 
survival was 69% (95% CI 1.8–2.2) for all intralesional treatments and 80% (95% 
CI 1.6–2.3) for resection (p=0.661; log rank test). Surgical treatment of the first 
local recurrence consisted of repeated curettage with adjuvants (three with 
phenol and four with PMMA) and repeated resection (one). One patient, who 
had a total of four local recurrences, is currently free of disease at 26 years after 
repeated curettage procedures with variations of phenol, bone grafting and 
PMMA (Table 2).
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Figure 2 GCTB of the 3rd metatarsal bone of the right foot in a 22-year old female patient. (A) Preoperative 
conventional AP radiograph demonstrating an expansive lytic lesion without cortical disruption in the 
metaphysis of the 3rd metatarsal bone of the right foot. (B) Conventional AP radiograph taken 3 months 
postoperatively, after primary curettage, phenol and bone grafting. (C, D) Conventional AP radiograph 
and T2-weighted MR imaging taken 1 year postoperatively, revealing signs of a local recurrence with 
secondary aneurysmal bone cysts. (E) Conventional AP radiograph 3 months after repeat curettage, 
phenol and bone grafting for local recurrence. (F) Conventional AP radiograph 1 year after treatment for 
local recurrence (curettage, phenol and bone grafting), demonstrating complete incorporation of the 
bone graft. At a final follow-up of 4 years, there are no signs of further recurrences or pulmonary 
metastasis.
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Figure 3 Kaplan Meier survival curve showing the estimated 5-years recurrence free survival after 
curettage (0.50; black line), curettage with adjuvants (0.75; light gray line) and resection (1.0; dark gray 
line) for GCTB of the small bones (p=0.160).  
There was no statistical association between the use of different local adjuvants 
and the respective recurrence rate (p=0.28; chi-squared test) or the number of 
recurrences (p=0.40; chi-squared test). The same held true for recurrence rate 
and type of intervention (p=0.12; chi-squared test), pathologic fracture (p=0.62; 
Fisher’s exact test) and soft tissue extension (p=0.31 Fisher’s exact test). 
The only minor complication reported was pain caused by remnants of PMMA 
in one patient that resolved completely after surgical removal of the PMMA 
fragment. No other complications were reported in this series.
The mean MSTS for functional outcome at final follow-up was 25 (range 15–30) 
for the four patients who underwent resection and 29 (range 20–30) for the 
18 treated by curettage with or without adjuvants (p=0.091; unpaired t-test) 
(Table 2).
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Discussion
GCTB of the small bones are believed to behave more aggressively than GCTB 
of the long bones [27-29]; high recurrence rates have been described after 
different types of surgery [6, 8, 17, 21]. 
Local recurrence rates from this study were comparable to those described in 
the literature: 50% versus 72% for curettage, 22% versus 13% for curettage with 
adjuvants and 17% versus 15% for resection. The rate of recurrence of GCTB of 
the small bones in the literature and in our group were at the higher end of the 
ranges reported in the literature for GCTB of the long bones, which are 27% 
to 65% after curettage [1, 12], 12% to 34% after curettage with adjuvants [12, 
13, 16] and 0% to 12% after resection [12, 14]. Risk factors for recurrence such 
as soft tissue extension were not more common (23%) than in those reported 
for long bones (22% to 25%) [15, 30]. Complete removal of GCTB of the small 
bones can be difficult for both intralesional and wide resections, which may 
be explained by the technically challenging anatomical locations, the difficulty 
of applying adequate local adjuvants due to anatomical restrictions, their 
very rare incidence, which is likely to result in the surgeon’s relative lack of 
experience. The differences between the rates of recurrence with the various 
treatment options in our study were not statistically significant and our sample 
size was too small to detect differences after the use of various local adjuvants. 
The mean time to local recurrence in our series was also consistent with the 
literature about GCTB of both long and small bones: only one patient had a first 
recurrence more than two years after surgery (Tables 2 and 3). 
En bloc resection and ray amputation have been advocated in technically 
challenging cases, as they are believed to minimize the risk of recurrence [6, 
8, 17, 21, 22, 25, 27]. However, similar recurrence rates have been reported 
for both resection (15%) and curettage with adjuvants (13%), indicating 
that resection is not necessarily better [18, 23]. Wide resection may also be 
associated with reduced function of the affected hand or foot. Reconstruction 
of a defect is often required such as bone grafting, osteosynthesis or joint 
replacement, thereby increasing the duration of rehabilitation and the risk of 
late complications [18, 23, 24, 31]. 
In this multicenter series the recurrence rate after curettage with adjuvants 
(22%) was somewhat higher than the mean rate of recurrence reported in the 
literature (13%) [6, 8, 9, 25] for GCTB of the small bones but remained within 
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the range reported after curettage with adjuvants for GCTB of the long bones 
(12% to 34%) [12-16]. Furthermore, in our study all first recurrences except one 
were successfully treated with repeated curettage and local adjuvants, thereby 
avoiding a more aggressive surgical approach. Finally, all patients were free of 
disease. This suggests that curettage with adjuvants can be a feasible treatment 
option for both primary and recurrent GCTB of the small bones. 
Neither the type of local adjuvant or surgical treatment nor the presence of a 
pathologic fracture or soft tissue extension was associated with a higher risk of 
recurrence. To our knowledge, such associations for GCTB of the small bones 
have not previously been studied. In the literature, authors often referred to 
the potentially more aggressive behavior of GCTB of the small bones, which 
reflect the higher rates of multicentricity (7% to 18%) [5, 20] compared with the 
rate of multicentricity in GCTB of the long bones (approximately 1%) [28]. Of 
all multicentric GCTB, up to 61% have been reported in the small bones of the 
hands and feet [28, 29]. Interestingly, our study does not describe any patient 
with multicentric GCTB and are unable to corroborate previous reports. 
Only a few studies reported post-operative complications, which included 
a reduced range of movement and wound necrosis after curettage with 
adjuvants [8, 9, 31]. We encountered only one minor complication of pain after 
curettage with PMMA due to cement remnants. 
The role of different local adjuvants should be considered, considering the 
complications they may cause. Phenol in high concentrations is toxic to soft 
tissues and some studies have questioned its efficacy [15, 16], whereas others 
reported no difference between phenol and other adjuvants [32, 33]. The use 
of a high-speed burr allows the removal of tumor cells from the walls of the 
tumor cavity but also destroys healthy cancellous bone and carries the risk 
of dissemination of tumor [34]. Cryosurgery may result in thermal injury to 
surrounding healthy soft tissues, bone or cartilage [35]. PMMA is used both 
as a local adjuvant and as filling material, which is believed to substantially 
reduce the risk of recurrence due to thermal necrosis and its direct toxic effect 
on tumor cells but without producing major complications [36]. However, it is 
not always necessary to fill the defect in a small bone. Nevertheless, to reduce 
the risk of recurrence we recommend the use of local adjuvants after curettage. 
Few authors have described functional outcome after surgery for GCTB of 
the small bones [9, 18, 23, 24]. In two studies it was described as satisfactory 
or excellent but the method of assessment was not reported [18, 23]. Three 
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other studies reported a limited or normal range of movement after resection 
or curettage for GCTB of the bones of the hand [9, 17, 24]. In this study we 
assessed functional outcome using the MSTS scoring system with the results 
being slightly better after intralesional surgery than after resection. 
Our study has several limitations. First, it was retrospective and even recruiting 
from several centers, to obtain a larger group of patients, the sample size 
remained too small to comment with confidence on differences in the rates of 
recurrence after the use of various adjuvants. Second, the multicenter design 
implies that multiple treatment strategies have been applied, which may have 
resulted in selection and treatment bias. 
In conclusion, we found the lowest rate of recurrence for resection, followed 
by curettage with adjuvants. Curettage alone was consistently associated with 
the highest rate of recurrence. We were unable to identify any factors that were 
associated with a higher risk of complication or recurrence. From the literature 
en bloc resection and ray amputation are associated with functional and 
aesthetic disability and are rarely indicated as a salvage procedure. Repeated 
curettage with adjuvants eventually resulted in the cure of all patients in our 
series. Therefore, curettage with adjuvants is a feasible treatment option for 
both primary and recurrent GCTB of the small bones of the hands and feet 
(Figure 4).
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Figure 4 Flowchart of evaluation and treatment of GCTB of the small bones of the hands and feet. *With 
extra-articular pathologic fractures, preoperative fracture healing may be awaited before curettage 
with adjuvants, while immediate surgery is required with intra-articular pathologic fractures. **Attention 
should be paid to the application of local adjuvants such as phenol, alcohol and liquid nitrogen in the 
vicinity of soft tissues, because it may induce (severe) soft tissue necrosis.
27935_Heijden.indd   128 25-06-14   11:32
5
GCTB of the small bones
129
References
1. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg [Am] 
1987;69-A:106–114.
2. Balke M, Henrichs M, Gosheger G, et al. Giant cell tumors of the axial skeleton. Sarcoma 
2012;410973.
3. Werner M. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int 
Orthop 2006;30:484–489.
4. Mirra JM. Giant cell tumors. In: Mirra JM, Picci P, Gold RH, eds. Bone tumours: clinical, radiologic and 
pathologic correlations. Philadelphia: Lea and Febiger, 1989:941–1020.
5. Averill RM, Smith RJ, Campbell CJ. Giant-cell tumors of the bones of the hand. J Hand Surg Am 
1980;5:39–50.
6. Biscaglia R, Bacchini P, Bertoni F. Giant cell tumor of the bones of the hand and foot. Cancer 
2000;88:2022–2032.
7. Minhas MS, Mehboob G, Ansari I. Giant cell tumours in hand bones. J Coll Physicians Surg Pak 
2010;20:460–463.
8. Athanasian EA, Wold LE, Amadio PC. Giant cell tumors of the bones of the hand. J Hand Surg Am 
1997;22:91–98.
9. Wittig JC, Simpson BM, Bickels J, Kellar-Graney KL, Malawer MM. Giant cell tumor of the hand: 
superior results with curettage, cryosurgery, and cementation. J Hand Surg Am 2001;26:546–555.
10. Saikia KC, Bhuyan SK, Ahmed F, Chanda D. Giant cell tumor of the metacarpal bones. Indian J 
Orthop 2011;45:475–478.
11. Al-Kindi H, George M, Malhotra G, Al-Muzahmi K. An uncommon presentation of giant cell tumor. 
Oman Med J 2011;26:359–361.
12. Balke M, Schremper L, Gebert C, et al. Giant cell tumor of bone: treatment and outcome of 214 
cases. J Cancer Res Clin Oncol 2008;134:969–978.
13. Becker WT, Dohle J, Bernd L, et al. Local recurrence of giant cell tumor of bone after intralesional 
treatment with and without adjuvant therapy. J Bone Joint Surg [Am] 2008;90-A:1060–1067.
14. Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumor of the extremity: a review of 349 cases from 
a single institution. Cancer Treat Rev 2010;36:1–7.
15. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recur-
rence. Clin Orthop Relat Res 2011;469:591–599.
16. Kivioja AH, Blomqvist C, Hietaniemi K, et al. Cement is recommended in intralesional surgery of 
giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time 
of 5 years. Acta Orthop 2008;79:86–93.
17. Ropars M, Kaila R, Cannon SR, Briggs TW. Primary giant cell tumours of the digital bones of the 
hand. J Hand Surg Eur Vol 2007;32:160–164.
18. Ge J, Chen G, Zhang Z, Wan Y, Lu X. Tumor-segmental resection of hand-foot-giant cell tumor of 
bone and autologous iliac bone graft reconstruction. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 
2010;24:922–925.
19. Sanjay BK, Raj GA, Younge DA. Giant cell tumours of the hand. J Hand Surg Br 1996;21:683–687.
20. Wold LE, Swee RG. Giant cell tumor of the small bones of the hands and feet. Semin Diagn Pathol 
1984;1:173–184.
21. Ozalp T, Yercan H, Okçu G, et al. Giant-cell tumor of the hand: midterm results in five patients. Rev 
Chir Orthop Reparatrice Appar Mot 2007;93:842–847.
22. Picci P, Baldini N, Sudanese A, Boriani S, Campanacci M. Giant cell reparative granuloma and other 
giant cell lesions of the bones of the hands and feet. Skeletal Radiol 1986;15:415–421.
23. Patradul A, Kitidumrongsook P, Parkpian V, Ngarmukos C. Allograft replacement in giant cell tu-
mour of the hand. Hand Surg 2001;6:59–65.
24. Vergara HF, Ortiz DA, Martínez BH, Mosiñoz RM, Arellano JA. Hand reconstructive surgery second-
ary to giant cell tumor. Acta Ortop Mex 2010;24:345–350.
25. Kamath S, Jane M, Reid R. Giant cell tumour around the foot and ankle. J Foot Ankle Surg 
2006;12:99–102.
27935_Heijden.indd   129 25-06-14   11:32
Chapter 5
130
26. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional 
evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal 
system. Clin Orthop Relat Res 1993;286:241–246.
27. Sanjay BK, Younge DA. Giant cell tumour of metacarpal with pulmonary and skeletal metastases. 
J Hand Surg Br 1996;21:126–132.
28. Cummins CA, Scarborough MT, Enneking WF. Multicentric giant cell tumor of bone. Clin Orthop 
Relat Res 1996;322:245–252.
29. Peimer CA, Schiller AL, Mankin HJ, Smith RJ. Multicentric giant-cell tumor of bone. J Bone Joint 
Surg [Am] 1980;62-A:652–656.
30. van der Heijden L, van de Sande MA, Dijkstra PD. Soft tissue extension increases the risk of local 
recurrence after curettage with adjuvants for giant-cell tumor of the long bones. Acta Orthop 
2012;83:401–405.
31. Krajca-Radcliffe JB, Thomas JR, Nicholas RW. Giant-cell tumor of bone: a rare entity in the hands of 
children. J Pediatr Orthop 1994;14:776–780.
32. Gortzak Y, Kandel R, Deheshi B, et al. The efficacy of chemical adjuvants on giant cell tumour of 
bone: an in vitro study. J Bone Joint Surg [Br] 2010;92-B:1475–1479.
33. Dürr HR, Maier M, Jansson V, Baur A, Refior HJ. Phenol as an adjuvant for local control in the treat-
ment of giant cell tumour of the bone. Eur J Surg Oncol 1999;25:610–618.
34. Algawahmed H, Turcotte R, Farrokhyar F, Ghert M. High-speed burring with and without the use 
of surgical adjuvants in the intralesional management of giant cell tumor of bone: a systematic 
review and meta-analysis. Sarcoma 2010.
35. Bickels J, Meller I, Shmookler BM, Malawer MM. The role and biology of cryosurgery in the treat-
ment of bone tumors: a review. Acta Orthop Scand 1999;70:308–315.
36. Nelson DA, Barker ME, Hamlin BH. Thermal effects of acrylic cementation at bone tumour sites. Int 
J Hyperthermia 1997;13:287–306.
27935_Heijden.indd   130 25-06-14   11:32
5
GCTB of the small bones
131
Addendum to Chapter 5
At the time of publication of this Chapter, the 2013 WHO Classification of 
Tumors of Soft Tissue and Bone was published, with updated nomenclature 
following rapidly increasing knowledge on cytogenetic and molecular data on 
bone and soft tissue sarcoma [1]. In this classification, osteoclastic giant cell-
rich tumors were subdivided in giant cell tumor of bone (GCTB) [2] and giant 
cell lesion of the small bones (GCLSB) [3]. 
Chapter 5 of this thesis describes GCTB in its very rare location in the small 
tubular bones of the hands and feet (1.7-5%) [4-6]. Patients with a tumor that 
was histopathologically identified as giant cell reparative granuloma at the 
time of diagnosis, nowadays described as giant cell lesion of the small bones, 
were not included in the study of Chapter 5. Furthermore, studies included in 
the systematic review in Chapter 5 included only GCTB of the small bones of 
the hands and feet; studies on giant cell reparative granuloma and other giant 
cell-rich tumors were not included.
A limitation of Chapter 5 and previously published articles on GCTB of the 
small bones of the hands and feet is that retrospective data were used and 
histopathology was not revised with respect to recent criteria for diagnosis 
of bone and soft tissue tumors. In the future, especially for multicenter and 
international studies, revision of histopathological diagnoses is recommended, 
to have a methodological sound (i.e. uniform) classification of the 
histopathological diagnosis.
However, in the presented study of Chapter 5, the authors found no implications 
for treatment and prognosis, even though GCTB had an intermediate, locally 
aggressive behavior with an increased tendency of developing multicentricity 
and metastases in the small bones compared to the long bones. Namely, both 
giant cell-rich tumors were best treated with curettage with local adjuvants 
resulting in similar recurrence rates and with the possibility of repeating 
curettage in case of recurrent disease.
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Abstract
Purpose Evaluation of recurrences, complications and function at mid-term 
follow-up after curettage for sacral giant cell tumor of bone (GCTB).
Methods We retrospectively studied all 26 patients treated for sacral GCTB 
in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6-229) 
months. All patients underwent intralesional excision, 21 with local adjuvants, 
five radiotherapy, three IFN-α, one bisphosphonates. Functional outcome was 
assessed using Musculoskeletal Tumor Society (MSTS) score. Statistics were 
performed with Kaplan-Meier, Cox regression, log rank and Mann-Whitney U.
Results Recurrence-rate was 14/26 after median 13 (3-139) months and was 
highest after isolated curettage (4/5). Soft tissue masses >10cm increased 
recurrence risk (HR=3.3, 95%CI=0.81-13, p=0.09). Complications were reported 
in 12/26 patients. MSTS was superior in patients without complications (27 vs. 
21; p=0.024).
Conclusion Recurrence rate for sacral GCTB was highest after isolated curettage, 
indicating that (local) adjuvant treatment is desired to obtain immediate local 
control. Complications were common and impaired function.




Giant cell tumor of bone (GCTB) is a benign, locally aggressive primary bone 
tumor, mostly affecting meta-epiphyseal regions of long bones. The sacrum is 
the most affected bone of the axial skeleton, accounting for 2-8% of all GCTB [1-
3]. Patients present with lower back pain, frequently radiating to the legs, and 
sometimes with bladder, rectal or sexual dysfunction. Surgical management 
of sacral GCTB is challenging because of large size due to late discovery, spinal 
instability and involvement of sacral nerve roots. Cortical destruction and soft 
tissue extension by expansive tumor growth are common [4]. Because of its 
rareness, only small case series on sacral GCTB have been published [1-3,5-12], 
and optimal treatment remains under debate. 
Selective arterial embolization can be performed to prevent extensive 
intraoperative hemorrhage [1,13], or repeatedly as primary treatment [1,14-16]. 
Radiation therapy may be given as adjuvant treatment for residual or recurrent 
disease; only rarely as primary treatment for inoperable tumors [1,3,10,17]. On 
the long term, it may result in radiation induced sarcoma (3-11%) [10,18].
In case of extended involvement of at least the proximal part of the sacrum, 
total sacrectomy has been advocated, as recurrence rates are low (0-
8%) [1,2,5,6,8,19]. However, as there is a high risk of infections (18-46%), 
neurological deficits (24-38%) and bladder, rectal or sexual dysfunction (18-
47%) [8,20], it could be considered overtreatment of this benign tumor. Partial 
sacrectomy is less mutilating and can be performed when distal from S2 [1], 
as pelvic support remains intact. Damage to lower sacral nerve roots results 
in less severe neurological complications compared with upper sacral nerve 
roots. Recurrence rates after marginal resection without local adjuvants range 
from 18-54% [3,6,19]. 
Curettage is less invasive but higher recurrence rates (10-75%) are reported 
[1-3,6,7,10-12,19] compared to GCTB of long bones, because of difficulties 
in complete tumor removal at this anatomical site and in application of local 
adjuvants including phenol or liquid nitrogen [3,11]. Advantages of curettage 
are salvage of nerve roots and visceral structures and maintenance of pelvic 
support. 
To summarize, sacral GCTB is a difficult condition, none of current treatment 
options are satisfactory and possibilities for using (local) adjuvant treatment 
with intralesional surgery need to be further explored. The aim of this study 
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was to evaluate mid-term results including recurrences, complications and 
functional outcome after intralesional excision of sacral GCTB in one country. 
Methods 
In this nationwide retrospective study, we reviewed all 28 patients treated for 
sacral GCTB between 1990 and 2010, via the Netherlands Committee on Bone 
Tumors. Two patients were excluded due to inoperability; one with extremely 
vascularized GCTB underwent repetitive selective arterial embolization; one 
with morbid obesity underwent primary radiation therapy. We included all 26 
patients that underwent surgery (15 females). Median age was 41 years (range 
14-66). All patients had a minimum follow-up of two years, except one patient 
who died from disease six months after surgery. Median follow-up was 98 
months (range 6-229).
Data were collected from medical records, imaging and histopathological 
reports: age, gender, preoperative symptoms, localization, tumor size, 
cortical destruction, soft tissue extension, involvement of sacral nerve roots, 
preoperative embolization, surgical treatment, (local) adjuvant treatment, 
reconstruction, recurrences, metastases, postoperative symptoms and 
complications, functional outcome and duration of follow-up.
Preoperative selective arterial embolization was performed in 19 patients. All 
patients underwent intralesional excision. In all but one patient, a standard 
midline posterior approach was used. Exposed sacral nerve roots were 
carefully detached and the cavity thoroughly curetted. In eight patients 
with extensive cortical destruction and/or large presacral soft tissue masses, 
no chemical adjuvant was used. Surgical margins were extended in four 
patients with anterior sacral wall excision (ASWE), performed with burring, 
milling or piecemeal excision of the anterior sacral wall after detachment and 
protection of sacral nerve roots. Two-stage curettage with combined anterior 
and posterior approach was indicated in five patients due to large presacral 
tumor masses (>10cm). One patient had an anterior approach because of 
ventral localization. Local adjuvants were liquid nitrogen (n=9), phenol (n=4), 
argon beam coagulation (n=3) and polymethylmethacrylate (PMMA; n=3). Two 
patients underwent adjuvant radiotherapy for suspected incomplete curettage. 
One patient underwent preoperative radiotherapy for suspected metastasis 
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of unknown primary tumor, before histopathological confirmation of GCTB 
after resection. Three patients received adjuvant IFN-α, one bisphosphonates. 
Median duration of surgery was 3.6 hours (range 1.5-11) for posterior and 6.2 
hours (range 5.3-8) for combined anterior and posterior approaches. Median 
estimated blood loss was 1,600ml (range 350-32,000) for posterior and 8,500ml 
(range 4,500-25,000) for combined anterior and posterior approaches. Despite 
selective arterial embolization, four patients had >12,000ml blood loss (two 
posterior and two combined approaches). 
After tumor removal, stability of remaining sacral segments and its potential for 
weight-bearing was assessed. When at least S1 remained intact after surgery, 
weight-bearing capacity was considered sufficient and no reconstruction 
was performed. Stability and weight-bearing capacity were insufficient 
in eleven of 20 patients with S1 involvement. Posterior stabilization with 
lumbopelvic fixation with PMMA or bone grafts was indicated in three patients, 
reconstruction with bone grafts in seven and with PMMA in one. Lumbopelvic 
instrumentation consisted of transpedicular screws L4-L5 with rods connected 
to 2-3 iliac screws and at least one rod connector (Figure 1). Double rods were 
used in case of large sacral destruction without remaining proximal sacral 
bone (S1-S2). In all patients, special attention was paid to soft tissue coverage; 
routine transposition of gluteal muscles was performed, but no free flaps were 
deemed necessary. 
In patients with sacral instability, postoperative treatment consisted of 
immobilization in a brace for 3-6 months. After lumbopelvic fixation and/or 
ingrowth of bone grafts, patients could mobilize immediately.
Current follow-up protocols generally consist of radiographs every six months 
up to two years and annually up to 10 years after surgery to detect recurrences 
or complications. Magnetic resonance (MR) imaging may be performed after 1, 
2, 5 and 10 years. In this study, all available imaging was reviewed. Functional 
outcome was evaluated with Musculoskeletal Tumor Society (MSTS) scores at 
latest follow-up [21], which were available from 22 patients and could not be 
obtained from three who died and one who relocated.
27935_Heijden.indd   140 25-06-14   11:32
6
GCTB of the sacrum 
141
Figure 1 (a, b) Preoperative sagittal T1-weighted MR images and T1-weighted SPIR images with fat 
suppression after gadolinium administration in a 58-year old female patient with centrally located 
primary GCTB in S1-S3. (c, d) Anteroposterior and lateral conventional radiographs after repeated 
intralesional surgery for a first recurrence and reconstruction with transpedicular screws L3-L5 with rods 
connected to six iliac screws, three rod connectors and bone grafts. The patient is continuously disease 
free at 10 years follow-up.




Kaplan-Meier survival analysis was performed to assess recurrence-free 
survival; log-rank to compare different treatments. Univariate Cox regression 
was performed to evaluate risk factors for recurrence. Mann-Whitney U tests 
were performed to compare numerical results.
Results 
GCTB was confined to upper sacral segments (S1-S2) in fifteen patients, upper 
and lower sacral segments in ten, and lower sacral segments (S3-S5) in one; five 
had extension into the ilium (Tables 1 and 2). Sacral nerve roots were involved 
in 20 patients. Twenty-five had cortical destruction. Twenty-three had soft 
tissue extension. Preoperative symptoms included pain in all patients, sensory 
impairment in 11, motor deficits in six, bladder dysfunction in five and rectal 
dysfunction in two (Tables 1 and 2).
Table 1 Patient and tumor characteristics
n %
Localization
S1 (+ ilium) 7 (3) 27
S1-S2 8 30
S1-S3 (+ilium) 2 (1) 8





S1 involvement 16 62
     Complete (>75) 8 31
     Over midline (51-75%) 6 23
     Until midline (26-50%) 5 19
     In sacral wing (≤25%) 1 4
     No involvement of S1 6 23
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Cortical destruction a 25 96
Extensive destruction both cortices (>75%) 9 36
Extensive destruction one cortex (>75%) 3 12
Moderate destruction both cortices (50-75%) 5 20
Moderate destruction one cortex (50-75%) 3 12
Minor destruction both cortices (<50%) 2 8
Minor destruction one cortex (<50%) 3 12
SI joint destruction b 16 62
Ingrowth into ilium or vertebra (L5) b 10 38
Soft tissue extension 23 88
<1 cm 8 35
1-5 cm 7 30
5-10 cm 3 13
10-15 cm 4 18
>15 cm 1 4
Sacral nerve root involvement 15 58
S1 5 33
S1-S2 (bilateral) 3 (3) 20
S1-S4 (bilateral) 1 (1) 7
S2 (bilateral) 2 (1) 13
S2-S3 (bilateral) 3 (1) 20
S3-S5 (bilateral) 1 (1) 7
Number of sacral nerve roots involved 15 58
1 sacral nerve root (bilateral) 7 (1) 47
2 sacral nerve roots (bilateral) 5 (3) 33
3 sacral nerve roots (bilateral) 2 (2) 13
4 sacral nerve roots (bilateral) 1 (1) 7
Preoperative complaints
Pain 26 100
Sensory impairment 11 42
Loss of motor function (e.g. dropped foot) 6 23
Bladder dysfunction 5 19
Rectal dysfunction 2 8
aEither both anterior and posterior sacral cortices were affected, or the anterior or posterior sacral cortex
bThis includes all sacro-iliac joints and os ilium that were affected (i.e. one or two sides in every patient)
Table 1 continued
n %
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Two patients had residual GCTB confirmed on postoperative MR imaging 
three months after surgery; both underwent adjuvant radiotherapy (50-60 
Gy). Fourteen of 26 (54%) patients had recurrence after median 13 months 
(range 3-139); one was a soft tissue recurrence (Table 3). Two years recurrence-
free survival was 20% for isolated curettage and 65% for curettage with 
local adjuvants (liquid nitrogen, phenol, argon beam coagulation or PMMA) 
(p=0.035). The only factor that increased risk for recurrence was soft tissue mass 
>10cm (hazard ratio 3.3, 95% confidence interval 0.81-13, p=0.09) (Table 4). Of 
14 first recurrences, 11 underwent second curettage (five with liquid nitrogen, 
two with ASWE, two adjuvant bisphosphonates, one adjuvant radiotherapy), 
one computed tomography (CT)-guided argon beam coagulation, one receptor 
activator of nuclear factor kappa-B ligand (RANKL) inhibitor denosumab 
and one remained expectative. Of four second recurrences, two underwent 
curettage and liquid nitrogen and two radiotherapy. A third recurrence was 
treated with curettage, liquid nitrogen and radiotherapy. Four patients had 
pulmonary metastases (after 4-17 months). Three died of metastatic disease 
(after 6-102 months); one had radiation-induced sarcoma, in the other two 
patients radiation-induced sarcoma was not confirmed. 
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aCurettage through anterior approach
bCurettage in two tempi through combined anterior and posterior approach
cPatient remains under observation for stable residual disease after radiation therapy
dSoft tissue recurrence
eThis patient had arterial embolization three years prior to surgery to reduce tumor size and stop tumor 
growth
fColostomy was performed during initial surgery because tumor involved rectum
Pt. = patient; preop embo = preoperative embolization; rec. = recurrences; mo = months; MSTS = Mus-
culoskeletal Tumor Society score; FU = follow-up; NED = no evidence of disease; AWD = alive with dis-
ease; DOD = died of disease; LN = liquid nitrogen; EBRT = external beam radiation therapy; ASWE = 
anterior sacral wall excision; IFN-α = interferon-α; PMMA = polymethylmethacrylate; BG = bone graft
Table 4 Univariate Cox regression analysis on risk factors for recurrence after intralesional excision for 
sacral GCTB








Confined to S1-S2 15 8 53% 1.1 0.37 3.3 0.85
Anterior cortex destruction  >50% 14 7 50% 1.0 0.35 2.9 0.98
Soft tissue extension 23 11 48% 0.54 0.15 2.0 0.35
     <5cm 16 7 44% - - - 0.25
     5-10cm 2 1 50% 1.1 0.13 8.6 0.96
     >10cm 5 3 60% 3.3 0.81 13 0.09
Use of any local adjuvant* 18 9 50% 0.48 0.16 1.5 0.19
Use of any systemic adjuvant** 8 2 25% 0.32 0.04 2.4 0.27
Use of radiotherapy*** 5 1 20% 0.24 0.03 2.0 0.19
*Local adjuvants at primary treatment included phenol, liquid nitrogen, argon beam coagulation, 
PMMA, ASWE
**Systemic adjuvants at primary treatment included bisphosphonates, IFN-α
***Radiotherapy was given as palliative treatment in two patients; complete response or local control 
was never aimed at in these patients
Complications were reported in twelve of 26 (46%) patients and included 
massive intraoperative hemorrhage (12,000-32,000ml; n=4), infection (n=3), 
permanent neuropraxia after freezing of sacral nerve roots (n=3), hardware 
failure (n=1), radiation-induced sarcoma (n=1), radiation-induced menopause 
(n=1), delayed wound healing (n=1) and pubic dissociation fracture due to 
osteopenia after radiotherapy (n=1) (Table 3). In eight patients, all preoperative 
symptoms resolved after surgery. Persistent pain was reported by eight 
patients. In five patients, neurological symptoms resolved completely during 
follow-up, including transient cauda syndrome (n=2) and transient nerve palsy 
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(n=3; after 12-30 months). Five patients sustained motor deficits during follow-
up, including permanent nerve palsy (n=3), permanent cauda syndrome (n=1), 
progressive motor deficits shortly before death (n=1), and bladder and rectum 
insufficiency (n=1). Two patients newly developed motor deficit after surgery: 
bladder and rectum dysfunction (n=1) and partial cauda syndrome including 
bladder and sexual dysfunction (n=1). 
Overall median MSTS score was 24 (range 15-30). Similar functional results were 
reported by patients without recurrence (median 26, range 15-30) and with 
multiple surgeries for recurrences (median 24, range 15-30; p=0.95). Superior 
functional results were reported by patients without complications (median 
29, range 15-30) compared with patients with complications (median 21, range 
15-30; p=0.024). Functional status was very poor shortly before death in three 
patients; all had progressive loss of motor function and were wheelchair bound. 
From all living patients, walking distance was normal in nineteen and limited 
in three (crutches outdoors); one patient with permanent cauda syndrome is 
currently wheelchair bound. 
Discussion 
Sacral GCTB is a rare lesion which is difficult to treat, and optimal treatment 
remains controversial. Several treatment options have been proposed, but all 
have disadvantages regarding tumor control, complications and functional 
outcome. Additionally, published case series are small and surgical approaches 
heterogeneous, impeding comparison of results. In this study, we evaluated 
mid-term results after intralesional excision for all patients treated for sacral 
GCTB in the Netherlands between 1990 and 2010. 
Recurrence rates reported in literature range from 0-8% for wide, 18-54% for 
marginal and 10-75% for intralesional resection (Table 5). Recurrence-rate in 
this study (14/26; 54%) was high but within ranges reported for marginal and 
intralesional surgery. As local adjuvant use depended on the center the patients 
were treated in, its use was not uniform in this series and different combinations 
of local adjuvants were used by different surgeons. Therefore, we were unable 
to specify which local adjuvant provided better oncologic results in sacral GCTB. 
However, recurrence rate was remarkably higher after isolated curettage (4/5; 
80%), indicating that this should not be performed as primary surgery.  
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Soft tissue extension is the only factor strongly increasing the risk for 
recurrence after curettage for GCTB of long bones [22,23]. From the limited risk 
analysis performed in this study, large soft tissue masses (>10cm) increased 
risk for recurrence three-fold. Possibly, volume measurements on CT or MR 
imaging may provide information regarding risk factors for recurrence of 
sacral GCTB in the future. Surgical management of recurrences is difficult due 
to adhesions and involvement of sacral nerve roots, bladder and rectum [5]. 
Therefore, immediate local control is key in order to avoid surgery for recurrent 
or residual disease. Since isolated curettage leads to 80% recurrence within 
two years, some kind of local adjuvant or systemic therapy is necessary—
equal to surgical management of GCTB of long bones. The choice for wide 
or intralesional resection of sacral GCTB depends mainly on tumor size and 
localization. Intralesional surgery is preferred for large tumors involving upper 
sacral segments (S1-S2); marginal or en bloc resection can be recommended 
for small GCTB in lower sacral segments (S3-S5), for malignant GCTB (e.g. 
radiation-induced sarcoma) and for preexistent severe neurological deficits 
[2,5,12,24]. 
Chemical and thermal agents phenol and liquid nitrogen have been used as 
local adjuvants in sacral GCTB treatment [7,9,11]. Advantages are preservation 
of lumbopelvic continuity, shorter operative time and less intraoperative blood 
loss. However, chemical agents are not recommended in vicinity of soft tissue 
and sacral nerve roots because of its necrotizing effects. Furthermore, phenol 
has demonstrated only limited penetration in cortical bone [25,26]. Additionally, 
it has been postulated that whenever chemical agents are not applicable on all 
cavity borders, which is often the case in sacral GCTB, complication risk may 
surpass expected clinical benefits [11], and its use should be discouraged. 
Thermal agent liquid nitrogen has variable penetration capacities which can 
be monitored, and may be used in proximity of sacral nerve roots as it often 
causes only transient nerve damage. Therefore, cryosurgery may be useful 
in relatively large GCTB and tumors proximal to S3. However, complication 
risk after cryosurgery is higher compared to chemical agents and with large 
presacral soft tissue masses it may damage the posterior rectal wall [7]. 
Mechanical adjuvants include high-speed burring and, in this study, anterior 
sacral wall excision (ASWE). The anterior sacral wall is not required for 
maintenance of structural integrity, especially in lower sacral segments. 
Furthermore, tumor removal from the thin rim of remaining cortex can be 
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difficult [4]. Thus, complete removal of anterior cortex is a logical and safe 
method to increase surgical margins. 
Radiotherapy has been used as adjuvant treatment for residual or recurrent 
disease; only rarely as primary treatment [1,3,10,17]. In this study, 9/26 patients 
underwent radiotherapy for residual or recurrent disease. Four patients are free 
of disease, two patients are alive with stable disease and three patients died of 
disease (one with confirmed radiation-induced sarcoma). Radiotherapy is not 
recommended for primary sacral GCTB, as lifelong risk for radiation-induced 
sarcoma is noteworthy (3-11%) [10,12,18]. With the advent of denosumab, the 
role of radiotherapy in the treatment of GCTB needs to be redefined. Given the 
promising short-term results of denosumab so far, use of radiotherapy should 
be restricted to rare cases of unresectable, residual or recurrent GCTB in which 
treatment with denosumab is not possible or proven to be ineffective, and 
when surgery would lead to unacceptable morbidity which is often the case 
in sacral GCTB.
Systemic treatment included bisphosphonates, IFN-α and denosumab in this 
study. After bisphosphonates, none of three patients had recurrence. After IFN-α, 
one of three patients had recurrence. One patient with recurrence is enrolled in 
a trial with denosumab, which showed clear clinical benefits in GCTB treatment 
and has recently been approved for unresectable GCTB [27,28]. Intralesional 
surgery may be facilitated after neoadjuvant denosumab, especially in difficult 
localizations including axial skeleton and sacrum. To date, it remains unknown 
whether systemic therapy with denosumab lowers the recurrence rate. The 
number of patients treated with systemic therapy in this study was small and 
its effect on oncological outcome needs to be further explored. 
Complication rates reported in literature range from 50-100% after wide and 
marginal resection and 0-71% after intralesional excision for sacral GCTB (Table 
5). In this study, complications were reported in 12/26 (46%) patients. Nineteen 
patients had selective arterial embolization to minimize intraoperative 
bleeding; yet, four patients had >12,000ml blood loss, possibly due to extreme 
vascularity of GCTB in these patients. In general, preoperative embolization is 
crucial for intraoperative hemorrhage control and although blood loss may 
be used to estimate its success, embolization of afferent arteries is not always 
feasible. Nerve palsy was most commonly reported after cryosurgery. This 
neuropraxia was often transient and may be taken for granted in exchange 
for a lower expected recurrence risk. Fortunately, with current cryosurgical 
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techniques, freezing temperatures can be monitored accurately and measures 
are undertaken to prevent nerve and other soft tissue damage, diminishing 
the complication risk [29]. Cauda syndrome can be caused by sacral nerve root 
involvement and multiple surgical interventions with subsequent adhesions 
in the operational area; another reason to advocate immediate local control. 
Radiotherapy related complications as reported in this study are considered 
very severe, which is the reason that the use of radiotherapy should be 
minimized in this relatively young patient category. 
Functional outcome was comparable in patients with and without recurrences, 
but superior in patients without complications. Worst function was seen in 
three patients with progressive disease shortly before death. In the literature, 
functional results were only expressed in terms of neurological, bladder and 
rectum dysfunction. Worse functional results were reported for involvement of 
multiple sacral nerve roots and after wide resection (Table 5). 
Our study has several limitations. First, we present a small cohort with 
patients treated by different surgeons in different centers over a long time 
period. However, it represents our nationwide experience with sacral GCTB 
and to date, only two larger series have been published of which one with 
comparable follow-up duration [11,19]. Second, treatment was uniform 
regarding intralesional surgery, but not when it comes to (local) adjuvant 
treatment, because patients were treated in different centers, each applying 
their standard treatment of musculoskeletal tumors. Overall recurrence and 
complication rates became visible with this study, and as both were high, the 
need for adequate local or systemic therapy is emphasized.
As sacral GCTB is rare and may present in many variations, different 
multidisciplinary approaches are required that seem favorable for each 
individual patient; treatment options are proposed in Figure 2. Definitive 
diagnosis should be obtained by accurate imaging and histopathological 
confirmation. In all patients, preoperative embolization should be considered 
to decrease risk of hemorrhage. Although accompanied by a higher recurrence 
risk, the preferred treatment for all patients is intralesional excision with local 
adjuvants, as this provides for better postoperative functional and quality of life 
results. If primary curettage is impossible, e.g. due to soft tissue extension and/
or neurovascular involvement, neoadjuvant systemic targeted therapy with 
denosumab should be considered. Recent results showed that denosumab 
is effective in facilitating intralesional surgery instead of performing more 
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mutilating surgery for the most complex cases of GCTB [27,28]. However, 
it remains unknown whether denosumab also lowers the recurrence risk. 
Until more becomes known, surgery will remain mainstay of sacral GCTB 
treatment. If intralesional excision remains impossible after systemic therapy, 
en bloc resection may be considered as this results in a lower recurrence risk. 
After surgery, spinopelvic stability should be assessed and reconstruction 
performed if necessary. Radiotherapy should be restricted to rare cases of 
multiple recurrent or refractory GCTB in which denosumab is unavailable, 
contraindicated or ineffective.
In conclusion, recurrence rate after intralesional excision for sacral GCTB was 
high, especially after isolated curettage. Complications were common and 
impaired functional outcome. (Local) adjuvant treatment is desired to obtain 
immediate local control, this would likely result in fewer recurrences and 
complications and superior functional outcome. 
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Figure 2 Multidisciplinary treatment recommendations for sacral GCTB. Definitive diagnosis should be 
obtained by accurate imaging and histopathological confirmation through either preoperative core 
needle biopsy or intraoperative frozen section. In all patients, preoperative embolization should be 
considered. Preferred treatment for all patients is intralesional excision. If primary curettage is 
impossible, e.g. due to soft tissue extension and/or neurovascular involvement, neoadjuvant systemic 
targeted therapy with denosumab should be considered. This may facilitate intralesional excision by 
creating a calcified rim around the tumor and its soft tissue component. It is yet unknown whether it 
also lower recurrence risk and therefore surgery remains mainstay of treatment. If intralesional excision 
remains impossible after systemic therapy, en bloc resection may be considered. After surgery, 
spinopelvic stability should be assessed and reconstruction performed if necessary. Radiotherapy 
should be restricted to rare cases of multiple recurrent or refractory GCTB, and when denosumab is 
unavailable, contraindicated or ineffective.
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Abstract
Background Risk factors for local recurrence of giant cell tumor of bone (GCTB) 
have mostly been studied in heterogeneous treatment groups, including 
resection and intralesional treatment. The aim of the study was the identification 
of individual risk factors after curettage with adjuvants in GCTB.
Patients and methods Of 147 patients treated for primary GCTB between 1981 
and 2009, 93 patients were included in this retrospective single-center study. 
All patients were treated with curettage and polymethylmethacrylate (PMMA) 
with (n=75) or without (n=18) phenol. Mean follow-up was 8 years (range 2–24). 
Recurrence-free survival was assessed for treatment modalities. Age, gender, 
tumor localization, soft tissue extension and pathologic fractures were scored 
for every patient and included in a Cox regression analysis.
Results The recurrence rate after the first procedure was 25 out of 93. 
Recurrence-free survival for PMMA and phenol and for PMMA alone was similar. 
Eventually, local control was achieved using one or multiple intralesional 
procedures in 85 patients. Resection was required in eight patients. A higher 
risk of local recurrence was found for soft tissue extension (hazard ratio 5; 95% 
confidence interval 2–12), but not for age below 30, gender, localization (distal 
radius versus other) or pathologic fracture.
Conclusions Curettage with adjuvants is a feasible first choice treatment option 
for GCTB, with good oncological outcome and joint preservation. Soft tissue 
extension strongly increased the risk of local recurrence, whereas age, gender, 
localization and pathologic fractures did not.




Giant cell tumor of bone (GCTB) is aggressive locally with recurrence rates of 27 
to 65% after curettage with bone grafting [1,2], 12 to 27% after curettage with 
adjuvants such as high-speed burr, phenol and polymethylmethacrylate (PMMA) 
[2-4], and 0 to 12% after en bloc resection [2,5]. In clinical practice, the choice of 
surgical procedure depends mostly on the feasibility of curettage and cementation 
versus resection, but in part also on the expected risk of local recurrence in individual 
patients. Cortex destruction, soft tissue extension, pathologic fractures, young age 
and localization in the distal radius have been suggested to be risk factors for local 
recurrence [2-8], but these have not been confirmed by others [9-11]. Most studies 
that aimed at identification of risk factors for local recurrence have included both 
resection and curettage in risk analyses [2-4,8], which results in a selection bias 
because of lower recurrence rates after resection. 
At our tertiary referral center for musculoskeletal oncology, curettage with 
phenol and PMMA is the preferred standard treatment for all GCTB. Over 75% 
of patients with primary or recurrent GCTB presenting at our center underwent 
curettage with adjuvants; the rest underwent en bloc resection. The indications 
for resection were localization in the axial skeleton or severe joint destruction. 
In contrast to other studies [4,5,12,13], soft tissue extension and pathologic 
fracture were not contraindications for intralesional treatment; this is in 
accordance with extended indications for curettage as described previously [1-
3,8,10]. The advantage is avoidance of prosthetic reconstruction at a relative 
young age. The disadvantage may be an increased risk of local recurrence. 
We retrospectively evaluated risk factors for local recurrence and recurrence-
free survival with these wide indications in 93 patients with primary GCTB and 
30 patients with recurrent GCTB.
Patients and methods
In this retrospective single-center study, we identified 147 patients with primary 
GCTB who had been treated at our tertiary referral center for orthopedic 
oncology between 1981 and 2009 (Figure 1). All patients had a minimum follow-
up of 2 years. As primary treatment, curettage with adjuvants (n=113; 77%), en 
bloc resection (n=28; 19%) or other treatment (n=6; 4%) was performed. We did 
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not evaluate patients who were primarily treated with resection (n=28); nor did 
we evaluate patients primarily treated with curettage without PMMA (n=10), 
with bisphosphonates (n=2), with denosumab (n=2), with radiotherapy (n=1) or 
with arterial embolization (n=1) because it was not standard treatment protocol. 
There was no statistically significant difference in the patient characteristics or 
tumor characteristics of excluded patients and of those who were included.
Figure 1 Flowchart of patients with primary and recurrent GCTB
*Excluded are patients primarily treated with curettage without PMMA (n=10), systemic treatment 
(n=5) or embolization (n=1) or follow-up of less than 24 months (n=10).
**Patients who were primarily treated for GCTB by curettage with adjuvants in a center not specialized 
in orthopedic oncology and who were later referred with a first recurrence to our Orthopedic Oncology 
Center for repeat curettage with adjuvants.
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We evaluated 93 patients (55 males) who underwent curettage with adjuvants 
for primary GCTB. Mean age was 33 years (range 11–61). In all patients, PMMA 
was used as filling of the cavity after curettage. Additional phenol was applied 
on cavity borders whenever adequate protection of surrounding tissues was 
possible (n=75).
We also identified 38 patients who developed local recurrence after primary 
curettage with adjuvants either at our center (n=25) or elsewhere (n=13). 
Eight patients who underwent resection for a first recurrence were excluded. 
The other 30 patients underwent re-curettage with adjuvants for recurrent 
GCTB at our center (17 from our center and 13 referred). Mean age was 35 
years (range 18–65). PMMA was used in all 30 patients and additional phenol 
in 21 of them.
Data were collected from the medical records and they included information on 
age, gender, tumor localization, soft tissue extension and pathologic fracture 
(Table 1). We defined soft tissue extension as a complete breakthrough of the 
cortex and additional extension into adjacent soft tissue (i.e. a tumor mass). 
Cortex destruction was first assessed on plain radiographs in all patients. 
Subsequently, extension into the surrounding soft tissues was assessed on 
MR imaging (unless the tumor was centrally located, confined strictly to bone, 
and with no cortex destruction in two planes on conventional radiographs). 
Preoperative MR imaging results were available for 84 patients and preoperative 
CT results for four patients. At our center, we had had access to an MRI scanner 
since 1987 but five patients were operated before this date. Nineteen patients 
had a pathologic fracture at presentation. Soft tissue extension in these cases 
was classified in the same way as in the other cases; pathologic fracture in itself 
was not classified as soft tissue extension. Preoperative MR imaging results 
were available for 17 of 19 patients with a pathologic fracture, preoperative 
CT results were available for one patient and conventional radiographs alone 
were available for one patient. Eight of 17 patients with preoperative MR 
imaging results also had a pathologic fracture and a soft tissue component. 
Only a fissure was reported in two patients (no soft tissue extension), none 
or a slight dislocation in 10 patients (three with soft tissue extension) and 
a moderate to substantial dislocation of the fracture was reported in seven 
patients (five with soft tissue extension). All the data were complete. Mean 
follow-up time was 8 years (range 2–24). The follow-up protocol consisted of 
conventional radiography at 1.5, 3, and 6 months postoperatively, followed 
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by half-yearly radiographs until 2 years postoperatively, and then radiographs 
taken annually over the next 10 years. MR imaging was performed at 1, 2, 5, 
and 10 years.
Table 1 Patient demographics
Primary GCTB Recurrent GCTB





Proximal humerus 3 1
Distal radius 13 5
Proximal femur 2 2
Distal femur 52 13
Proximal tibia 16 8
Distal tibia 5 1
Fibula 2 -
Tumor characteristics
Soft tissue extension 25 8
Pathologic fracture 19 -
Curettage with adjuvants
PMMA and phenol 75 21
PMMA 18 9
Statistical analysis
Recurrence-free survival (RFS) of curettage with PMMA with or without phenol 
was determined (Kaplan-Meier) for primary GCTB (n=93) and recurrent GCTB 
(n=30). Differences were assessed with log rank test. Time to recurrence was 
defined as time from primary surgery to the date on which a recurrence was 
confirmed by biopsy. Risk factors for local recurrence after primary curettage 
with adjuvants (n=93) were assessed by Cox regression analysis. Age below 30, 
gender, tumor localization (distal radius versus other), soft tissue extension and 
pathologic fractures were included. Interaction terms of variables that might 
interact (soft tissue extension, localization, pathologic fractures and young age) 
were assessed by successive incorporation in the regression model. There was 
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some evidence of interaction (interaction with soft tissue extension, p<0.05) 
but the numbers in this series were too small (n=4–10) for reliable estimation of 
this interaction effect and the results are not reported. Statistical analysis was 
performed with SPSS.
Results
Twenty-five out of 93 patients with primary GCTB had a local recurrence. Mean 
time to first recurrence was 19 months (range 4–78). Overall recurrence-free 
survival rates at 2 and 5 years were 0.82 and 0.74, respectively, and for recurrent 
GCTB they were 0.63 and 0.45 (Table 2). Four patients died after 4–9 years, all 
for reasons unrelated to GCTB. None of these patients had local recurrence or 
metastases at final follow-up. Local control was achieved using one or multiple 
intralesional procedures in 85 of 93 patients at 5 years postoperatively. 
Recurrence-free survival was similar in both primary and recurrent tumors that 
were treated with or without phenol in addition to PMMA (Figures 2 and 3). 
Table 2 Recurrence-free survival of primary and recurrent GCTB 
n recurrence 2-yrs RFS 95%CI 5-yrs RFS 95% CI p-value
Primary 
Curettage with adj. 93 25 0.82 0.73-0.90 0.74 0.65-0.83
PMMA + phenol 75 20 0.83 0.74-0.91 0.74 0.64-0.84 0.9
PMMA 18 5 0.78 0.59-0.97 0.72 0.51-0.93
Recurrent 
Curettage with adj. 30 14 0.63 0.45-0.81 0.45 0.25-0.65
PMMA + phenol 21 9 0.55 0.31-0.79 0.47 0.23-0.72 1.0
PMMA 9 5 0.56 0.23-0.88 0.44 0.12-0.77
RFS = Recurrence-free survival
Yrs = years
CI = Confidence interval
Adj. = Local adjuvants
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Figure 2 Kaplan-Meier estimated recurrence-free survival of primary GCTB treated with curettage with 
PMMA and phenol (n=75; light gray) or PMMA alone (n=18; black) (p = 0.94).
Figure 3 Kaplan-Meier estimated recurrence-free survival of recurrent GCTB treated with curettage with 
PMMA and phenol (n=21; light gray) or PMMA alone (n=9; black) (p = 0.99).
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Potential risk factors for local recurrence were soft tissue extension (14 out of 
25 recurred) and pathologic fracture (5 out of 19 recurred). For primary GCTB 
without soft tissue extension, the local recurrence rate was 12 out of 68; the 
risk of local recurrence was 5 times higher in tumors with soft tissue extension 
(Table 3). Age below 30, gender, presence of pathologic fracture or localization 
in the distal radius had no apparent influence on the risk of local recurrence.
Table 3 Potential individual and combined risk factors for recurrence in GCTB
n recurrence HR 95% CI p-value
Potential individual risk factors
Soft tissue extension 25 14 5 2-12 0.001
Distal radius 13 6 2 0.8-5 0.1
Pathologic fracture 19 5 1.3 0.5-3.5 0.7
Age under 30 46 13 1.4 0.6-3.2 0.4
Gender 93 25 0.8 0.3-1.8 0.6
Local adjuvants
PMMA 18 5 - - -
Phenol and PMMA 75 20 0.8 0.3-2.1 0.6
HR = Hazard ratio
CI = Confidence interval
Discussion
This study demonstrates that curettage with adjuvants is a feasible first 
choice treatment option for GCTB, even in the case of soft tissue extension 
or pathologic fracture. We performed intralesional treatment in the majority 
of GCTB with soft tissue extension, either alone or combined with pathologic 
fractures. This would explain the relatively high local recurrence rate, but if we 
only consider GCTB without a soft tissue component, the local recurrence rate 
is comparable to that reported in the recent literature (Table 4). However, the 
risk of a second recurrence after repeated curettage was relatively high (47%). 
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The survival rates were similar for curettage with PMMA and phenol and for 
curettage with PMMA alone. The beneficial effect of using additional phenol 
has been debated [4,8]. Phenol may have a limited additive effect on the 
recurrence rate; however, the risk-reducing effect of PMMA may be of greater 
importance. 
We found a 5-times higher risk of recurrence of tumors with soft tissue 
extension. This confirms the previously reported increase in recurrence risk 
with soft tissue extension: hazard ratio 2.7 (p=0.007) [3] and likelihood ratio 
4.0 (p=0.05) [2]. This can be explained by technical difficulties in the complete 
removal of tumor tissue when performing intralesional treatment and the lack 
of adequate applicable local adjuvants, in the presence of soft tissue extension. 
Previously proposed risk factors—age below 30, localization in distal radius, or 
pathologic fracture—could not be identified as risk factors for local recurrence 
in the present study. This may be due to the fact that most studies analyzing 
risk factors for local recurrence have included both intralesional treatment and 
resection, with a lower expected overall recurrence rate [2-4,8]. 
Young age has been suggested to be a risk factor [4,8], but it may in part be 
explained by selection bias. Younger patients could have been selected to have 
intralesional treatment instead of resection. We could not confirm localization 
in distal radius as a risk factor for local recurrence, as has been suggested 
previously. Balke et al. [2] found that 8 out of 9 GCTB located in the distal radius 
recurred, as compared to 6 out of 13 in our study. However, six of their cases had 
soft tissue extension and in five cases no PMMA was applied, which may have 
increased the local recurrence risk. Finally, we found no correlation between 
recurrence risk and pathologic fracture as reported by O’Donnell et al. [6]. This 
indicates that curettage with adjuvants could be a feasible treatment option 
for GCTB with a pathologic fracture [14,15]. 
In the near future, the treatment strategy could be changed given promising 
results from systemically targeted neoadjuvant therapy with RANKL inhibitor 
denosumab [16,17]. With this therapy, calcification of affected soft tissues 
occurs, which may extend the indications for curettage with adjuvants. 
In summary, curettage should at least include PMMA as local adjuvant, and the 
role of phenol after curettage with PMMA as local adjuvant is questionable. The 
recurrence risk after curettage with adjuvants is only increased with soft tissue 
extension—but not with age below 30, pathologic fracture or localization in 
distal radius.
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Abstract
Background It has been suggested that, when a patient has giant cell tumor 
of bone (GCTB), subchondral bone involvement close to articular cartilage and 
a hyperthermic reaction from polymethylmethacrylate (PMMA) are risk factors 
for the development of osteoarthritis. We determined the prevalence, risk 
factors, and clinical relevance of osteoarthritis on radiographs after curettage 
and application of PMMA for the treatment of GCTB around the knee.
Methods This retrospective single-center study included 53 patients with 
GCTB around the knee treated with curettage and PMMA between 1987 and 
2007. The median age at the time of follow-up was 42 years (range 23-70 years). 
There were 29 women. Radiographic evidence of osteoarthritis was defined, 
preoperatively and postoperatively, as Kellgren and Lawrence grade 3 or 4 (KL3-
4). We studied the influence of age, sex, tumor-cartilage distance, subchondral 
bone involvement (≤3 mm of residual subchondral bone), subchondral 
bone grafting, intra-articular fracture, multiple curettage procedures, and 
complications on progression to KL3-4. Functional outcomes and quality of life 
were assessed with the Short Form-36 (SF-36), Musculoskeletal Tumor Society 
(MSTS) score, and Knee injury and Osteoarthritis Outcome Score (KOOS).
Results After a median duration of follow-up of 68 months (range 60-285 
months), six patients (11%) had progression to KL3, two (4%) had progression 
to KL4, and one had preexistent KL4. No patient underwent total knee 
replacement. The hazard ratio for KL3-4 was 9.0 (95% confidence interval 
[CI]=2.0-41; p=0.004) when >70% of the subchondral bone was affected 
and 4.2 (95%CI=0.84-21; p=0.081) when the tumorcartilage distance was ≤3 
mm. Age, sex, subchondral bone-grafting, intra-articular fracture, multiple 
curettage procedures, and complications did not affect progression to KL3-4. 
Patients with KL3-4 reported lower scores on the KOOS symptom subscale (58 
versus 82; p=0.01), but their scores on the other KOOS subscales, the MSTS 
score (21 versus 24), and the SF-36 (76 versus 81) were similar to those for the 
patients with KL0, 1, or 2 (KL0-2).
Conclusion Seventeen percent of patients with GCTB around the knee had 
radiographic findings of osteoarthritis after treatment with curettage and 
PMMA. A large amount of subchondral bone involvement close to articular 
cartilage increased the risk for osteoarthritis. The function and quality of life 
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of the patients with KL3-4 were comparable with those for the patients with 
KL0-2, suggesting that radiographic findings of osteoarthritis at the time of 
intermediate follow-up had a modest clinical impact. Treatment with curettage 
and PMMA is safe for primary and recurrent GCTB, even large tumors close to 
the joint.
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Introduction
Giant cell tumor of bone (GCTB) is a benign primary bone tumor with a locally 
aggressive character. Usually, giant cell tumor occurs between thirty and fifty 
years of age [1-3]. GCTB is usually localized to the meta-epiphyseal area of 
long bones; 50% are located around the knee [1]. Approximately 1% to 4% of 
patients develop benign pulmonary metastases [1,4-8]. 
Standard treatment for GCTB consists of extended curettage and chemical 
adjuvants such as phenol, alcohol, hydrogen peroxide, argon laser, or liquid 
nitrogen [3,9-15]. The remaining cavity can be left empty awaiting new bone 
formation during partial immobilization [16-18], or it may be filled with 
cancellous bone graft [2,19,20]. However, reported recurrence rates following 
both options are high (27% to 65%) [1,10]. At present, the most commonly used 
filling material is polymethylmethacrylate (PMMA), which is associated with a 
lower recurrence risk (12% to 34%), provides immediate mechanical support, 
and facilitates easy and early detection of local recurrences [9,10,21]. PMMA is 
therefore widely recommended to fill the cavity left after curettage [3,9-13,21]. 
However, it has been suggested that curettage and PMMA may result in 
secondary osteoarthritis, although risk factors for this development remain 
unclear (Figure 1) [2,13,17,22-29]. PMMA is a thermal adjuvant increasing 
surgical margins up to 1.5 to 2 mm in cancellous bone and 0.5 mm in cortical 
bone [23-25]. Degenerative changes may be caused by this hyperthermic 
polymerization of PMMA [13,17,23,24], but a close relation of the tumor with 
articular cartilage and extensive subchondral bone involvement may be more 
important risk factors [22,25-27]. In addition, often large volumes of PMMA are 
used after curettage for GCTB, with possible increased thermal damage [24]. 
Finally, intra-articular pathologic fracture [28,29] and repeated curettage with 
application of PMMA for recurrences are also believed to increase the risk for 
degenerative changes [2,28]. 
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Figure 1 (A) Anteroposterior radiograph of a forty-two-year-old man demonstrates KL0 after curettage 
with application of subchondral bone graft and PMMA for primary GCTB in the proximal part of the 
tibia. (B) Follow-up radiographs demonstrate KL1-2 after fifty-five months, (C) KL3 after sixty-seven 
months and (D) KL4 after ten years. This patient underwent repeated curettage and application of 
PMMA for three recurrences. There was no evidence of GCTB at the time of final follow-up.
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Therefore, we evaluated (1) the prevalence of radiographic findings of 
osteoarthritis after treatment for GCTB around the knee with curettage and 
PMMA; (2) which patient, treatment, and tumor characteristics are associated 
with the risk of progression to osteoarthritis; and (3) the clinical relevance, as 
determined with functional outcome and quality-of-life scores, of radiographic 
findings of osteoarthritis.
Materials and methods
We retrospectively evaluated 68 patients treated with curettage and PMMA for 
GCTB in the distal part of the femur or the proximal part of the tibia from 1987 
to 2007. These patients were identified from the total group of 189 consecutive 
patients who had been treated for GCTB at our tertiary referral center during 
that period. The minimum duration of follow-up was five years. Fifteen patients 
were excluded: nine patients had missing preoperative radiographs, four 
patients had been treated with resection and endoprosthetic reconstruction 
for recurrence, and two patients had died of causes unrelated to the GCTB, all 
within five years after index surgery. We included 53 patients (29 of whom were 
female) with GCTB around the knee, with a median duration of follow-up of 
86 months (range 60-285 months). The median age at the index surgery was 
32 years (range 16-62 years). Two patients had multicentric GCTB. None of the 
included patients developed pulmonary metastases. No patient was recalled 
specifically for this study. This study was approved by the institutional medical 
ethics committee. 
The initial surgery was performed by fellowship-trained oncological orthopaedic 
surgeons. At our center, intralesional treatment was preferred for GCTB even 
in the presence of soft-tissue extension and intra-articular pathologic fracture 
[30,31]. En bloc resection was almost never performed as primary treatment for 
GCTB. Standard treatment consisted of curettage, local application of phenol 
and ethanol, and rinsing the cavity with high-speed pulse lavage with saline 
solution. During the evaluated time frame, high-speed burring was not standard 
at our center. In eight patients, no phenol was applied as adequate protection 
of surrounding tissues was impossible due to cortical defects. Subchondral 
cancellous bone grafting was considered after curettage when <10 mm of 
subchondral bone remained, and was performed in 25 patients. The cavity was 
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filled with PMMA in all patients. Cementation was performed under tourniquet 
control. The cement volume depended on the size of the GCTB and averaged 
30 to 60 mL. Postoperative treatment consisted of functional mobilization and 
immediate weight-bearing for most patients. Those with a pathologic fracture 
were permitted only partial weight-bearing for 6 to 12 weeks. There were no 
restrictions on sports or activities six months postoperatively. The follow-up 
protocol consisted of conventional radiographs after 1.5, 3, 6, 12, 18 and 24 
months and yearly up to ten years to detect recurrences and complications. 
Chest radiography to detect pulmonary metastases and magnetic resonance 
imaging (MRI) were performed after one, two, five, and ten years.
Table 1 Patient demographics
Number Median Mean Range
Age at primary intervention (yr) 53 32 34 16-62
Age at latest follow-up (yr) 53 42 43 23-70
Follow-up (mo) 53 86 120 60-285
Time to local recurrence (mo) 15 21 57 6-217
Mean Range Number Percent
Localization
    Distal part of femur 38 72
    Proximal part of tibia 15 28
Tumor-cartilage distance (mm) 4.9 0-23 53 100
    < 1 mm 15 28
    1-3 mm 11 21
    3-5 mm 5 9
    > 5 mm 22 42
Subchondral bone involvement* 49 7-100 26 49
    <30% 8 31
    30-49% 6 23
    50-69% 5 19
    ≥70% 7 27
Intra-articular pathologic fracture 4 8
Soft-tissue extension 11 21
Preoperative KL grade**
    KL0 33 62
    KL1 18 34
    KL2 1 2
    KL3 0 0
    KL4 1 2
*The amount of subchondral bone involvement was defined as the area of the involved knee compart-
ment in which ≤3 mm of subchondral bone thickness remained. Thus, for example, <30% indicates that 
≤3 mm of subchondral bone thickness remained in <30% of the involved knee compartment. **KL = 
Kellgren and Lawrence.
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Medical records and radiographs were reviewed to determine age, sex, 
localization, tumor-cartilage distance, subchondral bone involvement, intra-
articular pathologic fractures, subchondral bone grafting, multiple curettage 
and PMMA procedures for recurrence, complications, preoperative and 
postoperative Kellgren and Lawrence (KL) grades, and duration of follow-up 
(Table 1). All data were complete. 
KL grading was used to assess osteoarthritis on preoperative and postoperative 
anteroposterior non-weight-bearing radiographs [32]. Two observers each 
performed the grading twice. When three of four KL grades corresponded, 
that grade was assigned. When the two observers assigned different KL grades, 
consensus was reached. We defined KL grade-3 or 4 (KL3-4) osteoarthritis [32-
34] as moderate to pronounced osteophyte formation, definite joint space 
narrowing, and subchondral sclerosis (Table 2; Figure 1). The time until signs of 
osteoarthritis appeared was determined on follow-up radiographs. 
Table 2 Kellgren and Lawrence grading for radiographic evidence of osteoarthritis
Grade Description Radiographic findings of 
osteoarthritis
KL0 Normal joint None
KL1 Possible osteophytes, no joint space narrowing 
or sclerosis
Mild
KL2 Definite osteophytes, possible joint space narrowing 
and sclerosis
Mild
KL3 Moderate osteophytes, definite joint space narrowing, 
some sclerosis, and possible bone contour deformity
Moderate
KL4 Large osteophytes, marked joint space narrowing, 
severe sclerosis, and definite bone contour deformity
Severe
We assessed the influence of age, sex, follow-up duration, tumor-cartilage 
distance, subchondral bone involvement, subchondral bone grafting, intra-
articular pathologic fractures, number of curettage and PMMA procedures, 
and complications on osteoarthritis development. The amount of subchondral 
bone involvement was defined as the area of the involved knee compartment 
in which ≤3 mm of subchondral bone thickness remained (Figure 2); this was 
calculated as a percentage with a method similar to that described by Chen et 
al. [26]. Measurements were performed once by each of two observers.
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Figure 2 The amount of subchondral bone involvement by the GCTB was defined as the area of the 
femoral or tibial condyle in which there was ≤3 mm of subchondral bone thickness remaining. This was 
calculated, with a method similar to that described by Chen et al. as a percentage:  (a/A) x 100% or (b/B) 
x 100% [26]. 
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Functional outcomes and quality of life were evaluated with the Musculoskeletal 
Tumor Society (MSTS) score, Knee injury Osteoarthritis Outcome Score (KOOS), 
and Short Form-36 (SF-36) [35-37]. Questionnaires were obtained by mail at 
a mean of 11 years (range 5-25 years) after the initial surgery. Nine patients 
did not return questionnaires, so patient-reported outcome measures were 
available for 44 patients (83%).
Statistical analysis
Kaplan-Meier methodology was applied to assess the probability of 
progression to KL3-4. As no patient died, this probability can be estimated 
as one minus survival function. Univariate and multivariate (for relevant 
variables) Cox regression was performed to determine risk factors for 
radiographic osteoarthritis. Chi-square and Fisher exact tests were employed 
for dichotomous variables whereas nonparametric Mann-Whitney U tests 
were used for numerical data. Cohen’s kappa statistic was used to determine 
interobserver and intraobserver agreement for KL3-4 and interobserver 
agreement for subchondral bone involvement. Outstanding agreement was 
defined as κ>0.80; substantial agreement as κ=0.60-0.79; moderate agreement 
as κ=0.40-0.59; and poor agreement as κ<0.40 [38,39]. 
Results
Six patients (11%) had progression from KL0-1 to KL3 and two (4%) from KL0-
1 to KL4, the signs of which appeared on postoperative radiographs after a 
median of 57 months (mean 98 months; range 33-285 months); one patient 
had preexistent KL4. At the time of writing, none of these patients had required 
total knee arthroplasty. Figure 3 shows that the probability of progression to 
KL3-4 has not reached a plateau phase by the time of this study, indicating 
that the prevalence of KL3-4 grades may increase with time. In all patients, 
degenerative changes were localized to the involved knee compartment. 
Eighty-three percent of the patients did not develop radiographic findings 
of osteoarthritis: for 20 patients (38%), the grade remained stable at KL0-2; 
14 patients (26%) had progression from KL0 to KL1; five (9%) had progression 
from KL0 to KL2; and five (9%) had progression from KL1 to KL2. Cohen’s 
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kappa statistic for KL3-4 was outstanding for interobserver agreement, with 
κ=0.90 (95% confidence interval [CI]=0.76-1.0; p<0.001); it was outstanding 
for intraobserver agreement, with κ=0.83 (95%CI=0.66-1.0; p<0.001), for one 
observer and substantial, with κ=0.76 (95%CI=0.53-0.99; p<0.001), for the 
other [38,39]. 
Figure 3 Kaplan Meier one minus survival curve of the probability of progression to KL3-4, which was 
8% at five years and 18% at ten years after curettage and application of PMMA for GCTB around the knee 
joint.
In 26 patients, ≤3 mm of subchondral bone remained after curettage; their 
mean subchondral bone involvement was 49% (range 7%-100%). Sixteen 
of these patients were treated with subchondral bone graft. The mean 
subchondral bone involvement was 56% (range 10%-100%) in patients 
treated with subchondral bone graft and 38% (range 7%-85%) in patients not 
treated with subchondral bone graft (p=0.007). Six of the 16 patients who 
received bone graft and one of the ten patients who did not receive bone 
grafts developed radiographic evidence of osteoarthritis (KL3-4). When more 
subchondral bone was affected, the risk of development of KL3-4 increased, 
with a hazard ratio (HR) of 18 (95%CI=2.4-140; p=0.005) (Table 3). This risk was 
most apparent when >70% of the subchondral bone was involved by giant cell 
tumor, with an HR of 9.0 (95%CI=2.0-41, p=0.004). The HR for a tumor-cartilage 
distance of ≤3 mm was 4.2 (95%CI=0.84-21; p=0.081). Fifteen patients (28%)
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Table 3 Risk factors for progression of radiographic findings of osteoarthritis after curettage with PMMA 
for giant cell tumor around the knee





n % lower upper
Univariate Cox regression analysis
Affected subchondral bone
     % 26 7 27 18 2.4 140 0.005
     >70% 7 4 57 9.0 2.0 41 0.004
     >50% 12 5 42 4.9 1.2 20 0.032
     >30% 18 6 33 3.7 0.89 16 0.073
Tumor-cartilage distance
     0-1 mm 15 5 33 12 1.4 103 0.024
     1-3 mm 11 2 18 5.4 0.47 63 0.18
     0-3 mm 26 7 27 4.2 0.84 21 0.081
     Longer distance to articular cartilage (mm) 53 9 17 0.73 0.54 0.99 0.045
Complications 7 2 29 3.2 0.58 17 0.18
Subchondral bone grafting 25 7 28 2.5 0.49 13 0.28
Follow-up >10 years 21 7 33 1.5 0.24 10 0.66
Multiple curettage and PMMA procedures 15 3 19 1.2 0.56 2.6 0.63
Age at the time of follow-up >60 years 8 2 25 0.34 0.04 3.9 0.41
Female sex 29 3 10 0.22 0.04 1.1 0.063
Multivariate Cox regression analysis
Affected subchondral bone (%) - - - 18 2.3 148 0.006
Multiple curettage and PMMA procedures - - - 1.0 0.34 3.0 1.0
Affected subchondral bone (%) - - - 19 2.4 149 0.005
Age at the time of final follow-up - - - 1.0 0.95 1.1 0.69
Affected subchondral bone (%) - - - 19 1.9 186 0.013
Subchondral bone grafting - - - 0.97 0.15 6.3 0.98
Affected subchondral bone (%) - - - 16 2.1 118 0.007
Complications - - - 2.4 0.42 14 0.33
underwent repeat curettage and application of PMMA because of recurrences 
(nine had two repeat curettage procedures, four had three, and two had 
four). Three of the 15 patients with repeat curettage had KL3-4 at the time of 
follow-up. The prevalence of KL3-4 in patients with repeat curettage was not 
higher than that in the patients with a single surgical intervention (six of 38; 
p=0.63). The recurrence rate was comparable between the patients treated 
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with subchondral bone graft and PMMA (nine of 25) and those treated with 
PMMA alone (six of 28) (p=0.36). Of the nine patients with recurrence after 
subchondral bone grafting, only two had the recurrence in the subchondral 
area; the other recurrences were at the PMMA-bone junction.
There were seven complications: three patients had pain, two had postoperative 
fracture, one had pseudoarthrosis, and one had infection. In all cases, the PMMA 
was replaced with bone graft. Two of these patients had KL3-4 at the time of 
follow-up; one underwent high tibial osteotomy to correct varus deformity 
after fracture. 
An age at the time of final follow-up of more than 60 years, a follow-up 
duration of more than ten years, female sex, and intra-articular fracture did not 
significantly influence the development of KL3-4 at the time of follow-up (Table 
3). Cohen’s kappa statistic for interobserver agreement on subchondral bone 
involvement was substantial with κ=0.76 (95%CI=0.58-0.94; p<0.001) [38,39].
The functional outcome and quality of life were compared between different 
KL grades. There were no data from the one patient with preexistent KL4. 
Patients with KL3-4 reported lower scores only on the KOOS symptom subscale 
compared with patients with KL0-2 (p=0.01). The scores on the other KOOS 
subscales, MSTS, and all SF-36 subscales were similar between groups (Table 
4). Patients with KL4 reported lower scores only on the KOOS sports/recreation 
subscale when compared with patients with KL0-3 (p=0.044). 
Discussion
The intralesional treatment of GCTB with curettage, local adjuvants, and PMMA 
was hypothesized to increase the risk for degenerative changes [13,17,23,24]. A 
close relation with the articular cartilage, extensive subchondral bone defects, 
and larger tumor size, all characteristic of GCTB, are the most important factors 
for the development of osteoarthritis [22,24-27]. Additionally, intra-articular 
pathologic fractures [28,29] and multiple curettage and PMMA procedures 
have also been mentioned as possible risk factors [2,28]. In summary, risk 
factors for knee osteoarthritis after this surgical procedure remain unclear. 
Furthermore, quantification of degenerative changes after treatment for GCTB 
around the knee was presented in only two prior studies [28,40]. Therefore,
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Table 4 Patient and tumor characteristics, functional outcomes, and quality of life of patients with and 
without radiographic findings of osteoarthritis at the time of final follow-up
KL0-2 KL3-4
mean range mean range p
Age at the time of follow-up (yr) 42 23-67 51 37-70 0.034
Duration of follow-up (mo) 107 60-283 184 60-285 0.011
Tumor-cartilage distance (mm) 5.6 0-23 2.1 0-6.9 0.037
Subchondral bone involvement (%) 42 7-85 68 28-100 0.009
Number of curettage and PMMA procedures 1.4 1-4 1.6 1-4 0.80
MSTS score 24 11-30 21 16-30 0.094
KOOS 76 30-99 61 32-99 0.05
Pain 84 39-100 75 28-100 0.26
Symptoms 82 46-100 58 32-100 0.01
Activities of daily living 89 35-100 84 62-100 0.20
Sports / recreation 59 5-100 34 0-100 0.058
Quality of life 67 0-100 52 19-94 0.078
SF-36 81 42-95 76 48-99 0.38
Physical functioning 78 30-100 61 40-100 0.33
Role limitations due to physical problems 85 0-100 72 0-100 0.35
Bodily pain 86 45-100 73 45-100 0.08
General health 73 10-100 72 25-100 0.92
Vitality 71 30-100 82 50-100 0.092
Social functioning 90 38-100 84 38-100 0.54
Role limitations due to emotional problems 92 0-100 96 67-100 0.85
Mental health 79 52-100 87 72-100 0.21
KOOS = Knee injury Osteoarthritis Outcome Score, MSTS = Musculoskeletal Tumor Society, and SF-36 
= Short Form 36
we determined the prevalence of radiographic findings of osteoarthritis after 
curettage and application of PMMA for giant cell tumor around the knee, risk 
factors for progression to KL3-4 after this surgical procedure, and the functional 
outcomes and quality of life following the procedure.
Seventeen percent of patients had KL3-4 after curettage and application 
of PMMA for GCTB around the knee, a ten-fold increase compared with 
age-matched cohorts (0.3% to 1.8%) of the general population [34]. In the 
literature, the prevalence of osteoarthritis after curettage and application 
of PMMA has ranged from 4% to 25% in the upper and lower extremities 
[2,3,13,17,18,22,28,41,42] (Table 5). At the time of writing, none of our patients 
had required total knee replacement.

















































































































































































































































































































































































































































































































































































































































































































27935_Heijden.indd   194 25-06-14   11:32
8





























































































































































































































































































































































































































































































































































































































27935_Heijden.indd   195 25-06-14   11:32
Chapter 8
196
In our study of GCTB treated with curettage and PMMA, tumor size and 
proximity to joint surface were strongly associated with radiographic findings 
of osteoarthritis, confirming earlier results [24-27]. The risk of arthritis was 
increased nine-fold when >70% of the subchondral bone within 3 mm of articular 
cartilage was affected. If ≤3 mm of cancellous bone is spared by tumor, both 
the subchondral bone layer and articular cartilage can be exposed to necrotic 
effects of curettage, phenol application, and PMMA polymerization [25]. Along 
with others, we could not confirm whether the risk of osteoarthritis could be 
attributed to the use of PMMA, intralesional treatment, or characteristics of the 
GCTB, as there was no control group in this study [3]. Szalay et al. compared 
degenerative changes in two groups, treated with cement or bone graft, and 
found that the risk of osteoarthritis was increased for the bone graft group in the 
first two postoperative years, until full incorporation of the bone graft, and was 
increased in the PMMA group thereafter [22]. Placing subchondral bone graft 
in large subchondral bone defects may protect cartilage from degenerative 
changes by increasing the distance between the articular cartilage and the 
bone cement, thus creating a buffer against the thermal effects of PMMA on the 
joint cartilage [2,17,22]. In the present study, subchondral bone graft was used 
in patients with subchondral bone defects close to the joint, but we found no 
decrease in the prevalence of osteoarthritis, probably because the subchondral 
defects were larger in the patients treated with bone graft. These patients had 
a higher a priori risk for developing KL3-4 osteoarthritis compared with patients 
with less tumor involvement of subchondral bone. This suggests that articular 
damage may be caused by the curettage itself or by tumor characteristics rather 
than by thermal damage from PMMA; however, without a control group, this 
remains uncertain. Furthermore, it was hypothesized that recurrences would 
be more likely to appear at the site of bone grafting because of absent thermal 
effects of PMMA, but we could not confirm this finding. Repeat curettage and 
PMMA procedures for recurrences have been suggested to increase the risk of 
osteoarthritis [2,28], but that was not found in our series. The relatively high 
recurrence rate in our study may partly be explained by the fact that we did 
not perform extended curettage including high-speed burring during the 
evaluated time frame. Now, high-speed burring is performed whenever it is 
technically possible. However, the largest confounder of the high recurrence 
rate is our wide indication for curettage, including the majority of patients 
with soft-tissue extension and pathologic fracture. En bloc resection is rarely 
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the primary treatment for GCTB at our center [30,31]. Intra-articular pathologic 
fractures have also been suggested to increase the risk for osteoarthritis, but we 
could not confirm that finding [28,29]. Finally, we found no association between 
osteoarthritis and sex, age over sixty years, follow-up longer than ten years, or 
complications, but most patients were relatively young and osteoarthritis may 
appear with longer follow-up [34].
The functional outcome and quality-of-life scores were comparable between 
the patients with KL3-4 and those with KL0-2, and quality of life was 
comparable with that of age-matched cohorts of the general population 
[37]. Despite radiographic evidence of osteoarthritis in a small group of our 
patients, it is likely not a clinical concern at the time of mid-term follow-up. Yet 
this clinical relevance may increase with time, and longer follow-up is required. 
The discrepancy between the degree of osteoarthritis and clinical symptoms 
was found in 33% of patients with osteoarthritis in a previous study [34]. Other 
investigators have reported similar functional results and quality of life after 
curettage with and without PMMA [3,12,13,22,26], but no previous study to our 
knowledge compared functional results and quality of life between patients 
with and those without osteoarthritis after curettage and PMMA. Only Chen et 
al. demonstrated a decrease of 3% in the MSTS score for every 10% increase in 
subchondral bone involvement [26]. 
Since the risk of osteoarthritis was not increased after repeat curettage and 
application of PMMA, we concluded that PMMA is a safe material and that 
curettage is a good treatment option for primary and recurrent GCTB. When 
progression to KL3-4 is noted and patients have severe physical symptoms, 
PMMA may be removed and replaced with cancellous bone graft, potentially 
facilitating total knee replacement in the future. In future, PMMA substitutes 
with similar hyperthermic effects, better osteoconductive and osteoinductive 
properties, and more favorable elasticity may be used [43-45]. Resection and 
endoprosthetic replacement as primary treatment for GCTB close to the joint 
surface is not advocated, as the expected risk for eventual joint arthroplasty 
remains low.
Our study has several limitations. First, a control group without use of PMMA 
was not available. Ideally, we would have compared the results with the 
contralateral knees in the same patients or with curettage without use of 
PMMA. However, as radiographs were made for oncological follow-up, the 
contralateral knees were not depicted. Second, measurement of joint space 
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narrowing would have been valuable for objective assessment of radiographic 
findings of osteoarthritis. The KL graded is determined on non-weight-bearing 
radiographs, as proposed in the original publication on this system [32], and 
joint space narrowing could not be measured accurately. 
In conclusion, the prevalence of osteoarthritis on the latest follow-up radiograph 
was increased after curettage and application of PMMA for GCTB around 
the knee. Large subchondral bone defects and close proximity to the joint 
surface increased the risk of osteoarthritis. The role of PMMA in osteoarthritis 
development remains unclear. Overall, functional outcomes and quality of life 
were unaltered for patients with radiographic findings of osteoarthritis. None 
of the patients required surgery for osteoarthritis at the time of intermediate 
follow-up, but the clinical relevance may increase over time as our study 
population was young and prolonged follow-up is advocated. Curettage and 
application of PMMA is a safe option for primary and recurrent GCTB, even with 
a large amount of subchondral bone involvement close to articular cartilage.
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Abstract
Background Giant cell tumors of the synovium and tendon sheath can be 
classified into two forms: localized (giant cell tumor of the tendon sheath, GCT-
TS; or nodular tenosynovitis) and diffuse (diffuse-type giant cell tumor, Dt-GCT; 
or pigmented villonodular synovitis, PVNS). The former principally affects the 
small joints. It presents as a solitary slow-growing tumor with a characteristic 
appearance on MRI and is treated by surgical excision. There is a significant 
risk of multiple recurrences with aggressive diffuse disease. A multidisciplinary 
approach with dedicated MRI, histological assessment and planned surgery 
with either adjuvant radiotherapy or systemic targeted therapy is required to 
improve outcomes in recurrent and refractory Dt-GCT.
Treatment Although arthroscopic synovectomy through several portals has 
been advocated as an alternative to arthrotomy, there is a significant risk of 
inadequate excision and recurrence, particularly in the posterior compartment 
of the knee. For local disease, partial arthroscopic synovectomy may be 
sufficient, at the risk of recurrence. For both local and diffuse intra-articular 
disease, open surgery is advised for recurrent disease. Marginal excision with 
focal disease will suffice, not dissimilar to the treatment of GCT-TS. For recurrent 
and extra-articular soft-tissue disease adjuvant therapy, including intra-
articular radioactive colloid or moderate-dose external beam radiotherapy, 
should be considered.




Giant cell-rich tumors are classified according to their site of origin, namely 
bone, soft tissue, synovium or tendon sheath. Those that arise from tendons and 
synovium are now classified into two forms: localized (nodular tenosynovitis) 
and diffuse (pigmented villonodular synovitis). In the World Health Organization 
(WHO) classification [1] the former is described as giant cell tumor of tendon 
sheath (GCT-TS), whereas the latter, which was first recognized and described by 
Jaffe, Lichtenstein and Sutro [2] in 1941 as a reactive or inflammatory disorder 
of the synovium of large and small joints, is described as diffuse-type giant cell 
tumor (Dt-GCT). The disease is mono-articular, and chromosomal aberrations 
are seen in both forms, suggesting a neoplastic rather than a reactive origin [3].
Giant cell tumor of tendon sheath (GCT-TS)
This local form of the disease can occur in any age group but principally affects 
those between 30 and 50 years of age, with a female predominance [4]. Most 
commonly it presents as a soft-tissue swelling in the hand or foot, adjacent 
to a small joint and arising from a tendon sheath or the synovial lining of a 
joint or bursa. It is often painless and slow growing, fixed to deep structures 
and abutting the bone, which can be eroded by pressure to cause scalloping 
[4]. In >10% of patients it arises from the synovium [5]. Solitary disease is also 
common in the knee and may present as an incidental finding on MRI or, 
more commonly, with mechanical symptoms mimicking a meniscal injury or 
‘loose body’, which suggests a pedunculated tumor (Figure 1A). Extra-articular 
disease presents as a slow-growing non-painful, often palpable peri-articular 
mass. It is a benign condition, but may recur if incompletely excised [6].
Diffuse-type GCT (Dt-GCT)
This is a rare, usually benign proliferative tumor that develops in the synovium, 
with an incidence of two per 1,000,000 per year [1] in patients ≤40 years old, 
with an equal gender distribution. The knee is the most common site (Figure 
1B); the elbow, ankle and hip are less common, and rarely the foot and 
temporomandibular joint may be involved. The spine may be affected, notably 
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the sacroiliac joints and posterior vertebral elements [7]. Characteristically 
there is a long history, with a delay in diagnosis. The patient often presents 
with an intermittently tender and painful joint. In the knee and ankle there may 
be recurrent swelling with spontaneous haemarthrosis. Although considered 
to be a benign condition, the diffuse form is more aggressive, with a high 
recurrence rate after surgery of 25% with intra-articular and 25% to 50% with 
extra-articular disease [8]. 
Figure 1 (A) Sagittal gradient echo MRI in a 41-year-old man with persistent pain in the right knee, 
showing the local form of the disease (giant cell tumor of tendon sheath, GCT-TS). MRI shows a well-
defined soft-tissue mass dorsal to the posterior cruciate ligament and in close relationship to the knee 
capsule (white arrow). The lesion shows focal hypointense areas, owing to the ‘blooming’ artifact from 
haemosiderin. (B) Sagittal T1-weighted MRI in a 61-year-old man showing recurrence of the diffuse form 
of disease (Dt-GCT) (white arrow). MRI after intravenous gadolinium with fat suppression reveals an 
extensive proliferative synovial process of the left knee with a heterogeneous enhancement and areas 
of low signal intensity typical of iron deposition. Here, Dt-GCT is localized diffuse and intra-articular in 
relation to a large Baker’s cyst (black arrow).
A review of the management of this disease is merited for a number of reasons: 
The reclassification of the disease, according to the site and the tissue of origin, 
recognizes two distinct forms, nodular and diffuse, with the latter behaving in 
a more aggressive manner.
With improvements in imaging, notably MRI, a radiological and pathological 
diagnosis of the condition can be made, identifying the extent of disease and 
allowing for planned treatment and resection.
Recognition of this condition as a tumor rather than a reactive or inflammatory 
disorder, with a chromosome aberration identified in both the local and diffuse 
forms.
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The need for a multidisciplinary approach to the management of diffuse 
disease, with selective histology and planned surgical resection to avoid the 
high incidence of local recurrence.
The potential use of adjuvant radiation and novel targeted therapies, such as 
macrophage colony-stimulating factor 1 receptor (M-CSFR)-targeted tyrosine 
kinase inhibitors (e.g. imatinib) as non-surgical treatment for aggressive Dt-
GCT (PVNS) or for recurrent disease.
Imaging
Conventional radiographs combined with MR imaging will establish the 
diagnosis of Dt-GCT and accurately determine the extent of the disease. 
Although the appearance can be characteristic, image-guided percutaneous 
needle biopsy for histopathological examination may be indicated, particularly 
if there is doubt about the diagnosis. 
Conventional radiographs are often not diagnostic. With advanced disease 
there may be evidence of soft-tissue swelling, loss of joint space and peri-
articular erosion of bone. The peri-articular erosions are more notable in joints 
with a tight capsule, such as the hips, elbows, hands and feet (Figure 2). 
The joint space is preserved until late in the disease. In addition to the absence 
of peri-articular osteopenia this feature is helpful in differentiating Dt-GCT 
from an inflammatory synovitis. 
On MRI the appearance of Dt-GCT is often characteristic owing to the 
presence of haemosiderin [9]. The lesions demonstrate predominantly low 
signal intensity on T1- and T2-weighted spin echo sequences. The presence 
of haemosiderin deposits causes local changes in susceptibility (‘blooming 
effect’), especially on gradient echo sequences, resulting in disproportionately 
lower signal intensity areas. Marked enhancement is seen on T1-weighted MR 
images after the intravenous injection of gadolinium. 
The differential diagnosis on MRI includes rheumatoid pannus, amyloid 
arthropathy, synovial haemangioma, haemophilia, and desmoid-type 
fibromatosis, which can be resolved on the basis of clinical history and 
laboratory findings. MR morphology and enhancement characteristics can be 
confirmed with biopsy and formal histological examination.
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Figure 2 (A) Radiograph of the left hip of a 22-year-old man with a three-year history of progressive pain 
in his left groin, showing diffuse-type giant cell tumor (Dt-GCT) with erosive destruction of the hip joint. 
There are lytic lesions with well-defined sclerotic margins on both sides of the joint, (black arrows) 
consistent with a synovial process. (B) Corresponding coronal T2-weighted MRI with fat suppression 
demonstrates the erosive destruction of the acetabulum, femoral head and neck as a result of extensive 
synovial proliferation. The areas of low signal intensity within the synovial mass indicate the presence of 
haemosiderin deposits characteristic of Dt-GCT (white arrows).
Genetics
Dt-GCT and GCT-TS are giant cell tumors that both express an osteoclast-like 
antigenic phenotype; the cells show calcitonin receptors and are capable of 
lacunar resorption of bone [10-13]. It is thought that osteoclast-like giant cells 
are formed from mononuclear macrophage precursors by a receptor activator 
of nuclear factor-kappa B ligand (RANKL)-dependent mechanism similar to 
that seen in giant cell tumors of bone and soft tissues [10, 14-16]. 
The tumors are driven by overexpression of macrophage colony-stimulating 
factor 1 (M-CSF1). In 30% to 60%, M-CSF over-expression results from a t(1;2) 
translocation, which fuses the M-CSF gene on chromosome 1p13 to the collagen 
6A3 (COL6A3) gene on chromosome 2q35 [3, 17]. M-CSF1 is only expressed by 
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a minority of tumor cells, which in turn attract non-neoplastic inflammatory 
cells that express M-CSF1R through a paracrine or so-called landscape effect 
[3]. M-CSF is produced by synovial fibroblasts with increased expression of 
M-CSF by proliferating cells, leading to the accumulation of macrophages and 
the formation of a tumor-like mass [3]. In benign disease mitotic activity is less 
but in the aggressive form, mitotic rates are increased to > 20 mitoses per ten 
high-power fields. 
This molecular characterization of Dt-GCT has resulted in the development of 
new systemic targeted therapies for the aggressive form and for recurrent disease 
[18]. A malignant form of the disease was first reported by Bertoni et al. [19] but 
is thought to be a debatable entity that needs to be proven by linear studies [20].
Pathology
Macroscopically, Dt-GCT is red-brown or yellow and contains numerous 
capillary fronds and nodular areas that in the diffuse form often involve the 
whole synovium. However, focal interrupted areas in normal synovium may be 
a feature of disease in the knee [1]. 
Histological examination reveals villous hypertrophy of the synovial membrane 
with subintimal macrophage infiltration. There are numerous lipid-laden 
foamy macrophages and scattered multinucleated giant cells. The tumor has 
a fibrous stroma and may contain bands of collagen with brisk mitotic activity 
in the subintimal stromal cells. Haemosiderin may be present within the 
synovial lining cells and the subintimal macrophages (siderophages), and it 
may be extracellular within the subintima. Its presence is significant because it 
produces the characteristic signal appearances noted on MRI, which are useful 
for diagnosis of this disease.
Surgery
Giant cell tumor of tendon sheath (GCT-TS)
In the hand and foot this presents as a solitary swelling next to a small joint, 
whereas in the knee and ankle it may be an intra-articular solitary lesion or a 
peri-articular lesion fixed to a tendon sheath or bursa. 
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As with any solitary solid tumor that is fixed to the deep tissues it is important 
that imaging supports the diagnosis of GCT-TS; if there is any doubt about 
the diagnosis a formal tissue biopsy must be undertaken. Rarely peri-articular 
malignant conditions may mimic GCT-TS, including synovial, epithelioid and 
clear cell sarcoma in the hand; these conditions can present in similar fashion 
as can other common benign solid soft-tissue lesions (such as haemophilia, 
synovial hemangioma, rheumatoid pannus, amyloid arthropathy and 
desmoid-type fibromatosis) [4]. Careful clinical examination, MR morphology 
and enhancement characteristics can usually differentiate between these 
conditions. Planned surgical excision, aiming for a clear margin, is advised 
when a solid diagnosis is established. 
In the hand and the foot GCT-TS is a solitary non-invasive firm tumor, generally 
0.5 cm to 3.5 cm in size [4]. As it is a slow-growing lesion it displaces adjacent 
structures and rarely involves nerves and blood vessels. In our opinion an 
extensile approach centered over the lump in the long axis of the digit is 
recommended, so that adjacent neurovascular structures can be identified 
first and separated from the pseudo-capsule. Skin flaps need to be developed 
carefully, fully identifying the tumor, which has the characteristic appearance of 
a well-circumscribed lobular mass. The cut surface has a variegated pink-grey 
appearance with flecks of yellow and brown tissue. In principle, a solitary tumor 
can be excised marginally with associated affected soft tissue. After careful 
excision of solitary tumors of the digits and of the larger joints, a recurrence 
rate of <15% is expected [21]. Histological confirmation is mandatory, and the 
patient must be advised that if further soft-tissue masses develop they should 
seek review that should include MR imaging. 
Arthroscopic resection has been advocated for solitary tumors of the large 
joints, notably the knee [22, 23], which in expert hands can be technically 
successful for focal intra-articular disease and small accessible solitary solid 
tumors. However, if the lesion is misdiagnosed pre-operatively and afterwards 
appears to be malignant (i.e. not Dt-GCT), intra-articular spread of a malignant 
tumor and incomplete excision of the disease may result. 
We would recommend open excision for extra-articular solitary tumors of 
large joints and for inaccessible intra-articular disease, such as for the posterior 
knee or fixed synovial disease, an extensile approach should be used, with 
arthrotomy, which can be extended if revision surgery is required [22, 23]. 
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Formal excision, either marginally or with a cuff of tissue, is required and 
histological examination mandatory.
Diffuse-type giant cell tumor (Dt-GCT) 
The current management of this is controversial, owing in part to the rarity and 
heterogeneity of the disease and the limited evidence available, particularly 
in the knee. What is recognized is the high recurrence rate, at 25% for intra-
articular and 50% for extra-articular disease, which is dependent on the site, 
volume of disease, intra- or extra-articular extent and previous surgery [1, 8].
In the knee arthroscopic synovectomy has been advocated, with better 
functional results and lower rates of post-operative stiffness. Local recurrence 
can occur if excision is incomplete [24]. 
Arthroscopic synovectomy requires technical expertise, and complete excision 
is rarely achieved even by experienced arthroscopic surgeons. In order to treat 
diffuse disease, many portals may be required to access the posterior and 
collateral joint recesses, with the risk of seeding the disease into the soft tissues 
around the portals. 
The posterior joint, collateral ligaments and cruciate attachments are often 
difficult to visualize and treat arthroscopically. The recommended treatment 
for large-volume diffuse disease therefore remains open arthrotomy [25-27]. 
Combined or staged surgery may be considered if there is limited anterior 
disease that is accessible to arthroscopic synovectomy. However, with posterior 
disease an open posterior approach is required. We prefer an extensile approach, 
with a lazy-S incision, and elevation of the origin of the medial or lateral heads 
of gastrocnemius to allow protection of the neurovascular structures. Formal 
arthrotomy to visualize the posterior cruciate ligament and articular surfaces 
must be undertaken to obtain access to the synovium. 
A midline anterior approach is advised for anterior disease, as this allows good 
visualization of the synovial cavity, fat pad, cruciate and collateral ligaments. 
Residual tumor adjacent to the joint line and unilateral gutters can be safely 
resected. 
Although an open approach with complete synovectomy for diffuse disease 
remains the standard treatment, high recurrence rates can still be expected. A 
multidisciplinary approach, including careful assessment with MRI of the knee 
and complete synovectomy, either as a single or a staged procedure, results in 
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a lower recurrence rate and fewer complications [28]. However, arthrotomy of 
the knee is associated with a prolonged hospital stay and rehabilitation, with 
the incidence of joint stiffness as high as 24% [29]. 
Dt-GCT is also not uncommonly found in the elbow and ankle joints. A similar 
approach as for the knee is advised, with careful imaging and a tissue diagnosis 
with planned open surgery [30]. An extensile approach with identification and 
protection of the neurovascular structures should be undertaken, and attention 
should be paid to complete clearance of the synovium under direct vision. 
With extensive joint destruction or the development of secondary arthritis, 
arthroplasty is indicated. In the hip, ankle or knee a conventional procedure 
is advocated, although with Dt-GCT the failure rate is reported as higher than 
with conventional arthritis [31, 32]. A failure rate of 22% has been reported 
following total knee replacement and complete synovectomy for Dt-GCT 
[32]. A marginally improved rate is reported in the hip [33]. These patients are 
generally younger than those who undergo conventional joint replacement 
and often have multiple procedures, with an increased risk of complications.
Radiosynovectomy
Intra-articular injection of yttrium-90 (90Y)-labeled colloid can be used as a local 
adjuvant after synovectomy, but only for localization of intra-articular disease. 
At present, doses of 15 mCi to 25 mCi (555 MBq to 925 MBq) are administered 
six to eight weeks post-operatively, depending on the volume of the joint and 
body size [34-37]. Although caution is needed when using radioactive agents 
in the treatment of benign lesions, instillation of intra-articular radioactive 
colloids seems safe and effective after subtotal synovectomy. Recurrence rates 
of 0% to 25% are reported, but there is little evidence regarding outcomes, 
as the number of cases in most series is small [34, 35, 38]. Ottaviani et al. [39] 
presented the largest, albeit mixed, group of patients with Dt-GCT (n=122) 
treated by radiosynovectomy with a relatively high recurrence rate of 30% 
in the knee (15 of 50) and 9% in other locations (two of 23). However, it is 
unclear from their report whether the lesions were localized or diffuse, and for 
which lesions an open or arthroscopic approach was used. Both parameters 
significantly influence the recurrence rate.




External beam radiotherapy can be used as primary treatment for unresectable 
disease or as local adjuvant treatment in incompletely resected or extensive 
Dt-GCT, improving local tumor control [40-44]. An average dose of 30 Gy to 
50 Gy (in 15 to 20 fractions) has the advantage of staying under the threshold 
for fibrosis formation and avoiding long-term radiotherapy-related toxicity. 
Recurrence is reported to be between 7% and 67% for different tumor sites [41, 
43, 45-47]. No significant complications of radiotherapy were seen in this group 
of patients [7, 34, 44, 45, 48, 49].
Neo-adjuvant systemic targeted therapy
The molecular characterization of Dt-GCT facilitates the use of systemic targeted 
therapies as a novel method of treatment for patients in whom surgery would 
produce significant functional impairment, or for those with unresectable Dt-
GCT. 
Although M-CSF over-expression is present in a minority of neoplastic cells, the 
majority of mononuclear and multinucleated stromal cells in Dt-GCT express 
high levels of M-CSFR, which is thought to be responsible for the formation 
of a tumor mass [3, 17, 50]. This signaling pathway seems a promising target 
for systemic therapy with tyrosine kinase inhibitors such as imatinib or related 
compounds. Imatinib is an approved drug for the treatment of chronic myeloid 
leukemia (CML) and gastrointestinal stromal tumors (GIST); it acts on cells of 
the monocyte/macrophage lineage with M-CSFR [50]. Recently, it has been 
shown to induce some tumor regression in patients with advanced Dt-GCT [18, 
28, 51]. 
In 2008, the first case report of the activity of imatinib in recurrent M-CSFR-
dependent Dt-GCT was published [51]. The patient was treated with imatinib 
400 mg/day. After a complete response at five months, the Dt-GCT recurred 
when the drug was stopped. At re-introduction a secondary complete 
remission was reported. 
Additionally, it showed promising activity in two preliminary case series [18, 
28]. In one, five of six patients reported pain relief, three had regression of 
disease, and two patients found the disease stabilized with this treatment [28]. 
The second series revealed one complete remission, four partial remissions, 
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and in 20 of 27 patients the disease was stabilized [18]. The most common side 
effects were mild fluid retention, fatigue, nausea and skin toxicity. 
Although blockade of M-CSFR by imatinib in Dt-GCT would seem to be the 
most likely mechanism of action, the potential contribution of blockade of 
other tyrosine kinases by imatinib cannot be ruled out. Currently the role of 
imatinib and other tyrosine kinase inhibitors (e.g. nilotinib and sunitinib) is 
under investigation as a neo-adjuvant systemic treatment in advanced Dt-GCT 
(www.clinicaltrials.gov, NCT01261429 and NCT01207492). There may also be 
a therapeutic role for blockade of M-CSFR through other cytokines, notably 
interleukin (IL)-34, which interacts with this receptor [52]. In addition, as the 
formation of giant cells in Dt-GCT is known to be by a RANKL-dependent 
mechanism [16], there may be a role for RANKL antibody treatment to inhibit 
the formation of giant cells in this lesion, as in giant cell tumor of bone [14].
Summary
GCT of the tendons and synovium is now classified into two forms: localized 
(GCT-TS, nodular tenosynovitis) and diffuse (Dt-GCT, pigmented villonodular 
synovitis). The former principally affects the small joints and presents as a 
solitary slow-growing tumor with a characteristic MRI appearance, and is 
treated by planned surgical excision. 
Dt-GCT is a more aggressive intra-articular form affecting both small and 
large joints, most commonly the knee. Both local and diffuse diseases were 
previously thought to be of reactive inflammatory origin; however, both forms 
are now regarded as tumors of peri-articular tissue, as they share a common 
chromosomal aberration. 
There is a significant risk of multiple recurrences in diffuse disease. A 
multidisciplinary approach with dedicated MR imaging, histological assessment 
and planned surgery, with either adjuvant radiotherapy or systemic targeted 
therapy, is required to improve outcome in recurrent and refractory Dt-GCT 
(Figure 3). 
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Figure 3 Multidisciplinary integrated treatment protocol for local (GCT-TS) and diffuse (Dt-GCT) forms of 
disease (* although good results have been published on arthroscopic treatment, an open approach 
prevents contamination and potentially reduces the risk of recurrence); EBRT, external beam radiation 
therapy.
Although good results have been published for arthroscopic treatment 
of diffuse intra-articular disease [23-25], particularly of the knee, an open 
approach allows a more complete resection and potentially reduces the risk 
of recurrence. It is recommended that with both local and diffuse forms of the 
disease, resection and formal histological examination of the lesion should be 
undertaken. 
Open synovectomy is recommended for diffuse intra-articular involvement of 
the joint. After arthroscopic synovectomy for Dt-GCT of the knee, there is a 
high risk of incomplete excision and hence a risk of recurrence. Arthroscopy is 
advised to obtain a tissue diagnosis or for treatment of easily accessible solitary 
or focal disease. 
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In selected cases without extra-articular spread, instillation of intra-articular 
radioactive colloid can be a safe and potentially effective local adjuvant 
treatment, although there is still little evidence to support its universal 
application. 
Diffuse local recurrences in the knee can be treated with open two-stage 
synovectomy and resection of all affected tissues, possibly followed by 
moderate-dose external beam radiation. Moderate-dose radiotherapy 
will improve midterm local control (75% to 98%) and minimize long-term 
radiotherapy complications. Radiotherapy is recommended prior to advanced 
joint destruction, particularly in recurrent disease; it can safely be used for the 
knee, shoulder and hip, but is not advocated for the hands and feet. 
If the Dt-GCT has an extra-articular component, one- or two-stage open 
synovectomy with resection of all affected soft tissues is advised. Radioactive 
colloid instillation is not indicated, and external beam radiotherapy should be 
considered in the presence of extensive soft-tissue disease. 
For unresectable disease, MRI with radical planned resection, joint 
reconstruction with joint replacement and consideration of radiotherapy is 
advised. Inclusion in a trial of neo-adjuvant systemic targeted therapy (targeting 
MCSFR, for example imatinib or related tyrosine kinase inhibitors) can be 
considered, notably when radiotherapy is contraindicated. Data on systemic 
treatment in large study populations will follow in the near future, and with 
the new systemic targeted treatments for Dt-GCT treatment optimization will 
require review and validation. This includes mono versus combination therapy, 
obtaining the optimal balance between the benefits of alleviating functional 
impairment against the potential toxicity of the treatment and its duration, the 
timing of operation and the mechanism of resistance to treatment. 
Although arthroscopic synovectomy through multiple portals has been 
advocated as an alternative to arthrotomy [20, 39-41], there is a significant risk 
of inadequate excision and subsequent recurrence, particularly in the posterior 
compartment of the knee. For local disease, partial arthroscopic synovectomy 
may be sufficient at the risk of recurrence. Open surgery for both local and 
diffuse intra-articular disease is advised for recurrent disease. Marginal 
excision with focal disease will suffice, not dissimilar to the treatment of GCT-
TS [42]. With recurrent and extra-articular soft-tissue disease adjuvant therapy, 
including intra-articular radioactive colloid or moderate-dose external beam 
radiotherapy should be considered.
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Abstract
Background Giant cell tumors deriving from synovium are classified into a 
localized (giant cell tumor of tendon sheath; GCT-TS) and diffuse form (diffuse-
type giant cell tumor, Dt-GCT). We propose a multidisciplinary management 
based upon a systematic review and authors’ opinion. 
Treatment Open excision for GCT-TS and open synovectomy (plus excision) for 
Dt-GCT is advised to reduce the relatively high recurrence risk. External beam 
radiotherapy should be considered in severe cases, as Dt-GCT commonly 
extends extra-articular.




Although pigmented villonodular synovitis (PVNS) was first described as entity 
by Jaffe et al. in 1941 [1], the histological, clinical and radiological definition 
of this lesion remained unclear for years. Ambiguous naming was used for 
synovial lesions resulting in controversies in literature [2, 3]. In 2002, the World 
Health Organization differentiated giant cell-containing tumors to their origin: 
bone, soft tissue, synovium and tendon sheath (Table 1). Diffuse PVNS was 
renamed to diffuse-type giant cell tumor (Dt-GCT) and local PVNS into giant 
cell tumor of tendon sheath (GCT-TS) [4]. 
Table 1 WHO classification of giant cell rich soft tissue tumors 
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Dt-GCT is a benign proliferative lesion which develops in the synovial lining 
of joints, tendon sheaths and bursae [5]. The incidence is approximated at 
two per million people per year, mostly under the age of 40 and with an equal 
distribution between the sexes [4]. Multiple joint involvement is rare [6]. A 
distinction is made between localized and diffuse lesions. Local forms (GCT-TS) 
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are confined to a distinct area of synovium (Figure 1), whereas diffuse forms 
(Dt-GCT) demonstrate extensive involvement of the whole synovial membrane 
and capsule (Figure 2; Table 1). 
Figure 1 (A) Sagittal T1-weighted and (B) sagittal fast spin-echo proton density-weighted MR images of 
localized GCT-TS of the knee in a 43-year old male patient, presenting with locking symptoms. A well-
defined soft tissue mass is revealed in Hoffa’s fat pad.
Figure 2 (A) Sagittal T1-weighted MR image after intravenous contrast injection with fat suppression in 
a 61-year old man with recurrent Dt-GCT reveals an extensive proliferative synovial process of the left 
knee with a heterogeneous enhancement with areas of low signal intensity typical for iron deposition. 
(B) Sagittal fast-spin echo proton density-weighted MR image shows Dt-GCT located in both anterior 
and posterior knee compartments, intra-articular around the anterior and posterior cruciate ligaments 
and in relation to a large Baker’s cyst.
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Main complaints are pain, (hemorrhagic) joint effusion and a limited range of 
motion [7]. With slow-growing tumors of synovium it is important to exclude 
other diagnoses prior to surgical intervention: e.g. synovial hemangioma, 
synovial chondromatosis and synovial sarcoma (the latter is usually extra-
articular but may be seen in the joint occasionally and should not be missed). 
The atypical pattern of complaints and wide differential diagnosis can result in 
delays of years in diagnosing this disease. 
The purpose of this article is outlining a framework for the diagnosis and 
management of giant cell tumors of synovium and tendon sheaths. Making 
use of recent literature (1990–2011)—containing all available cases with 
clear descriptions of disease extent—and local experience we aim for a 
multidisciplinary integrated recommendation on treatment for local and 
diffuse forms of synovial giant cell tumors.
Literature search
We performed a systematic literature search reviewing all available literature 
on Dt-GCT until October 7, 2011. We limited ourselves to the systematic review 
of literature on Dt-GCT, since there are fewer consensuses about its optimal 
treatment when compared with localized GCT-TS. Search terms and MeSH 
headings were ‘PVNS’, ‘pigmented villonodular synovitis’, ‘synovitis, pigmented 
villonodular’, ‘diffuse type giant cell’, ‘giant cell tumors’ and ‘GCT’ and we laid 
particular emphasis on the large joints such as the knee, hip, and ankle. We 
identified 1,057 titles in PubMed, EMBASE, Web of Science and ScienceDirect.
All titles and abstracts were screened by one reviewer (LH) according to the 
following inclusion and exclusion criteria. We included only case series of five 
or more patients published after 1990 and articles must have been written in 
the English, Dutch, French, Italian or German language; other languages were 
excluded. Furthermore, we excluded articles focusing purely on radiological 
and/or pathological assessment of Dt-GCT, reviews without new clinical cases 
and articles on Dt-GCT in animals. Finally, we included 59 articles for systematic 
review (Figure 3) and critical appraisal according to the Newcastle-Ottawa 
Scale (NOS) for quality assessment of cohort studies (Table 2; Figure 4); this was 
performed by two independent reviewers (LH and MAJS).
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Figure 3 Flowchart of systematic literature search. Articles in the Chinese, Danish, Japanese, Norwegian, 
Russian, Serbian, and Spanish languages were excluded.
Figure 4 Newcastle-Ottawa Scale for quality assessment of cohort studies; overview of all studies. 
Studies with 5–6 points were considered of good quality, 3–4 points intermediate quality, and 2 points 
poor quality. Results correspond with NOS scores as provided in Tables 3-8.
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Table 2 Critical appraisal of all included studies (n=59) by means of Newcastle-Ottawa quality 
assessment Scale (NOS); one point could be obtained for each item of the NOS.
n %
Selection
Representativeness of the exposed cohort 59 100%
Selection of non-exposed cohort* N.A. N.A.
Ascertainment of exposure** 45 76%
Demonstration that outcome of interest was 
not present at start of study†
13 22%
Comparability of cohorts*
Study controls for most important factor N.A. N.A.
Study controls for any factor N.A. N.A.
Outcome
Assessment of outcome‡ 45 76%
Follow-up long enough (minimum 2 years) 25 42%
Adequacy of follow-up (≥ 90% of all patients) 51 86%
Scores
6 points 3 5%
5 points 21 36%
4 points 20 34%
3 points 8 14%
2 points 7 12%
N.A. = Not applicable
*In this modified NOS, no points were accredited for selection of the non-exposed cohort and compara-
bility of cohorts, because all studies were descriptive and contained only one cohort.
**Through secure records (e.g. medical records, radiological, pathological and surgical reports) or struc-
tured interviews.
†Explicit demonstration that all included patients were treated for primary Dt-GCT and not for local 
recurrence; this might induce bias.
‡Through independent blind assessment (e.g. by independent surgeons, radiologists or pathologists) 
or record linkage.
Imaging
Conventional radiographs are followed by MR imaging to establish a proper 
diagnosis and determine the extent of the lesion. Although Dt-GCT has in most 
cases a characteristic appearance on MR imaging, image guided percutaneous 
needle biopsy can be necessary to confirm the diagnosis. In experienced 
centers, small localized intra-articular lesions with characteristic MR imaging 
appearances may be removed open or arthroscopically without prior biopsy. 
Conventional radiographs often appear normal or demonstrate a nonspecific 
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peri-articular soft tissue swelling or joint effusion [3]. Associated bone 
erosions with a sclerotic margin may be present on both sides of the affected 
joint, especially in joints with a tight capsule such as the hip (Figure 5). The 
preservation of the articular joint space until relatively late in the disease, and 
the absence of peri-articular osteopenia is helpful to differentiate between Dt-
GCT and inflammatory synovitis. 
Figure 5 (A) Anteroposterior conventional radiograph of the pelvis demonstrates Dt-GCT with erosive 
destruction of the hip joint in a 22-year old man with a history of progressive pain in his left groin since 
three years. The right hip joint is normal. Conventional radiograph of the left hip shows geographic lytic 
lesions with well-defined sclerotic margins on both sides of the joint consistent with a synovial process. 
(B) Corresponding coronal T1-weighted MR image demonstrates the erosive destruction of the 
acetabulum and femoral neck as a result of extensive synovial proliferation. The lesions show areas of 
remarkable low signal intensity indicating the presence of hemosiderin depositions characteristic for 
Dt-GCT.
Hemosiderin depositions cause local changes in susceptibility—the so-called 
blooming effect—resulting in the characteristic appearance of Dt-GCT on 
MR images, demonstrating predominantly low signal intensity on T1- and T2-
weighted spin echo sequences (Figure 1) [8]. After intravenous Gadolinium 
administration marked enhancement is often noted. The differential diagnosis 
on MR includes hemophilia, synovial hemangioma, rheumatoid pannus, 
amyloid arthropathy, and desmoid-type fibromatosis. One can differentiate 
between these diagnoses on the basis of clinical history (in case of rheumatoid 
arthritis and hemophilia), laboratory findings (for amyloid arthropathy in 
patients with renal failure undergoing long-term hemodialysis), and MR 
morphology and enhancement characteristics. Pathognomonic MR imaging 
findings of synovial hemangioma consist of a lobulated intra-articular mass 
with marked hyperintensity on T2-weighted MR images reflecting blood within 
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vascular spaces in combination with septae and serpiginous vascular structures. 
Desmoid-type fibromatosis are usually centered in an intermuscular location 
with irregular infiltrative margins. Extension along fascial planes (‘fascial tail 
sign’) is also a common manifestation which helps in the differential diagnosis 
with Dt-GCT.
Genetics
Giant cells within Dt-GCT express an osteoclast-like antigenic phenotype 
(CD45+, CD68+, CD14–, CD11/18–, HLA-DR–, CD51) [9–12]. They also express 
calcitonin receptors and are capable of lacunar bone resorption. Only recently 
it was identified that the osteoclast-like giant cells in Dt-GCT are formed from 
CD14+ macrophage precursors and that CD14– subintimal stromal cells express 
receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage 
colony-stimulating factor (M-CSF) [13]. It is thus likely that the osteoclast-
like giant cells in Dt-GCT are formed from CD14+ mononuclear macrophage 
precursors by a RANKL-dependent mechanism in a manner similar to that seen 
in giant cell tumor of bone and soft tissues [12, 14, 15]. 
M-CSF is produced by synovial fibroblasts and abnormal expression of M-CSF 
and its receptor (M-CSFR) has been noted in mononuclear cells in Dt-GCT [16]. 
M-CSF is required for macrophage formation and survival and it plays a role 
in osteoclast formation [17–19]. A translocation involving chromosome 1p13, 
a locus that includes M-CSF gene, has been noted in local and diffuse forms 
of Dt-GCT [20–22]. It has been postulated that Dt-GCT arises on the basis of 
a tumor landscaping effect in which there is increased M-CSF expression by 
proliferating cells within the lesion; this would lead to an abnormal accumulation 
of macrophages that expressed M-CSFR, resulting in the formation of a tumor-
like mass [23]. This signaling pathway could potentially be a good target for 
systemic therapies as a new treatment for Dt-GCT requiring mutilating surgery, 
diffuse unresectable and recurrent Dt-GCT.
Histopathology
Grossly, the synovium in Dt-GCT is thickened, red-brown or yellow, and contains 
numerous papillary frond or larger nodular areas. Local lesions (GCT-TS) have 
a pedunculated, lobular form and are confined to one area of the synovium. 
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Diffuse lesions (Dt-GCT) usually involve all of the synovium, but focal areas of 
normal synovium may be found. 
Histologically, there is villous hypertrophy of the synovial membrane with 
intimal thickening and heavy subintimal macrophage infiltration. Synovial lining 
cells contain hemosiderin and extracellular hemosiderin deposits are present 
in the subintima (Figure 6). Hemosiderin is also present within subintimal 
macrophages (siderophages). Collections of lipid-laden foamy macrophages 
and multinucleated giant cells are present. Scattered lymphocytes, plasma 
cells, and occasionally large lymphoid aggregates are also commonly found. 
The lesion has a fibrous stroma which may contain broad bands of collagen. 
Brisk, typical mitotic activity may be seen in subintimal stromal cells.
Figure 6 Hematoxylin eosin staining showing histologic characteristics of Dt-GCT. (A) Overview 
photograph of Dt-GCT. (B, C) Close-up photographs of Dt-GCT. Villonodular protrusions are seen with 
overlying synovial lining cells. There is villous hypertrophy with intimal thickening and subintimal 
macrophage infiltration. Characteristic brownish intracellular hemosiderin is seen in synovial lining cells 
and macrophages (siderophages) and extracellular hemosiderin depositions in the subintima. (D) 
Close-up photograph of Dt-GCT showing brown cytoplasmic intracellular hemosiderin and the 
presence of multinucleated giant cells.





Arthroscopic synovectomy through multiple portals has been advocated 
as alternative for open synovectomy in localized GCT-TS in the knee [7, 24–
26]. At the cost of a higher recurrence risk, arthroscopy has been advocated 
as it presents possibilities for biopsy and other pathology can be treated 
simultaneously. Morbidity, joint stiffness, postoperative infections, and 
reported pain may be reduced [7]. Either partial or complete arthroscopic 
synovectomy can be performed, dependent on disease extension. For local 
disease in the knee and other large joints, partial arthroscopic synovectomy 
(limited to the lesion) can be sufficient (Tables 3 and 4). 
Table 3 Surgical resection of localized GCT-TS in the knee




Stroz [52] 1990 4 6 40 (30-60) 0 0%  
Moskovich [53] 1991 5 9 48 (25-108) 0 0%  
Ogilvie-Harris 
[24]
1992 5 5 54 (24-120) 0 0%  
Rader [54] 1995 5 8 58 0 0%  
LeTiec [55] 1998 4 5 108 (36-204) 1 20% Arthroscopic 
synovectomy
Rochwerger [56] 1998 4 3 64 (24-168) 0 0%  
Zvijac [7] 1999 4 2 48 (42-53) 0 0%  
Kim [57] 2000 5 11 30 (24-48) 0 0%  
Muscolo [58] 2000 4 5 37 (12-55) 0 0%  
Perka [59] 2000 5 2 (36-108) 0 0%  
Rauh [60] 2002 5 3 66 (47-83) 0 0%  
Akgün [61] 2003 2 7 24 (12-33) 0 0%  
Calmet [62] 2003 2 5 36 (12-84) 0 0%  
De Ponti [26] 2003 2 4* 60 (12-128) 0 0%  
Pinaroli [63] 2006 3 2 97 (12-309) 1 50% Open synovectomy
Dines [64] 2007 3 12 21 (3-47) 0 0%  
Neubauer [65] 2007 5 4 30 (12-60) 1 25% Synovectomy  
Sharma [66] 2009 5 5 74 (12-156) 2 40% Open synovectomy 
(n=2)
Baroni [67] 2010 6 4 102 (46-143) 0 0%  
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Kubat [69] 2010 5 4 84 (28-127) 0 0%  
Total 117 7 6% (0-50%)  
Open resection
Groulier [70] 1991 4 5 N/A 0 0%  
Rader [54] 1997 5 2 58 0 0%  
LeTiec [55] 1998 4 2 108 (36-204) 0 0%  
De Visser [28] 1999 4 9 48 (12-228) 1 11% Synovectomy + 
EBRT (n=1)
Perka [59] 2000 5 16 (36-108) 0 0%  
Dürr [71] 2001 4 8 18 (1-54) 1 13% None
Calmet [62] 2003 2 4 36 (12-84) 0 0%  
Akgün [61] 2003 2 1 24 (12-33) 0 0%  
Chiari [72] 2006 5 9 80 (26-294) 0 0%  
Pinaroli [63] 2006 3 7 97 (12-309) 0 0%  
Dines [64] 2007 3 14 21 (3-47) 0 0%  
Sharma [73] 2007 5 4 72 (12-168) 0 0%  
Pannier [74] 2008 5 2* 58 (36-81) 0 0%  
Sharma [66] 2009 5 7 74 (12-156) 2 29% Open synovectomy 
(n=2)
Akinci [75] 2011 2 4 80 (15-156) 0 0%  
Total 94 4 4% (0-29%)  
EBRT = External beam radiation therapy 
*All patients were children
NOS = Newcastle-Ottawa Scale for quality assessment of cohort studies 
Table 3 Continued
 Year NOS n FU (months) Recurrences Recurrence 
rate (range)
Re-interventions
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Table 4 Surgical resection of localized GCT-TS in other locations







Stroz [52] 1990 4 1 Shoulder 40 (30-60) 0 0%  
Neubauer [65] 2007 5 1* Ankle 30 (12-60) 0 0%  
Total 2 0 0% (0%)  
Open resection
Looi [76] 1999 3 55 Hand (12-60) 4 7% Open syn-
ovectomy 
(n=1)
Chiari [72] 2006 5 12 Hand 80 (26-294) 0 0%  
Neubauer [65] 2007 5 1 Hand 30 (12-60) 1 100% Open syn-
ovectomy
Groulier [70] 1991 4 1 Hip N/A 0 0% THA (n=1)
Scapinelli [77] 1993 4 8 Hip (8-156) 0 0% THA (n=8)
Bisbinas [78] 2004 4 7* Ankle 41 (12-150) 0 0%  
Sharma [79] 2006 5 9 Ankle 55 (2-121) 0 0%  
Rochwerger 
[80]
1999 4 3 Foot 48 (13-110) 1 33% Amputa-
tion
Chiari [72] 2006 5 2 Foot 80 (26-294) 0 0%  
Carpintero [81] 2007 3 1 Foot 95 (12-174) 0 0%  
Total 99 6 6% 
(0-100%)
 
NOS = Newcastle-Ottawa Scale for quality assessment of cohort studies
* All patients were children
THA = Total hip arthroplasty
N/A = Not available 
For diffuse disease located in the knee, complete arthroscopic synovectomy is 
preferred over partial arthroscopic synovectomy as it lowers the recurrence risk 
(Table 5) [7, 24, 26, 27]. However, the risk of a subtotal synovectomy remains 
present because of the difficulty in visualizing the posterior compartment of 
the knee when performing a complete arthroscopic synovectomy and the 
recurrence risk remains high (~40%). Modern arthroscopic techniques and the 
approach through multiple portals are believed to reduce this risk [25].
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Open synovectomy
An open approach can be desirable for both GCT-TS and Dt-GCT and can be 
performed in all joints. 
For local disease, open resection limited to the lesion is sufficient (Tables 3 
and 4). Although local recurrences are rare for local lesions, open instead of 
arthroscopic resection is recommended to keep the recurrence risk as low as 
possible. 
For diffuse lesions about the knee, (two-stage) open synovectomy with a 
separate anterior and posterior approach is reported to be a safe surgical 
treatment option [2, 5, 27, 28]. Average recurrence rates are considerably lower 
than for arthroscopic synovectomy (14% versus 40%; Table 5). In other joints, 
open complete synovectomy is more often performed than arthroscopic 
synovectomy, with acceptable results (Table 6) [5, 27–31].
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Arthroplasty
Arthroplasty is indicated in case of joint destruction or development of 
secondary osteoarthritis. The hip, ankle, hand, and foot joints have tight 
capsules and lack the capacity to expand and provide space for larger tumor 
masses. As a consequence, the lesion can erode articular cartilage and extend 
into bone and surrounding soft tissues. Total hip replacement is therefore more 
often necessary than in joints with a less tight capsule. Expected revision rates 
for standard arthroplasty, i.e., for primary osteoarthritis, are 6% after 5 years and 
12% after 10 years and are identical for hip and knee [32]. Expected functional 
results are worse and risk for failure of prostheses placed for Dt-GCT (22% at 10 
years) is higher when compared to standard arthroplasty [33].
Intra-articular radioactive isotopes treatment
Instillation of 90-Yttrium (90Y) labeled colloid in the affected joint can be a 
safe local adjuvant after subtotal synovectomy. 90Y is a pure beta emitter with 
an energy of 935Kev, physical half-life of 64 hr, penetrating up to 10.8 mm 
in soft tissue although the effective therapeutic range is 2.8 mm (defined as 
the distant soft tissue in which 90% of the absorbed dose is deposited) [34]. 
Despite high radiation doses to (peri)articular tissues, there are no reports of 
subsequent synovial, chondral or periarticular bone tumor formation. However, 
some activity may escape from the joint and since this is in colloidal form, 
draining lymph nodes can receive significant absorbed dose and lymphocyte 
chromosomal damage may occur. The clinical impact of this chromosomal 
damage is unknown. 
For many years, dosages of 5 mCi (185 MBq) were given out of fear of inducing 
chromosomal damage by higher dosages, resulting in high recurrence rates 
(~50%) [35, 36]. At present, doses of 15–25 mCi (555–925 MBq) are administered 
at 6–8 weeks postoperatively, with dose adjustment according to joint volume 
and body size [36–39]. Intra-articular radioactive colloids seem safe and 
effective after subtotal synovectomy, even if caution is advised when treating 
benign lesions with radioactive agents. However, there is little evidence to 
support this practice, as case series are small and prospective trials are lacking 
(Table 7).
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Radiation therapy
External beam radiation can be a primary treatment in unresectable disease 
or an adjuvant treatment in incompletely resectable or recurrent Dt-GCT, 
improving local tumor control [25, 40–43]. Moderate dose external beam 
radiation (total of 35 Gy) offers a high chance of local control (75–98%) 
with avoidance of long-term radiotherapy induced toxicity. Most authors 
recommend radiotherapy prior to the moment that significant joint destruction 
occurs, particularly in recurrent disease. Radiotherapy is not advocated in 
the joints of hand and foot. Results of arthroscopic and open synovectomy 
followed by adjuvant radiotherapy for Dt-GCT in the knee are listed in Table 
8. Radiation doses ranged between 16–50 Gy. All patients had unresectable 
primary disease, unresectable residual disease after subtotal synovectomy or 
recurrent disease. Average recurrence rates ranged between 6 and 13% and 
were comparable for different tumor sites (Tables 6 and 8). No significant 
complications of radiotherapy were seen in any of the patients.
Systemic targeted therapy
Systemic targeted therapy against the M-CSFR can be a novel treatment—given 
the molecular characterization of Dt-GCT—for patients in whom surgery would 
result in significant functional impairment or who present with unresectable or 
rapidly recurring Dt-GCT. 
Although the M-CSF overexpression is present in a minority of neoplastic 
cells, the majority of mononuclear and multinucleated stromal cells in Dt-GCT 
express high levels of M-CSFR, responsible for the earlier described landscape 
effect and formation of a tumor mass (see Genetics section) [23, 44]. This 
signaling pathway seems a promising target for systemic therapy targeting 
M-CSFR such as imatinib, nilotinib or sunitinib [45]. 
This section focuses on the available literature for imatinib. This is a small 
molecule registered for chronic myeloid leukemia (CML), dermatofibrosarcoma 
protuberans (DFSP), and gastrointestinal stromal tumor (GIST). Besides the 
Abelson (Abl), Arg (abl-related gene), stem cell factor receptor (Kit) and platelet-
derived growth factor receptor A and B (PDGFRA and PDGFRB) tyrosine kinases, 
M-CSFR is one of its main targets [46]. Tumor regression is seen in patients with 
advanced Dt-GCT after treatment with imatinib [47–49].
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In 2008, the first case report of the activity of imatinib in recurrent M-CSFR 
dependent Dt-GCT was published [47]. The patient was treated with imatinib 
400 mg/day and a complete response was induced after 5 months of therapy. 
Following discontinuation of imatinib, the disease recurred. Reintroduction 
induced a secondary complete remission. 
In two case series, promising results of imatinib therapy were reported [45, 49]. 
Pain reduction (5 out of 6), disease regression (3 out of 6), and stable disease 
(2 out of 6) were achieved in the first report [45]. Additionally, results from 
27 evaluable patients were presented in a multi-center retrospective study. 
This series revealed one complete remission, four partial remissions, and 20 
patients with stable disease. Two patients had pulmonary or bone metastases. 
In 16 patients, symptomatic improvement was seen. Six patients discontinued 
therapy because of side effects and four because of non-medical reasons 
[49]. The most common side effects were fatigue, nausea, mild fluid retention 
and skin toxicity. Therefore the risk-benefit ratio should be considered in 
determining the utility of this treatment approach. 
Although the action of imatinib in Dt-GCT seems clear, the potential 
contribution of the blockade of other tyrosine kinases by imatinib cannot be 
ruled out. Currently, the role of nilotinib and PLX108-01 are investigated as 
systemic treatment in advanced Dt-GCT (www.ClinicalTrials.gov) [50, 51].
Conclusions
Results of a systematic literature search on surgical and adjuvant treatment, 
recurrence rates, and complications are listed in Tables 2-8. In all tables, the 
mean and range of the recurrence rates is provided for different treatment 
modalities, to estimate the true recurrence rates with more precision. The results 
were difficult to compare due to significant differences in location, disease 
extent, treatment protocols, and the small number of patients in reported case-
series and the absence of randomized trials. Therefore, recurrence rates varied 
widely, suggesting heterogeneity of the included studies and lack of reliable 
evidence. Our multidisciplinary treatment recommendations, based on both 
authors’ opinion and available evidence, are displayed in Figure 7.
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Figure 7 Multidisciplinary integrated treatment protocol for different forms of giant cell tumors of 
synovium and tendon sheath. Although good results have been published on arthroscopic treatment, 
an open approach is preferred preventing contamination and potentially reducing recurrence risk in the 
authors’ opinion. EBRT = Moderate dose external beam radiation therapy. 
First, good results have been published on arthroscopic treatment. However, 
an open approach prevents contamination and potentially reduces the (low) 
recurrence risk. Therefore, in the authors’ opinion localized GCT-TS would 
require an open resection of the lesion, even though recurrences are rare.
Second, in case of diffuse intra-articular joint involvement, one or two-stage 
(separate) open complete synovectomy is recommended. We believe that 
an arthroscopic approach for Dt-GCT about the knee presents a high risk 
of leaving residual tumor behind and thus increasing the recurrence risk. In 
selected cases without extra-articular in-growth, instillation of intra-articular 
radioactive colloids can be a safe and effective local adjuvant, although there 
is little evidence. Local recurrences can be treated with open (two-stage 
separate) repeated synovectomy and resection of all affected tissue followed 
by moderate dose external beam radiation.
Third, in case of diffuse extra-articular joint involvement, we recommend 
one- or two-stage (separate) open synovectomy with resection of all affected 
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soft tissues. There is no indication for the use of intra-articular instillation of 
radioactive colloids for Dt-GCT with an extra-articular component. Recurrences 
can be treated by open complete synovectomy, resection of all affected 
surrounding tissues and postoperative moderate dose radiotherapy.
Fourth, in case of unresectable disease we recommend radical resection and 
joint reconstruction followed by radiotherapy. Treatment with neoadjuvant 
systemic therapy targeting M-CSFR (e.g. imatinib, nilotinib in studies) can be 
considered for unresectable disease and when radiotherapy is not an option. 
Data on large study populations will be available in the near future. The use of 
systemic targeted therapy as primary treatment or as neoadjuvant treatment 
before surgery would need further testing in prospective trials. Optimal agent, 
mono- versus combination therapy, optimal balance between benefits of 
alleviating functional impairment against potential toxicity of therapy, therapy 
duration, surgery timing and mechanisms of therapy resistance require further 
investigation to optimize systemic treatment of Dt-GCT.
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Abstract
Background We evaluated influence of type of surgery on functional outcome 
and quality of life (QOL) for diffuse-type giant cell tumor (Dt-GCT) about the 
knee, previously known as pigmented villonodular synovitis (PVNS). 
Patients and methods We retrospectively reviewed 30 patients; 15 primarily 
treated at our tertiary center, 15 referred with recurrence (1980-2011). Median 
follow-up was 95 months (24-393). Functional outcome and QOL were assessed 
with range of motion, Knee injury and Osteoarthritis Outcome Score (KOOS), 
Musculoskeletal Tumor Society (MSTS) score, Toronto Extremity Salvage Score 
(TESS), SF-36. Results were compared with Chi-squared, Fisher’s Exact and 
Mann-Whitney U tests.
Results From 14 patients with open synovectomy as index surgery, 4/14 
recurred. Local control was achieved after second procedure in 75%. From 
16 patients with arthroscopic synovectomy as index surgery, 15/16 recurred. 
These patients underwent mean 1.8 arthroscopies (range 1-8) before open 
synovectomy at our center; the latter resulting in local control after one attempt 
in 47% and two attempts in 73%. After initial arthroscopic synovectomy and 
subsequent surgical procedures, impaired function and QOL were reported 
compared to initial open synovectomy: range of motion (114vs.127 degrees, 
p=0.03), KOOS (48vs.71, p=0.003), MSTS (19vs.24, p=0.02), TESS (75vs.86, 
p=0.03) and SF-36 (62vs.80, p=0.01).
Conclusions The majority of patients referred with recurrence underwent 
initial arthroscopy and multiple re-synovectomies. At latest follow-up, these 
patients had impaired function and QOL compared to patients who underwent 
initial open synovectomy and fewer subsequent surgeries. We may therefore 
conclude that the course of extensive disease treated with arthroscopic 
synovectomy is not favorable and that primary open synovectomy should be 
treatment of choice for severe Dt-GCT to prevent recurrent or residual disease 
activity.




Tenosynovial giant cell tumors are classified as localized and diffuse type [1,2]. 
In this study, we focused on diffuse-type giant cell tumor (Dt-GCT; previously 
known as pigmented villonodular synovitis), a benign but locally aggressive 
tumor with the capacity for autonomous growth and invasion of bone. The 
presence of chromosomal aberrations suggests a neoplastic rather than 
reactive origin [3]. Dt-GCT develops in synovial lining of joints, tendon sheaths 
and bursae [4]. It is mostly monoarticular and involves the knee in 75%, the 
hip in 15% and other localizations such as ankle, elbow and shoulder in 10%. 
It often involves the entire synovium and may have extra-articular, infiltrative 
soft tissue masses. There is an equal distribution between sexes, it mainly 
occurs between the ages of 30-40. Incidence is estimated at two per million 
annually [1,5]; but this may be an underestimation as the awareness on this 
disease is growing and diagnostic methods are improving. Patients present 
with nonspecific symptoms as pain, locking, limited range of motion and 
hemorrhagic joint effusion [1,6]. There may be delays of years between onset 
of complaints and diagnosis [6]. 
Several treatment options exist for Dt-GCT about the knee, including 
arthroscopic or open synovectomy, intra-articular radioactive colloids, 
radiation therapy, systemic targeted therapy, or a combination of the above 
[7]. At present, surgery remains treatment of choice as there is little evidence 
supporting single use of abovementioned therapies [5,7]. 
Arthroscopic synovectomy is commonly performed for Dt-GCT and is 
propagated in some papers for hypothesized better functional results and 
possibly lower complication rates (e.g. joint stiffness, infection) [8,9]. However, 
mean recurrence rate after arthroscopic synovectomy for Dt-GCT about the 
knee remains high at 40% (range 0-92) [7]. As it may be technically difficult 
to resect all tumor mass, especially with extra-articular spread, adjuvant 
treatments or multiple reoperations are often required to treat residual disease 
[7,10-12]. Additionally, there is a risk for disease progression with arthroscopic 
synovectomy due to use of a shaver and recurrences have been reported in the 
tract of arthroscopic portals [6,11].
Open synovectomy is mainly advocated to minimize recurrence rate 
[5,7,10]. Mean reported recurrence rate after open synovectomy for Dt-GCT 
about the knee is 14% (range 0-67) [7]. Although open synovectomy may 
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decrease risk for recurrence, this may be at the cost of prolonged hospital 
stay and rehabilitation time, joint stiffness, increased morbidity and possibly 
functional loss.
Residual disease and multiple recurrences may result in functional impairment 
and often necessitate multiple interventions and eventually even joint 
replacement. Therefore, primary treatment decision should decrease 
recurrence rates, minimize surgical morbidity and provide optimal functional 
outcome and quality of life (QOL). The purpose of this study was to evaluate 
influence of disease severity and surgical treatment on functional outcome and 
QOL for Dt-GCT about the knee. We hypothesize that open synovectomy as 
index surgery does not in itself result in impaired function and QOL compared 
to arthroscopic synovectomy and subsequent surgical procedures required for 
obtaining local control.
Patients and methods 
In this retrospective single-center study, we evaluated 38 consecutive patients 
with Dt-GCT about the knee treated in a tertiary center for musculoskeletal 
oncology between 1980 and 2011. Eight patients were excluded: three 
died unrelated to Dt-GCT, three had incomplete data, one had an unclear 
diagnosis and in one patient Dt-GCT was an incidental finding during total 
knee replacement. Thirty patients were included, 17 were female. Mean age 
was 34 years (range 6-73). Median follow-up was 95 months (range 24-393). 
Fifteen patients were primarily treated at our center and fifteen patients were 
referred with recurrent Dt-GCT (Figure 1). No patients were recalled specifically 
for this study; all data were obtained from medical records, imaging, 
histopathological evaluation and questionnaires. We included demographic 
data, clinical presentation, imaging, histopathological evaluation, surgical 
treatment, recurrences, complications, functional outcome, QOL and follow-
up. Initial disease severity was assessed on preoperative magnetic resonance 
imaging (MRI). Dt-GCT only includes the diffuse type of tenosynovial GCT, 
which was further subcategorized as mild and severe Dt-GCT. Mild Dt-
GCT was defined as an isolated involvement of either anterior or posterior 
knee compartment. Severe Dt-GCT was defined as involvement of both the 
anterior and posterior knee compartment, with or without extra-articular 
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extension. Diagnosis was confirmed by preoperative (n=9) or intraoperative 
(n=21) biopsy. All data were complete. This study was approved by the local 
ethics committee.
Figure 1 Flowchart of patients with Dt-GCT about the knee
Arthroscopic synovectomy was performed with the use of both a 30° and 70° 
arthroscope through standard portals and techniques [13,14]. As arthroscopic 
synovectomy was performed in referring hospitals, specifics on surgical 
techniques cannot be provided. 
At our center, standard treatment consisted of open synovectomy, performed 
by fellowship-trained oncological-orthopedic surgeons. For good visualization, 
we use a midline anterior approach for anterior disease and an extensile 
lazy-S incision for posterior disease [5]. For primary and recurrent Dt-GCT in 
both anterior and posterior compartments, we nowadays standard perform 
combined surgery with posterior open synovectomy followed by anterior open 
synovectomy 4-6 weeks later. For severe recurrent disease and osteoarthritis 
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of the knee, resection with endoprosthetic replacement was considered in 
individual cases. Postoperative treatment involved early active and passive 
mobilization, including continuous passive motion after anterior open 
synovectomy and extension splint after posterior open synovectomy. Follow-
up protocol included clinical evaluation at 2, 6 and 12 weeks postoperative, 
annually up to 5 years and biannually up to 10 years as local recurrence and 
osteoarthritis are likely to occur.
Diagnosis at presentation was not always certain and in some patients Dt-
GCT was an incidental finding during knee surgery. Initial synovectomy in 
referring hospitals was therefore hypothesized to be incomplete and was often 
repeated. After referral, histopathological diagnosis of Dt-GCT was confirmed 
at our center and MR imaging was repeated for all patients; this allowed for 
optimal surgical planning in case of recurrent or residual disease. 
Functional outcome was assessed with range of motion, Knee injury and 
Osteoarthritis Outcome Score (KOOS) [15], Musculoskeletal Tumor Society 
(MSTS) score [16], Toronto Extremity Salvage Score (TESS) [17]; QOL with SF-36 
[18] at mean 8 years (range 2-32) after index surgery.
Statistical analysis
Differences in dichotomous data were calculated with Chi-squared and Fisher’s 
exact tests and in numerical data with Mann-Whitney U tests. We used SPSS 
20.0 (SPSS Inc, Armonk, NJ, USA) for statistical analysis. The level of statistical 
significance was set at p<0.05.
Results
Preoperative disease severity was mild in 15 and severe in 15 patients. Fourteen 
patients underwent initial open synovectomy (one in referring hospital) and 
16 initial arthroscopic synovectomy (14 in referring hospital) at index surgery 
(Table 1). 
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n n % n %
Total 30 14 - 16 - -
Primary treatment in 
tertiary center
15 13 93 2 12 <0.001
Referred with recurrence 15 1 7 14 88 -
Mild Dt-GCT 15 10 71 5 31 0.033
Severe Dt-GCT 15 4 29 11 69 -
mean range mean range
Age (years) 44 11-77 43 17-69 1.0
Follow-up (months) 128 29-396 120 24-403 0.94
Number of recurrences 1.4 1-4 3.4 1-10 -
Number of open 
synovectomies
- 1-4 - 0-4 0.31
Number of arthroscopic 
synovectomies
- 0-1 - 1-8 <0.001
From 14 patients with initial open synovectomy, 10 had mild Dt-GCT and four 
had severe Dt-GCT. After initial open synovectomy, four of 14 had recurrence 
(three of four with severe Dt-GCT); three had one recurrence and one had three 
recurrences. 
From 16 patients with initial arthroscopic synovectomy, five had mild Dt-GCT 
and 11 had severe Dt-GCT. After initial arthroscopic synovectomy, 15 of 16 had 
recurrence (11 of 11 with severe Dt-GCT); five had one recurrence and 10 had 
multiple recurrences (range 2-9) (Table 2). 
From the patients initially treated with arthroscopic synovectomy, fifteen 
underwent open synovectomy after a mean of 1.8 surgical interventions 
(range 1-8) with arthroscopic synovectomy. Within this group, the first open 
synovectomy at our tertiary center resulted in local control for seven patients 
(47%) with a mean follow-up of 55 months (range 24-124). Secondary open 
synovectomy was performed in an additional four cases without any further 
recurrences (73%; mean follow-up 123 months; range 47-212) (Table 2) .
27935_Heijden.indd   264 25-06-14   11:32
11





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































27935_Heijden.indd   266 25-06-14   11:32
11
Dt-GCT about the knee
267
After initial open synovectomy, complications were reported in two patients. 
One patient had recurrent hemarthrosis that required repeated surgical 
debridement. This patient also developed secondary osteoarthritis at the age 
of 35, ten years after initial surgery; radiological and clinical progression of 
osteoarthritis was noted in the next years. Another patient had refractory Dt-
GCT and knee osteoarthritis after three open synovectomies; this was treated 
with resection and endoprosthetic reconstruction. After initial arthroscopic 
synovectomy, complications were reported in three patients. Two patients 
had refractory Dt-GCT and developed knee osteoarthritis (after two and 
nine surgical interventions); both underwent open resection, one total knee 
replacement and one endoprosthetic reconstruction. One patient sustained a 
urinary tract infection, successfully treated with antibiotics.
Patients with initial open synovectomy reported higher scores for all functional 
and QOL results compared to initial arthroscopic synovectomy and all 
subsequent surgical procedures and similar scores as healthy controls from 
an age- and gender matched general population (Figure 2). Mean range 
of motion was 127 degrees (range 95-140) in the open synovectomy group 
and 114 (range 90-140) in the arthroscopy group (p=0.03). Similar differences 
were seen in reported outcomes of KOOS (71 vs. 48, p=0.003), MSTS (24 vs. 19, 
p=0.02), TESS (86 vs. 75, p=0.03) and SF-36 (80 vs. 62, p=0.01) (Table 3). 
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Figure 2 (A) KOOS and (B) SF-36 for patients with initial open or arthroscopic synovectomy for Dt-GCT 
about the knee, compared with age-matched healthy peer controls. ADL=Activities of daily living, 
QOL=Quality of life, PF=Physical functioning, RP=Role limitations due to physical functioning, BP=Bodily 
pain, GH=General health, VT=Vitality, SF=Social functioning, RE=Role limitation due to emotional 
functioning, MH=Mental health.
Table 3 Functional outcome and quality of life after initial open synovectomy or initial arthroscopic 






mean range mean range
Range of motion (degrees) 127 95-140 114 90-140 0.03
MSTS 24 10-30 19 8-30 0.02
TESS 86 46-100 75 45-96 0.03
KOOS 71 12-99 48 14-95 0.003
SF-36 80 63-98 62 26-94 0.01
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Discussion 
Most studies on tenosynovial GCT are case series including diffuse and localized 
types, primary and recurrent disease, different localizations, and arthroscopic 
and open synovectomy. Authors did not always distinguish between these 
factors when analyzing their data [13,19-22]. The majority of studies on 
treatment of Dt-GCT about the knee reported only oncological results; few 
studies described objectified functional results, and to our knowledge QOL has 
never been evaluated. Therefore, we evaluated influence of type of surgery on 
functional outcome and QOL for Dt-GCT about the knee.
Standard primary treatment of Dt-GCT at our center consisted of open 
synovectomy. From thirteen patients, three had recurrent Dt-GCT (23%)—all had 
severe Dt-GCT. Primary arthroscopic synovectomy was performed in referring 
hospitals, most of these patients had severe Dt-GCT. Disease eradication can 
be difficult in case of wide spread disease and multiple re-synovectomies were 
needed after initial arthroscopy, suggesting that disease extent increases the 
recurrence risk. Additionally, MRI was not routinely used after surgery in most 
series and recurrence rates after arthroscopy may be underestimated [9,13,23].
Complication rate was low in this study and was not altered after multiple 
synovectomies. In literature, most common complications were joint stiffness 
(8-32%) [12,13,24], wound healing disorders and infection (2-20%) [24-26]. 
Secondary osteoarthritis has been reported in 24-48% after open synovectomy 
[10,24,26], and was objectified with Kellgren and Lawrence grading in one 
study [10,27]. Total knee arthroplasty was required in 8-10% of patients with 
osteoarthritis [24,26]. We observed osteoarthritis in four patients (13%), two 
after open synovectomy with 1-3 reinterventions and two after arthroscopic 
synovectomy with 2-9 reinterventions. Three underwent resection and total 
knee or endoprosthetic replacement; one is under observation. 
Functional results after surgical treatment for Dt-GCT have been reported 
[6,9,10,13,19-24,28-33], but comparison is difficult as studies were 
heterogeneous and functional results were not specified for diffuse and 
localized types, primary and recurrent disease and different localizations 
(Table 4). In this study, both knee function and QOL were impaired for patients 
with initial arthroscopic synovectomy, of whom the majority presented with 
severe Dt-GCT and underwent multiple surgeries, compared with patients with 
initial open synovectomy and with healthy controls from an age- and gender-
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matched general population (Figure 2) [18,34]. The long course of disease and 
the need for multiple surgeries has previously been reported to result in worse 
functional results in a large number of patients [20]. Patients who underwent 
initial open synovectomy, often for mild Dt-GCT and with fewer reoperations, 
had good functional results and QOL compared with patients with initial 
arthroscopy and with healthy controls from an age- and gender-matched 
general population [18,34], suggesting that preventing recurrent disease with 
open synovectomy does not have a negative influence on functional outcome 
and QOL. 
Our study has several limitations. First, it is unknown how many patients were 
treated successfully in peripheral hospitals, so we were unable to provide a 
reliable recurrence rate after arthroscopic synovectomy. This may have resulted 
in selection bias, probably overestimating the inferior results of arthroscopic 
synovectomy. Second, numbers in this study may have been too small to 
conclude that open synovectomy has a lower recurrence rate than arthroscopic 
synovectomy for severe Dt-GCT (3/4 vs. 11/11).
In conclusion, the majority of patients referred with recurrence presented 
with severe Dt-GCT and underwent arthroscopic synovectomy before referral. 
Multiple re-synovectomies were required with the intent to cure. At latest 
follow-up, these patients reported lower functional and QOL results compared 
with patients who underwent initial open synovectomy in a tertiary center, 
affirming our hypothesis that open synovectomy does not result in impaired 
function or QOL. We may therefore conclude that the course of extensive 
disease treated with arthroscopic synovectomy is not favorable and that 
primary open synovectomy should be treatment of choice for severe Dt-GCT 
to prevent recurrent or residual disease activity. 
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Chapter 12
General summary




Patients with giant cell tumor of bone and tenosynovial tissue pose challenging 
problems for surgical treatment. For giant cell tumor of bone (GCTB), the clinical 
challenge is to extend indications for intralesional excision, while providing 
optimal oncological, functional and quality of life results. For tenosynovial 
giant cell tumor (Dt-GCT), the clinical challenge is to improve oncological 
results and maintain a functional joint and quality of life. Therefore, the aims of 
this thesis were to improve patient selection for different types of surgery by 
identifying risk factors for recurrences and complications, to define indications 
for systemic targeted therapy and to evaluate clinical outcome after treatment 
for both diseases by providing a clinical decision analysis based on outcome 
data. 
Giant cell tumor of bone
Chapter 2 provided an overview of imaging, genetics, histopathology and 
multidisciplinary treatment of GCTB. Overexpression of receptor activator of 
nuclear factor kappa-B ligand (RANKL) by mononuclear neoplastic stromal 
cells promotes recruitment of numerous reactive multinucleated giant cells 
capable of bone resorption. Radiologically, GCTB shows typical eccentric lytic 
lesions. Computed tomography can be performed to assess cortical thinning, 
pathologic fractures and (pending) joint involvement. MR imaging is required 
to evaluate extent of GCTB within the bone and surrounding soft tissues for 
surgical planning. MR imaging typically shows low to intermediate intensity 
on T1-weighted images and intermediate to high signal intensity on T2-
weighted images. The preferred treatment for the majority of GCTB is extended 
curettage with local adjuvants. A large oval window is made in the cortex, 
creating sufficient exposure of the tumor cavity. The tumor is then carefully 
curetted with different sizes curettes followed by high-speed burring of cavity 
walls. Local adjuvants can be phenol, alcohol or liquid nitrogen. The remaining 
cavity may be filled with either bone grafts or polymethylmethacrylate 
(PMMA); advantages of the latter are a hypothesized lower recurrence risk 
through hyperthermic properties, immediate mechanical support and early 
radiographic detection of local recurrences. Reported recurrence rates are 




comparable for different local adjuvants (27-31%); most recurrences occur 
within two years after surgery. Resection can be performed when joint salvage 
is not feasible and in expandable bones. Denosumab (RANKL-inhibitor) blocks 
and zoledronic acid (bisphosphonate) inhibits GCTB-derived osteoclast 
resorption. With zoledronic acid, stabilization of local and metastatic disease 
has been reported, although level of evidence was low. Denosumab has 
been studied to a larger extent and seems to be effective in enabling less 
invasive forms of surgery. Denosumab was recently registered by the FDA 
for unresectable disease. Therefore, the role of systemic therapy in standard 
treatment of GCTB needs to be further explored. Moderate dose radiotherapy 
should be restricted to rare cases of unresectable, residual or recurrent GCTB 
when surgery would lead to unacceptable morbidity.
Chapter 3 compared the relative effectiveness of several local adjuvants in a 
retrospective cohort study in two tertiary referral centers in which different 
standard treatments are applied. Treatment assignment depended purely on 
the center patients were admitted to and both centers had similar indications 
for intralesional surgery and comparable surgical expertise (i.e. pseudo-
randomization). Thus, 132 patients with primary GCTB who underwent either 
curettage with phenol and PMMA (P-PMMA; n=82), liquid nitrogen and 
PMMA (LN-PMMA; n=26) or liquid nitrogen and bone grafts (LN-BG; n=24) 
between 1990 and 2010 were retrospectively analyzed. Mean follow-up was 
8 years (range 2 to 22). The three cohorts were comparable, except for tumor 
localization: bone grafts were more commonly applied instead of PMMA in non-
weightbearing bones in the center specialized in cryosurgery. Recurrence rates 
were comparable for P-PMMA (28%; 23/82), LN-PMMA (31%; 8/26) and LN-BG 
(38%; 9/24) (p=0.52). Soft tissue extension increased risk for recurrence two-
fold. When using liquid nitrogen, attention should be paid to the complication 
risk, as this was increased after LN-BG (33%; 8/24) and LN-PMMA (27%; 7/26) 
compared with P-PMMA (11%; 9/82) (p=0.019). In addition, preoperative 
pathologic fractures increased risk for complications four-fold. Functional 
outcome was excellent and comparable in all three cohorts (p=0.52). 
Approximately 20% of patients with GCTB present with a pathologic fracture, 
which may impede adequate intralesional surgery. Chapter 4 involved a 
retrospective multicenter analysis of 48 patients with a pathologic fracture, 
treated with curettage plus adjuvants (n=23) or en bloc resection (n=25) in one 
of three tertiary referral centers between 1981 and 2009. Mean follow-up was 
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8.4 years (range 2.3 to 24). Local recurrence rate was higher after intralesional 
surgery (30%; 7/23) compared with en bloc resection (0%) and was five-fold 
increased in patients with soft tissue extension. Complication rate was lower 
after intralesional surgery (4%; 1/23) compared with resection (16%; 4/25). 
Fracture healing after curettage occurred in all but one patient. Functional 
outcome was superior after intralesional surgery. 
Approximately 2-5% of all GCTB occur in the small bones of the hands and feet. 
Chapter 5 described a systematic review including twelve papers comprising a 
total of 91 patients with GCTB of the small bones. Published mean recurrence 
rates were 72% after curettage, 13% after curettage with local adjuvants, 15% 
after resection and 10% after amputation. Second, a retrospective multicenter 
analysis was performed of all 30 patients treated for GCTB of the small bones 
in one of five tertiary referral centers between 1987 and 2010. Mean follow-
up was 7.9 years (range 2 to 26). Recurrence rates were 50% after curettage 
(3/6), 22% after curettage with adjuvants (4/18) and 17% after en bloc resection 
(1/6; p=0.40). No individual factors associated with a higher risk of recurrence 
or complication could be identified. Functional outcome was superior after 
intralesional surgery compared with resection. Repeated curettage and 
adjuvants finally resulted in cure of all patients.
Around 2-8% of all GCTB are localized in the sacrum. Chapter 6 contained a 
nationwide retrospective evaluation of all 26 patients surgically treated for 
sacral GCTB in the Netherlands between 1990 and 2010. The majority of our 
patients had cortical destruction, large soft tissue components and sacral nerve 
root involvement at presentation. Preoperative selective arterial embolization 
was performed in nineteen patients. All patients underwent intralesional 
excision of which 21 with different local adjuvants, systemic therapy or 
adjuvant radiotherapy. In eight patients with extensive cortical destruction 
and soft tissue masses, no chemical adjuvants were used. Surgical margins 
were extended in four patients with anterior sacral wall excision. Posterior 
stabilization with lumbopelvic fixation with PMMA or bone grafts was indicated 
in three patients, reconstruction with bone grafts in seven and with PMMA in 
one. All but one patient had a minimum follow-up of two years (mean 8.3; range 
0.5 to 19). Two patients died from tumor progression and metastases and one 
died from radiation-induced sarcoma (after 6-102 months). Overall recurrence 
rate was 54% (14/26). Soft tissue masses larger than 10 cm increased the risk 
for recurrence three-fold. Complications were reported in 46% (12/26) patients 




and included massive hemorrhage, infection, neuropraxia, hardware failure, 
radiation-induced sarcoma, radiation-induced menopause, pubic dissociation 
fracture due to osteopenia after radiotherapy and delayed wound healing. 
Functional outcome in patients without complications was good. In eight 
patients, all preoperative symptoms resolved after surgery. Persistent pain was 
reported by eight patients. Neurological symptoms were transient in eight and 
permanent in five patients. Recurrence rate was highest after curettage alone 
(80%; 4/5), indicating that some kind of local or systemic adjuvant treatment 
is necessary. 
Chapter 7 aimed at retrospectively analyzing individual risk factors for 
recurrence in 93 patients treated with curettage, phenol and PMMA (n=75) 
or curettage with PMMA (n=18) in one tertiary referral center between 1981 
and 2009. Mean follow-up was 8 years (range 2 to 24). Twenty-five patients 
had recurrent GCTB (27%). Seventeen patients were disease free after second 
curettage with adjuvants and eight patients eventually required en bloc 
resection. We found a five-fold increased risk for recurrence in presence of soft 
tissue extension, whereas age, gender, localization and pathologic fracture did 
not increase recurrence risk. 
Chapter 8 was a radiological study on the prevalence and impact of 
radiological osteoarthritis (Kellgren and Lawrence grades 3-4) in 53 patients 
who underwent curettage and PMMA for GCTB around the knee in one tertiary 
referral center between 1987 and 2007. Mean follow-up was 7 years (range 5 to 
24). Radiological osteoarthritis was found in 17% of patients at a median of 57 
months (range 33-285) after curettage and PMMA. None of these patients had 
surgery for clinical osteoarthritis at latest follow-up. A nine-fold increased risk 
for radiological osteoarthritis was found when more than 70% of subchondral 
bone was involved by GCTB and a four-fold increased risk for radiological 
osteoarthritis for a distance between GCTB and the articular cartilage of less 
than 3 mm. Functional outcome and quality of life were comparable for patients 
with Kellgren and Lawrence grades 3-4 and 0-2, suggesting modest clinical 
impact of radiological osteoarthritis at intermediate follow-up. However, this 
may increase with time and a prolonged follow-up is required. 
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Giant cell tumor of tenosynovial tissue
Chapter 9 outlined an overview of imaging, genetics, histopathology and 
multidisciplinary treatment of localized (GCT-TS) and diffuse type (Dt-GCT) 
tenosynovial giant cell tumor. Overexpression of macrophage colony-
stimulating factor 1 (M-CSF) and its receptor (M-CSFR) by synovial fibroblasts 
promotes formation of a tumor-like mass. On MR images, hemosiderin 
depositions cause local changes in susceptibility, resulting in the characteristic 
low signal intensity appearance of Dt-GCT on T1- and T2-weighted spin echo 
and gradient echo sequences. Although arthroscopic synovectomy has been 
advocated as an alternative to open synovectomy, there is a significant risk 
of inadequate excision and recurrence, particularly in the posterior knee 
compartment. In addition, there is a risk of seeding the disease into the soft 
tissues around the portals. For GCT-TS or limited anterior Dt-GCT, arthroscopic 
synovectomy may be sufficient. For initial and recurrent Dt-GCT, especially in 
the posterior knee compartment, open synovectomy is advised. Combined or 
staged surgery may be considered. For posterior disease, a lazy-S incision is 
performed with elevation of the origin of the gastrocnemius muscle to protect 
neurovascular structures. This is followed by arthrotomy to visualize the 
posterior cruciate ligament and articular surfaces and a complete capsulotomy 
to achieve adequate synovectomy. For anterior disease, a midline anterior 
approach is advised, as this allows good visualization of the synovial cavity, 
fat pad, cruciate and collateral ligaments. Residual tumor adjacent to the joint 
line and unilateral gutters can also be safely resected. For recurrent and extra-
articular disease, moderate dose radiotherapy or systemic targeted therapy 
can be considered. Although there is yet little evidence on the efficacy of 
neoadjuvant M-CSFR-targeted tyrosine kinase inhibitors (e.g. imatinib) for Dt-
GCT treatment, it may in the future be incorporated in the treatment strategy 
for more extended disease, in analogy with systemic treatment for GCTB.
Chapter 10 presented a systematic review on tenosynovial giant cell tumor 
including 59 papers comprising a total of 313 patients with GCT-TS and 777 
patients with Dt-GCT. Methodological quality (Newcastle-Ottawa Scale for 
quality assessment of cohort studies) was good in 40%, intermediate in 50% 
and poor in 10% of the included papers. Reported mean recurrence rates were 
4% after open and 6% after arthroscopic synovectomy of GCT-TS in the knee 
and 14% after open and 40% after arthroscopic synovectomy of Dt-GCT in the 




knee. With use of intra-articular radioactive colloids, mean recurrence rates 
were 15% after open and 22% after arthroscopic synovectomy for intra-articular 
Dt-GCT in the knee and hip. With adjuvant radiotherapy, mean recurrence 
rates were 12% after open and 13% after arthroscopic synovectomy for extra-
articular Dt-GCT in the knee. In general, open synovectomy of the lesion plus 
excision of extra-articular disease is recommended to reduce the relatively 
high recurrence risk.
Chapter 11 retrospectively evaluated the influence of disease severity and 
type of surgery on functional outcome and quality of life in 30 patients 
treated for Dt-GCT in the knee between 1980 and 2011. Fifteen patients were 
primarily treated at our tertiary referral center; 15 were referred to our center 
with recurrence. Disease severity was assessed on preoperative MR imaging 
or imaging reports. Sixteen patients (53%) had simple disease, defined as a 
solitary pedunculated lesion or diffuse involvement of the anterior or posterior 
knee compartment. Fourteen patients (47%) had severe disease, defined 
as involvement of anterior and posterior compartments or extra-articular 
extension. Patients with initially severe Dt-GCT often underwent multiple 
surgeries including initial arthroscopic synovectomy and open synovectomy 
for latest recurrence. After a mean follow-up of 8 years (range 2-33), these 
patients reported significantly lower functional and quality of life results. In 
this study, primary open synovectomy did not result in impaired function or 
decreased quality of life when compared to arthroscopic synovectomy.
Conclusions, clinical implications and future perspectives for the subjects of 
this thesis are discussed in Chapter 13.
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Chapter 13
General discussion




Although giant cell tumors of bone and tenosynovial tissue are benign 
neoplasms, both have a locally aggressive character [1-3]. Therefore, treatment 
should be locally extended, which typically consists of intralesional excision 
with local adjuvants for giant cell tumor of bone and complete synovectomy 
with removal of all affected tissue for tenosynovial giant cell tumor. Local tumor 
control on the one hand and maintenance of a functional joint and quality of 
life on the other hand are the main pillars of surgical treatment for both disease 
entities. 
Previously, treatment of both giant cell tumor of bone and tenosynovial tissue 
primarily consisted of surgical resection. Current knowledge and development 
in the fields of imaging, functional biology and systemic targeted therapy are 
forcing us into a paradigm shift from a purely surgical towards a multidisciplinary 
approach. 
This thesis outlines the current state of the art concerning treatment of giant 
cell tumor of bone and tenosynovial tissue and the opportunities for further 
optimization of this multidisciplinary approach in the future. This thesis aims 
at improving patient selection for different types of surgery by identifying risk 
factors for recurrences and complications, defining indications for systemic 
targeted therapy and evaluating clinical outcome after treatment for both 
types of disease by providing for a clinical decision analysis based on outcome 
data.
Giant cell tumor of bone
Treatment decisions for giant cell tumor of bone (GCTB) should be made 
by a multidisciplinary team consisting of dedicated experts in the field of 
musculoskeletal oncology. This should include radiography, MR imaging, 
histopathological assessment and planned surgery, supplemented with 
systemic therapy if indicated, to improve oncological outcome especially in 
GCTB with a high risk for local recurrence or in uncurettable GCTB. These high-
risk GCTB include, but are not limited to, cases with soft tissue extension, intra-
articular pathologic fracture or localization in sacrum or spine.
Imaging




Existing classifications of Campanacci et al. [4] and Enneking et al. [5] are based 
on radiographic aspects of GCTB and became outdated with the advent of MR 
imaging. Hence, a new radiological classification is needed that incorporates 
other imaging modalities providing for a more accurate estimation of disease 
extent, evaluation of response to systemic therapy and detection of local 
recurrence. In addition, this should be integrated into a multidisciplinary 
classification with clinical and histopathological features in order to predict 
clinical behavior of GCTB and allow for optimal patient selection for specific 
treatment modalities based on individual risk profiles [6].
The appearance of GCTB on conventional radiographs is rather characteristic 
and this remains the first step in diagnosing primary and recurrent GCTB. 
Computed tomography (CT) may be used in selected patients to assess cortical 
thinning and pathologic fractures before intralesional surgery. Dynamic 
contrast-enhanced magnetic resonance imaging (DCE-MRI) is required to 
evaluate the extent of GCTB within the bone and surrounding soft tissues 
in order to plan a surgical approach. On DCE-MRI, GCTB shows early and 
rapidly progressive enhancement followed by washout [7-9] and high signal 
intensity on T2-weighted images. On fluorodeoxyglucose-positron emission 
tomography (FDG-PET), GCTB demonstrates high FDG uptake due to high 
metabolic activity of osteoclast-like giant cells [10,11]. 
An important topic that needs to be evaluated in the future is monitoring of 
tumor activity during systemic therapy with use of DCE-MRI and FDG-PET. 
If GCTB responds well to denosumab, DCE-MRI signal-intensity curves are 
expected to change gradually and eventually mimic that of healthy bone. 
A reduction in FDG uptake during systemic therapy was shown to correlate 
with reduced tumor activity, making FDG-PET a second promising sensitive 
instrument to monitor response to systemic targeted therapy for GCTB. 
Differentiation between viable and necrotic tumor cells may be a valuable 
tool in future decision making for GCTB treatment, analogous to other 
musculoskeletal tumors [12].
Histopathology and genetics
To date, histopathological and genetic features of GCTB have not been clearly 
predictive for clinical behavior such as local progression and risk for recurrence 
or metastasis. With advancing fundamental knowledge on GCTB, this could 
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be further evaluated and merged with clinical and radiological features into 
a multidisciplinary classification of GCTB predicting its clinical behavior and 
creating individual risk profiles [6].
The following elements may predict clinical behavior. Macroscopically, GCTB 
associated with lung nodules commonly showed large areas of hemorrhage 
and thrombus formation, that were not seen in GCTB without recurrence 
or metastasis [13]. Microscopically, atypical mitotic figures are suggestive 
of malignancy, but a potential association between cellular atypia and a 
locally more aggressive behavior needs evaluation. Genetically, centrosome 
amplification and aneuploidy were reportedly higher in recurrent and 
metastatic GCTB, suggesting a relation with clinical behavior [14,15]. Expression 
of epidermal growth factor receptor (EGFR), a tyrosine kinase expressed by 
neoplastic stromal cells that promotes osteoclastogenesis in the presence of 
M-CSF, was more frequent in recurrent and metastatic GCTB, also suggesting a 
relation with disease progression [16].
To target tumor cells directly, more fundamental knowledge on the neoplastic 
stromal cells is necessary. An in vitro method involved isolation of neoplastic 
stromal cells to further study its capacities for osteoblastic differentiation 
and osteoclastogenesis [17]. Recently, a driver mutation has been identified 
in H3F3A in GCTB; these alterations were seen exclusively found in neoplastic 
stromal cells and not in precursor or mature osteoclasts [18]. Currently, there is 
a lack of suitable in vivo models for GCTB due to complex interactions between 
the neoplastic and reactive cellular components; therefore little is known 
about tumor growth, invasion, angiogenesis and metastasis. A method of 
grafting and growing GCTB on chick chorio-allantoic membranes (CAM) has 
been presented to further study interactions between all cellular components 
of GCTB [19]. This technique may be further exploited to gain vital insights in 
this disease and to test new therapeutic agents.
Surgical treatment
For GCTB, surgical treatment traditionally consists of either curettage with 
local adjuvants or en bloc resection. Ideally, curettage with local adjuvants 
should be treatment of first choice in all patients with GCT, achieving joint 
salvage and maintaining functionality. Concurrently, recurrence risk should be 
minimized to rates similar to those reported after en bloc resection (0-12%). 




Overall recurrence rates in our studies varied between 27-31% after curettage 
with an adjuvant, i.e. phenol, liquid nitrogen and/or PMMA, and are therewith 
at the higher end of ranges reported in literature. This can be explained by the 
extended indications for intralesional surgery in participating centers, including 
high-risk GCTB. Contrariwise, lower recurrence rates of 7-18% were reported 
after curettage and local adjuvants for low-risk GCTB. Overall, local control was 
achieved after one or multiple intralesional procedures in 85-100% of patients 
with GCTB, indicating that primary intralesional surgery allows for acceptable 
results, even in patients with high-risk GCTB. Surgical treatment of axial GCTB is 
subject to multiple problems including complex anatomy for surgical resection 
and difficulty in using adequate local adjuvants near neurovascular structures. 
In our series on sacral GCTB, recurrence rate was high after intralesional 
excision (54%), especially after isolated curettage (80%). Therefore, oncological 
outcome after intralesional excision of sacral or spinal GCTB remains doubtful.
An emerging phenomenon in general oncologic surgery is intraoperative 
optical imaging with systemic injection of tumor-specific fluorescence agents, 
which can help determining adequate resection margins [20,21]. Especially 
during intralesional surgery after systemic therapy, it may be valuable to be 
able to identify and remove viable neoplastic stromal cells and reactive giant 
cells, in order to further reduce recurrence risk.
Concerning the optimal combination of local adjuvants in terms of oncological 
outcome, effectiveness of liquid nitrogen and phenol appeared to be 
comparable. Phenol may have a limited effect when used combined with 
PMMA [22,23], as recurrence rates were similar for phenol and PMMA versus 
PMMA alone. Efficacy of PMMA with or without phenol has to be studied in a 
prospective randomized trial. The latter is also true for the role of mechanical 
adjuvants such as the use of a high-speed burr in a uniform and validated 
manner, although designing and executing such a trial will be challenging [24]. 
Soft tissue extension is the only individual parameter to strongly increase 
recurrence risk [25,26]. This can be explained by the locally aggressive character 
of GCT and by technical difficulties in complete tumor excision and application 
of local adjuvants in the presence of exposed neurovascular structures. In 
these cases, feasibility of intralesional surgery depends on the extent of the 
soft tissue component, which is likely to improve with the advent of systemic 
targeted treatment options. 
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The complication rate was higher after en bloc resection compared to curettage 
with adjuvants (16% versus 4%), including aseptic loosening of endoprosthetic 
replacement, allograft failure and non-union. With curettage, complications 
were observed more frequently after cryosurgical treatment (30% versus 
11% with use of phenol), and this risk was especially elevated in combination 
with use of bone grafts for reconstruction. Complications included secondary 
osteoarthritis, infection, postoperative fracture, non-union and neuropraxia. 
Whereas postoperative fractures were the most important concern after 
cryosurgery in the past, current techniques with adequate monitoring of 
freezing temperatures and prophylactic osteosynthesis in selected cases 
have decreased fracture rates dramatically (from 25-50% to 0-7%). Secondary 
osteoarthritis of the knee was seen in 17% of patients after curettage and 
PMMA; risk factors were extensive subchondral bone involvement (>70%) and 
proximity to the articular cartilage (<3 mm). In the future, PMMA substitutes 
with a similar hyperthermic local adjuvant effect but with more favorable 
osteoconductive, osteoinductive and elasticity properties might be used to 
decrease the risk of secondary osteoarthritis [27-29]. When osteoarthritis does 
develop after curettage and PMMA, the bone cement can be replaced by 
bone grafts prior to total knee replacement, which is considered less invasive 
compared to primary en bloc resection. 
Functional ability reported by patients at the latest follow-up was superior 
after curettage with different types of local adjuvants compared to en bloc 
resection. Functional outcome and quality of life were not impaired in patients 
with radiographic osteoarthritis of the knee at mid-term follow-up, but 
clinical relevance may become more important at longer follow-up since our 
patients were relatively young. In an ideal situation, the biggest gain in terms 
of functional outcome and quality of life can be achieved by expanding the 
indication for intralesional surgery to all patients, by means of neoadjuvant 
systemic therapy that creates a curettable situation in uncurettable GCT and 
thereby avoiding more rigorous and mutilating resections—especially for 
sacral and spinal GCT.
Finally, en bloc resection should be reserved for patients in whom intralesional 
surgery and systemic therapy are impossible, contra-indicated or unavailable, 
as it results in more complications and worse functional outcome. Thus, en bloc 
resection would only be indicated in patients with intra-articular pathologic 
fractures requiring immediate stabilization or in which reconstruction of bony 




remains after curettage is impossible; with soft tissue components adjacent to 
vital structures; with acute myelum compression; and with GCT in “expandable” 
bones such as proximal fibula or distal ulna.
Systemic targeted therapy
Whereas en bloc resection previously constituted the only treatment option for 
uncurettable GCT, receptor activator of nuclear factor kappa-B ligand (RANKL)-
inhibitor denosumab and bisphosphonate zoledronic acid have recently 
entered the arena of treatment armamentarium and are promising therapies 
for local down-staging of high-risk GCT before surgery. Rather than to divert 
to more mutilating resections for advanced disease adjacent to neurovascular 
structures, neoadjuvant therapy with denosumab may facilitate intralesional 
surgery by creating a calcified rim around the entire tumor including its soft 
tissue component [30,31]. A reduction in tumor size and a calcified rim around 
the tumor and its soft tissue component are already seen after an average of 3 
months and further calcification is seen with longer therapy duration. In axial 
and sacral GCT, locally advanced disease is often seen and local recurrence risk 
is therefore high. Creating an operable situation and achieving immediate local 
control are of the utmost importance. It is, among others, precisely in those 
cases that denosumab may allow for intralesional surgery and in addition to 
that it may render radiotherapy redundant.
RANKL is expressed by neoplastic stromal cells and RANKL-inhibitor 
denosumab blocks osteoclast maturation and bone resorption [32,33]. The 
efficacy of denosumab has been proven in prospective randomized trials and 
it has recently been registered for advanced GCT by the FDA [30,31]. However, 
inhibition of RANKL only indirectly affects GCT, as the tumor cells are not 
directly targeted. Targets for systemic therapy which more specifically address 
neoplastic stromal cells should be identified in order to turn systemic therapy 
into a definite therapy for GCT. Currently, therapy effects of denosumab are 
hypothesized to be temporary—after discontinuation of denosumab, regrowth 
of GCT was seen in some patients—and until more becomes known on the 
subject, surgery is indicated as definite treatment in all patients. In addition, it 
remains unsure whether systemic therapy with denosumab reduces recurrence 
risk when used in an adjuvant postoperative setting. Finally, long-term toxicity 
and optimal therapy duration need to be further explored.  
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Bisphosphonates are assumed to bind to bone mineral, inhibit osteoclast 
formation, migration and osteolytic activity at sites of bone resorption and 
promote apoptosis of osteoclasts [34]. In small retrospective series, stabilization 
of local and metastatic disease was achieved with bisphosphonates [35-37]. A 
prospective randomized trial with adjuvant zoledronic acid is currently ongoing 
in patients with high-risk GCT. The efficacy of zoledronic acid in neoadjuvant 
setting has not yet been validated.
Thus far, there are no randomized trials comparing the clinical effectiveness 
of RANKL-inhibitors and bisphosphonates [38]. Although denosumab seems 
to be more potent compared to zoledronic acid in regulating the RANK/
RANKL-pathway and inhibiting osteolytic properties of multinucleated giant 
cells in GCT, the latter may have a more direct anti-tumor effect by addressing 
neoplastic stromal cells. In a recent in vitro study, reduced cell growth and 
apoptosis were seen in neoplastic stromal cells treated with zoledronic acid, 
but not in those treated with denosumab [34]. Also, zoledronic acid inhibited 
mRNA expression of RANKL by neoplastic stromal cells, whereas denosumab 
did not [34]. These findings reinforce the hypothesis that recurrence may occur 
after discontinuation of denosumab.
Based on new findings in functional biology and genetics of GCT, new targets 
for systemic therapy may be studied in the future. First, Wnt/β-catenin and 
recombinant human bone morphogenetic protein-2 (BMP-2) are pathways 
that regulate osteoclast-inducing activity of neoplastic stromal cells and 
are potential clinical targets for direct anti-tumor targeted therapy [17]. 
Second, DD33+ is a characteristic feature of the osteoclast-like phenotype of 
multinucleated giant cells and may be targeted with gemtuzumab—an anti-
CD33+ antibody—in analogy to the treatment of acute myeloid leukemia [39]. 
Third, there are RANKL-substitutes that demonstrated osteoclastogenesis and 
formation of multinucleated giant cells capable of lacunar bone resorption 
(e.g. TNF-α, IL-6, TGF-β, APRIL, BAFF, NGF, IGF-I and IGF-II). Although these 
mechanisms are less potent than the RANK/RANKL-pathway, they may be 
further investigated as new targets for systemic therapy.
Radiotherapy
Finally, radiotherapy should be restricted for rare cases of unresectable, 
residual or recurrent GCT (e.g. axial localizations) when surgery leads to 




unacceptable morbidity. After radiotherapy, operability of the irradiated area 
becomes problematic and recurrences complicate further surgical treatment. 
Additionally, lifelong risk for radiation induced sarcoma is noteworthy (3-11%). 
Therefore, its use should absolutely be minimized and the possibilities of 
systemic therapy should be explored before considering radiotherapy.
Giant cell tumor of tenosynovial tissue
Awareness of giant cell tumors arising from synovium (diffuse-type GCT; Dt-
GCT) and tendon sheath (GCT of tendon sheath; GCT-TS) has increased over 
the last decades and with improvements in radiological and histopathological 
techniques, diagnosis and disease extent can be identified more accurately. 
Treatment decisions for tenosynovial giant cell tumor, especially for Dt-GCT, 
should be made by a multidisciplinary team consisting of dedicated experts 
in the field of musculoskeletal oncology and should include MR imaging and 
histopathological assessment before surgery. The latter may be supplemented 
with systemic therapy or adjuvant radiotherapy, as optimal oncological 
outcome may interfere with maintaining a functional joint and quality of life. 
Imaging
Although currently lacking, a multidisciplinary classification that combines 
clinical, radiological and histopathological features in order to predict clinical 
behavior of tenosynovial GCT is desirable as this would enhance patient 
selection for individually tailored treatment.
Conventional radiographs are often not diagnostic for tenosynovial GCT but 
can be performed to rule out other diagnoses, including malignancies. Only 
in case of advanced disease, there may be evidence of soft tissue swelling, 
diminished joint space width and periarticular bone erosion on radiographs. 
MR imaging of tenosynovial GCT has a highly characteristic appearance 
with low signal intensity on T1- and T2-weighted spin echo sequences and a 
“blooming effect” owing to the presence of haemosiderin; this is therefore the 
most important step in radiological evaluation of the lesion [40]. A distinction 
is easily made between localized and diffuse types of disease based on the 
dimensions and extent of the lesion. On DCE-MRI, tenosynovial GCT shows 
marked enhancement on T1-weighted images with a delayed wash-out. To 
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date, there is no evidence that DCE-MRI is helpful in differentiating tenosynovial 
GCT from other hemorrhagic joint effusions [41]. On FDG-PET, tenosynovial 
GCT shows high FDG uptake due to the high metabolic activity of osteoclast-
like giant cells [42-45]. 
In the future, both DCE-MRI and FDG-PET should be evaluated as potentially 
sensitive instruments to monitor response of tumor activity to systemic 
targeted therapy in more advanced cases of tenosynovial GCT. 
Histopathology and genetics
To date, no evident histopathological or genetic features have been identified 
that are associated with a more aggressive clinical behavior of tenosynovial 
GCT and its tendency for local recurrence, impeding the design of a 
histopathological classification. With advancing fundamental knowledge on 
tenosynovial GCT, this would need further evaluation, in order to combine 
histopathological with clinical and radiological features into a multidisciplinary 
classification of tenosynovial GCT to predict its clinical behavior based on 
individual risk profiles.
The following parameters may be related with more aggressive forms of 
tenosynovial GCT. Macroscopically, a distinction is made between localized and 
diffuse types of tenosynovial GCT, which show different clinical features and 
biological behavior, but share similar histopathological features and etiology. 
While the localized type is non-destructive and non-invasive, the diffuse type 
is locally aggressive and capable of bone resorption in the periarticular bone. 
Furthermore, Dt-GCT may recur as a secondary malignant neoplasm, but 
primary malignant tenosynovial GCT has also been reported. Malignant lesions 
show increased mitotic rates compared to benign lesions (>20 instead of >5 
mitosis per 10 high power fields) [3]. In addition, areas of necrosis, presence of 
abundant eosinophilic cytoplasm and stromal myxoid changes are also seen, 
but none of those form solitary criteria for malignancy [3].
To target tumor cells directly, more fundamental knowledge on the neoplastic 
cell component of tenosynovial GCT should be gained in the future. Genetically, 
only a small subset of tenosynovial GCT has a t(1;2) translocation which fuses 
the M-CSF gene on chromosome 1 to the collagen 6A3 (COL6A3) gene on 
chromosome 2, resulting in high levels of M-CSF expression by neoplastic 
cells [46,47]. This overexpression of M-CSF and its receptor M-CSFR promotes 




formation of a tumor mass, and forms a pathway for systemic targeted therapy 
[46]. Other pathways that are present in all patients with Dt-GCT still need to 
be identified. 
Surgical treatment 
For tenosynovial GCT, surgical treatment traditionally exists of either arthroscopic 
or open synovectomy, and differs for localized and diffuse types of disease. 
Surgical removal of localized type tenosynovial GCT is relatively easy, either 
through open excision of solitary lesions in the digits or arthroscopic or open 
partial synovectomy of intra-articular lesions in the knee. Although comparable 
recurrence rates are published for arthroscopic and open synovectomy 
confined to the lesion (6% and 4% respectively) [48-51], there is a significant 
risk of inadequate excision with arthroscopic synovectomy particularly in the 
posterior knee compartment. To minimize recurrence risk, open excision would 
be recommended in most cases of GCT-TS and arthroscopic synovectomy 
should be reserved for small and well-accessible lesions in the anterior knee 
compartment. Generally, GCT-TS is a non-invasive and non-destructive 
lesion, and recurrences may be treated with repeated surgical excision. 
Surgical removal of diffuse type tenosynovial GCT can be performed through 
arthroscopic or open complete synovectomy. As arthroscopic techniques 
have improved over the last decades and are continuously evolving, this is 
preferred by numerous knee surgeons. However, the arthroscopic endpoint, 
i.e. when the procedure is terminated, is often more dependent on maximum 
operating time than on macroscopically remaining Dt-GCT and suboptimal 
tumor removal is sometimes taken for granted. Unfortunately, oncological 
results have been disappointing due to the significant risk of incomplete 
tumor removal and high recurrence rates (~40%). Therefore, one or two-stage 
open complete synovectomy is recommended for Dt-GCT to prevent tumor 
spill, allow for complete resection and reduce risk of recurrence (~14%). There 
exists a wide variation in what is meant by open synovectomy in the literature. 
Open synovectomy may consist of only debulking or curetting macroscopically 
visible Dt-GCT, in addition it may involve dissection of the joint capsule, and 
even performing a true capsulectomy with removal of the entire synovium. This 
variation is logically directly associated with variable recurrence rates, with the 
latter leading to the best results. For extra-articular disease, attention should 
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be paid to the complete excision of all affected soft tissue. For diffuse disease 
in joints with a tight capsule such as the hip or ankle, joint destruction and 
secondary osteoarthritis may occur, which may necessitate joint arthroplasty. 
All recurrences, especially after primary arthroscopic synovectomy, would 
better be treated with open synovectomy. 
With increasing knowledge regarding efficacy of systemic therapy for Dt-GCT, 
it would be interesting to compare oncological results after arthroscopic and 
open synovectomy combined with systemic therapy; less invasive forms of 
surgery may become standard treatment. As already performed in general 
oncological surgery and as previously proposed in this thesis for the surgical 
treatment of giant cell tumor of bone, there may be a place for optical surgery 
with tumor-specific fluorescent targeting agents to facilitate complete 
resection of advanced tenosynovial GCT, especially after systemic targeted 
treatment [20,21]. 
Recurrence rate is dependent on site, volume of disease, intra- or extra-articular 
extent, type of surgery and previous surgery. Besides, with arthroscopic 
synovectomy there is always a risk of seeding the disease into the soft tissues 
around the portals. In our series, patients with more severe Dt-GCT, defined as 
involvement of both anterior and posterior knee compartments or with extra-
articular extension presented a higher risk for recurrence compared to patients 
with mild Dt-GCT, defined as a solitary pedunculated lesion (conform GCT-TS) 
or involvement of the anterior or posterior knee compartment. Furthermore, 
in our series half of the patients were referred to our center with recurrent or 
residual disease after one or multiple attempts of arthroscopic tumor removal. 
Subsequently, multiple open re-synovectomies were required with the intent 
to cure. The patients that initially underwent open synovectomy at our center 
developed fewer recurrences during follow-up. 
The most commonly reported complication after open synovectomy is joint 
stiffness (24%) [52]. This is one of the arguments in favor of arthroscopic 
synovectomy, which hypothetically results in a shorter recovery time and a 
superior function without joint stiffness. Additionally, taking into account the 
high risk for reoperation after arthroscopy and the subsequent higher risk for 
complications including infection, deep venous thrombosis and joint stiffness, 
initial open synovectomy and the accompanying chance of immediate local 
tumor control may result in fewer complications in the end. A higher failure 
rate (22-25%) is reported after complete synovectomy and joint replacement 




compared to joint replacement surgery for conventional osteoarthritis [53,54].
Regarding functional outcome, arthroscopic synovectomy may provide 
better results compared to open synovectomy. In our series, many patients 
underwent primary arthroscopy in a peripheral hospital with the intent of 
maintaining preoperative function and quality of life after surgery for Dt-GCT. 
Eventually, these patients were referred to our tertiary center with recurrent or 
residual disease after one or multiple attempts of arthroscopic tumor removal. 
Multiple open re-synovectomies were required with the intent to cure. At 
final follow-up, these patients reported worse functional outcomes and 
quality of life, compared to their counterparts that initially underwent open 
synovectomy at our center and who developed fewer recurrences and needed 
fewer reoperations during follow-up. This indicates that open synovectomy 
does not inevitably result in the hypothesized impaired function or quality of 
life compared to (repetitive) arthroscopy.
Finally, many patients with tenosynovial GCT still undergo primary surgical 
treatment in peripheral hospitals without multidisciplinary expertise in 
the field of musculoskeletal oncology, but as a severe course of disease is 
common, we recommend referral to a tertiary center. In concordance with 
recent suggestions, better care and cure would be achieved by centralization, 
especially with the advent of systemic targeted therapy [55].
Systemic targeted therapy
Patients with unresectable diffuse disease are particularly suitable for 
neoadjuvant systemic targeted therapy with imatinib or related tyrosine 
kinase inhibitors which block M-CSFR, as this could down-stage the disease 
and facilitate complete synovectomy on the long term in analogy to systemic 
therapy for giant cell tumor of bone. Imatinib has shown tumor regression 
in patients with advanced Dt-GCT in preliminary studies, and together with 
related tyrosine kinase inhibitors (e.g. nilotinib and sunitinib) it is currently 
studied in prospective randomized trials. 
Based on new findings in functional biology and genetics of tenosynovial GCT, 
new targets for systemic therapy can be identified. First, there may be a role for 
blockade of M-CSFR through other cytokines than tyrosine kinase inhibitors that 
are currently under study and that interact with the same receptor, for example 
IL-34 [56]. Second, as the formation of multinucleated giant cells in Dt-GCT 
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is RANKL-dependent, there may be a place for therapy with RANKL-inhibitor 
denosumab, conform systemic targeted therapy in giant cell tumor of bone 
[57]. However, in Dt-GCT multinucleated giant cells are often less numerous 
or even absent and it remains unsure what the effect of therapy will be. With 
the introduction of systemic therapy for Dt-GCT, treatment optimization will 
require further review and validation, including optimal agent, toxicity profile, 
mechanism of resistance, therapy duration and timing of surgery. 
Radiotherapy 
Whereas radiotherapy is restricted to exceptional cases of unresectable, residual 
or recurrent giant cell tumor of bone, it is more commonly applied in the 
multidisciplinary treatment of tenosynovial GCT. For recurrent or refractory Dt-
GCT with extra-articular extension, moderate dose external beam radiotherapy 
(30-50Gy) may be considered several weeks after surgical removal; the optimal 
dose should be investigated. Radiotherapy may kill residual tumor cells in 
case of incomplete resection and in this way it can prevent reoperation with 
its accompanying risk for complications and impaired functional outcome. 
However, if reoperation is indicated, the risk of complications is increased 
especially in the extremities. Another option for locally delivered radiotherapy 
in intra-articular Dt-GCT is instillation in radioactive colloids in the affected 
joint (i.e. synoviorthesis with 90Yttrium). Although this treatment is most often 
used as adjuvant therapy with Dt-GCT, there is little evidence to support its 
universal application and one should be critical about its use.
Methodological considerations
Published case series on surgical treatment of giant cell tumor of bone and 
tenosynovial tissue are generally small and often provide only levels III-IV 
evidence. Also, most studies are retrospective and histopathology was not 
revised with respect to recent criteria for diagnosis of bone and soft tissue 
tumors. Hence, even systematic reviews of recurrence rates, complications and 
functional outcome after surgery and adjuvant treatment for different types of 
disease provide little evidence and meta-analysis of gathered data is often not 
warranted.




Randomized controlled trials (RCT) are preferred when comparing safety 
and efficacy of different interventions, but this design may be inappropriate 
for many musculoskeletal tumors due to rareness and heterogeneity of 
disease, required long-term follow-up, ethical objections and surgical 
expertise. However, several improvements of methodological approaches 
are imaginable. First, the role for alternative research methodologies that 
approximate RCTs, including stepped wedge cluster designs, expertise-
based designs and instrumental variable analyses, all comparing treatment in 
different centers, should be further explored [58-64]. Second, a higher quality 
of non-randomized studies can be obtained by standardized data collection 
with use of (inter)national prospective databases and registries including 
technical, clinical and patient reported outcome measures (PROMs) [58,65]. 
Data from larger study populations and prolonged follow-up are required 
to that aim. In addition, studies should apply standard reporting protocols 
similar to CONSORT and STROBE requirements for randomized controlled trials 
and observational studies, respectively [66,67]. Third, with quickly advancing 
knowledge on genetics and molecular biology of musculoskeletal tumors, 
revision of histopathological diagnoses is recommended in future multicenter 
and international studies of retrospective nature. Finally, the IDEAL consortium 
proposed a five-stage model for the regulation of innovation of surgical 
techniques based on the principles of evidence-based medicine, analogous to 
the phased approach for drug development [68]. To achieve these objectives 
and to improve clinical decision making for the multidisciplinary treatment 
of giant cell tumors of bone and tenosynovial tissue, a high degree of (inter)
national cooperation is key.
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Patiënten met reusceltumoren van bot of tenosynoviaal weefsel vormen 
een uitdaging voor de orthopaedisch chirurg. De klinische uitdaging in 
de behandeling van reusceltumoren van bot is het verbreden van de 
indicatiestelling voor intralesionale excisie met inachtneming van het verkrijgen 
van optimale oncologische resultaten en het behoud van functionaliteit en 
kwaliteit van leven. Voor tenosynoviale reusceltumoren, in het bijzonder van 
het diffuus type, is de klinische uitdaging het verbeteren van oncologische 
resultaten en het behoud van een functioneel gewricht en kwaliteit van leven. 
Derhalve waren de onderzoeksdoelen van dit proefschrift het verbeteren 
van de selectie van patiënten voor verschillende chirurgische behandelingen 
door de identificatie van risicofactoren voor lokale recidieven en complicaties, 
het definiëren van indicaties voor systemische therapie en het evalueren van 
klinische en functionele uitkomstmaten na behandeling van beide typen 
reusceltumoren. 
Reusceltumoren van bot
Hoofdstuk 2 schetst een overzicht van de beeldvorming, genetica, 
histopathologie en multidisciplinaire behandeling van reusceltumoren 
van bot. Over-expressie van receptor activator of nuclear factor kappa-B 
ligand (RANKL) door mononucleaire neoplastische stromacellen bevordert 
de werving van talrijke reactieve meerkernige reuscellen. Röntgenologisch 
gezien tonen reusceltumoren typische excentriek gelegen lytische laesies. 
Computertomografie (CT) kan worden uitgevoerd om corticale verdunning, 
dreigende pathologische fracturen en dreigende gewrichtsbetrokkenheid te 
beoordelen. Magnetische-resonantietomografie (MRI) is noodzakelijk om de 
uitbreiding van de reusceltumor binnen het bot en de omliggende weke delen 
te bepalen ten behoeve van de chirurgische planning. MRI toont doorgaans een 
lage tot gemiddelde signaalintensiteit op T1-gewogen beelden en intermediaire 
tot hoge signaalintensiteit op T2-gewogen beelden. De behandeling van eerste 
keuze voor de meeste reusceltumoren is curettage met lokale adjuvantia. Bij 
curettage wordt eerst een groot ovaal venster in de cortex gemaakt welke 
voldoende blootstelling geeft van de tumorholte. Vervolgens wordt de tumor 




zorgvuldig gecuretteerd met verschillende maten curettes gevolgd door high-
speed boren van de overgebleven wanden. Lokale adjuvantia kunnen fenol, 
alcohol of vloeibare stikstof zijn. De resterende holte kan worden gevuld met 
een autoloog of allogeen bottransplantaat of polymethylmethacrylaat (PMMA) 
botcement; voordelen van de laatste zijn een hypothetisch lagere recidiefkans 
door de hyperthermische eigenschappen, directe mechanische ondersteuning 
en belastbaarheid en vroegtijdige radiografische detectie van lokale recidieven. 
Gerapporteerde recidiefkansen zijn vergelijkbaar voor de verschillende 
lokale adjuvantia (27-31%); de meeste recidieven treden op binnen twee 
jaar na de eerste operatie. Wanneer behoud van het aangrenzende gewricht 
onmogelijk is en tevens in het geval van reusceltumoren in "misbare" botten 
kan de behandeling bestaan uit en bloc resectie. Denosumab (RANKL-remmer) 
blokkeert en zoledroninezuur (bisfosfonaten) onderdrukt de botresorptie 
door osteoclast-achtige reuscellen. Na gebruik van zoledroninezuur werd 
stabilisatie van lokale en gemetastaseerde ziekte gemeld, hoewel de mate van 
bewijslast laag was. Denosumab is uitgebreider bestudeerd in prospectieve 
gerandomiseerde trials en lijkt effectief voor de lokale down-staging van de 
tumor voor chirurgische behandeling. Denosumab is recent geregistreerd door 
de US Food and Drug Administration (FDA) voor inoperabele reusceltumoren. 
De plaats van systemische therapie binnen de standaard behandeling voor 
reusceltumoren moet in de toekomst verder ondergezocht worden. Een 
middelmatige dosis radiotherapie moet voorbehouden blijven aan zeldzame 
casus van inoperabele, residuele of multipel recidiverende reusceltumoren 
waarbij chirurgische behandeling tot een onacceptabele morbiditeit zou 
leiden.
Hoofdstuk 3 vergelijkt de relatieve effectiviteit van verschillende lokale 
adjuvantia in een retrospectieve cohort studie. De studie is uitgevoerd in twee 
topreferente centra met een regionale functie die beiden een verschillende 
standaardbehandeling hanteerden. De verwijzing en daarmee het type 
behandeling was slechts afhankelijk van de geografische locatie van de 
patiënt (pseudo-randomisatie). Beide centra waren gelijk qua indicatiestelling 
voor intralesionale chirurgie en chirurgische expertise. Tussen 1990 en 2010 
ondergingen 132 patiënten met een primaire reusceltumor curettage met 
fenol en PMMA (F-PMMA; n=82), met vloeibare stikstof en PMMA (N-PMMA; 
n=26) of met vloeibare stikstof en een autologe of allogene bottransplantatie 
(N-BG; n=24). De gemiddelde follow-up duur was 8 jaar (range 2 tot 22). De drie 
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cohorten waren vergelijkbaar behoudens voor lokalisatie: bottransplantaten 
werden vaker toegepast in plaats van PMMA in niet-gewichtdragende botten 
in het centrum dat gespecialiseerd is in cryochirurgie. De recidiefkansen waren 
vergelijkbaar na curettage met F-PMMA (28%; 23/82), N-PMMA (31%; 8/26) en 
N-BG (38%; 9/24) (p=0.52). Een tweevoudig verhoogde recidiefkans werd gezien 
in geval van weke delen uitbreiding. Bij het gebruik van vloeibare stikstof moet 
men bedacht zijn op complicaties, aangezien het complicatierisico verhoogd 
was na curettage met N-BG (33%; 8/24) en N-PMMA (27%; 7/26) vergeleken 
met F-PMMA (11%; 9/82) (p=0.019). Preoperatief aanwezige pathologische 
fracturen leidden tot een viervoudig verhoogd complicatierisico. De functionele 
uitkomsten waren uitstekend en vergelijkbaar in alle drie de cohorten (p=0.52).
Ongeveer 20% van de patiënten met een reusceltumor presenteert zich 
met een pathologische fractuur, welke adequate intralesionale chirurgie kan 
bemoeilijken. Hoofdstuk 4 was een retrospectieve multicenter studie van 
48 patiënten met een pathologische fractuur, behandeld met curettage en 
lokale adjuvantia (n=23) of en bloc resectie (n=25) tussen 1981 en 2009 in 
één van de drie deelnemende topreferente centra. De gemiddelde follow-
up duur was 8.4 jaar (range 2.3 tot 24). De lokale recidiefkans was hoger 
na intralesionale chirurgie (30%; 7/23) dan na en bloc resectie (0%) en was 
vijfvoudig verhoogd in geval van weke delen uitbreiding. De complicatiekans 
was lager na intralesionale chirurgie (4%; 1/23) dan na en bloc resectie (16%; 
4/25). Fractuurgenezing na curettage trad bij op één na alle patiënten op. De 
functionele uitkomst was het beste na intralesionale chirurgie.
Ongeveer 2-5% van alle reusceltumoren bevindt zich in de kleine hand- 
en voetbeentjes. Hoofdstuk 5 bevat een systematische review van twaalf 
artikelen met in totaal 91 patiënten met een reusceltumor in de kleine hand- 
en voetbeentjes. De gemiddelde recidiefkansen in deze publicaties waren 72% 
na curettage, 13% na curettage met lokale adjuvantia, 15% na resectie en 10% 
na amputatie. Tevens is een retrospectieve multicenter studie verricht waarin 
alle 30 patiënten zijn geïncludeerd die behandeld zijn voor een reusceltumor 
in de kleine hand- of voetbeentjes tussen 1987 en 2010 in één van de vijf 
deelnemende topreferente centra. De gemiddelde follow-up duur was 7.9 
jaar (range 2 tot 26). De recidiefkansen waren 50% na curettage (3/6), 22% na 
curettage met lokale adjuvantia (4/18) en 17% na en bloc resectie (1/6; p=0.40). 
Individuele factoren geassocieerd met een hogere recidief- of complicatiekans 
konden niet worden geïdentificeerd. Betere functionele resultaten werden 




behaald na intralesionale chirurgie in vergelijking met en bloc resectie. 
Herhaalde curettage met lokale adjuvantia resulteerde uiteindelijk in de 
genezing van alle patiënten. 
Ongeveer 2-8% van alle reusceltumoren is gelokaliseerd in het sacrum. 
Hoofdstuk 6 bevat een landelijke retrospectieve studie van alle 26 patiënten 
die een chirurgische behandeling ondergingen voor een sacrale reusceltumor 
in Nederland tussen 1990 en 2010. Bij presentatie had de meerderheid van de 
patiënten enige mate van corticale destructie, uitbreiding in de weke delen 
en betrokkenheid van één of meerdere sacrale zenuwwortels. Negentien 
patiënten ondergingen preoperatieve selectieve arteriële embolisatie. Alle 
patiënten ondergingen intralesionale excisie en bij 21 patiënten werd dit 
aangevuld met lokale adjuvantia, systemische therapie of radiotherapie. Bij 
acht patiënten met uitgebreide corticale destructie en weke delen uitbreiding 
werden geen chemische adjuvantia gebruikt. Chirurgische marges werden bij 
vier patiënten uitgebreid door middel van anterieure sacrale wandresectie. 
Posterieure stabilisatie met lumbale fixatie en PMMA of bottransplantatie was 
geïndiceerd in drie patiënten, reconstructie met alleen bottransplantatie in 
zeven patiënten en met alleen PMMA in één patiënt. De minimale follow-up 
duur was twee jaar in op één na alle patiënten (gemiddelde follow-up 8.3 jaar; 
range 0.5 tot 9). Twee patiënten zijn overleden door lokale tumor progressie 
en metastasen op afstand en één vanwege een straling geïnduceerd sarcoom 
(na 6-102 maanden). De totale recidiefkans was 54% (14/26). Het recidiefrisico 
was drievoudig verhoogd in geval van weke delen uitbreiding groter dan 10 
cm. Complicaties werden gerapporteerd in 46% (12/26) van de patiënten en 
omvatten massieve bloeding, infectie, neuropraxie, materiaalbreuk, radiatie-
geïnduceerd sarcoom, radiatie-geïnduceerde menopauze, dissociatie fractuur 
van het os pubis vanwege osteopenie na radiotherapie en vertraagde 
wondgenezing. De functionele uitkomst was goed bij patiënten welke geen 
complicaties hadden. Bij acht patiënten waren alle preoperatieve symptomen 
verdwenen na de operatie. Aanhoudende pijn werd gemeld door acht 
patiënten. Neurologische symptomen waren van voorbijgaande aard bij acht 
en permanent bij vijf patiënten. De recidiefkans was het hoogst na geïsoleerde 
curettage (80%; 4/5), wat aangeeft dat enige vorm van lokale of systemische 
adjuvante behandeling noodzakelijk is voor lokale tumorcontrole.
Hoofdstuk 7 had tot doel de identificatie van individuele risicofactoren voor 
lokale recidieven in een retrospectieve studie met 93 patiënten die behandeld 
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zijn met curettage, fenol en PMMA (n=75) of alleen PMMA (n=18) tussen 
1981 en 2009 in één topreferent centrum. De gemiddelde follow-up duur 
was 8 jaar (range 2 tot 24). Vijfentwintig patiënten ontwikkelden een lokaal 
recidief (27%). Zeventien patiënten waren ziektevrij na een tweede curettage 
met lokale adjuvantia en bij acht patiënten was en bloc resectie vereist voor 
lokale tumorcontrole. We vonden een vijfvoudig verhoogde recidiefkans in 
geval van uitbreiding in de weke delen; terwijl leeftijd, geslacht, lokalisatie 
en de aanwezigheid van een pathologische fractuur de recidiefkans niet 
beïnvloedden.
Hoofdstuk 8 was een radiologische studie naar de prevalentie en impact van 
radiologische gonartrose (Kellgren en Lawrence graad 3-4) bij 53 patiënten 
die curettage met PMMA ondergingen voor een reusceltumor rondom het 
kniegewricht tussen 1987 en 2010 in één topreferent centrum. De gemiddelde 
follow-up duur was 7 jaar (range 5 tot 24). Radiologische gonartrose werd 
gezien in 17% van de patiënten na een mediane follow-up van 57 maanden 
na curettage met PMMA. Geen van deze patiënten was ten tijde van laatste 
follow-up chirurgisch behandeld voor klinische gonartrose. Een negenvoudig 
verhoogd risico op radiologische gonartrose werd gevonden wanneer meer 
dan 70% van het subchondrale bot aangetast was door de reusceltumor 
en een viervoudig verhoogd risico voor een afstand van minder dan 3 mm 
tussen de reusceltumor en het gewrichtskraakbeen. De functionele uitkomst 
en kwaliteit van leven waren vergelijkbaar voor patiënten met Kellgren en 
Lawrence graad 3-4 en graad 0-2, hetgeen impliceert dat de klinische impact 
van radiologische gonartrose op middellange termijn bescheiden is. Dit kan 
echter nog toenemen met de tijd en langdurige follow-up is dan ook vereist.
Reusceltumoren van tenosynoviaal weefsel
Hoofdstuk 9 schetst een overzicht van de beeldvorming, genetica, 
histopathologie en multidisciplinaire behandeling van het lokaal en diffuus 
type tenosynoviale reusceltumoren. Over-expressie van macrophage 
colony-stimulating factor 1 (M-CSF) en zijn receptor (M-CSFR) door synoviale 
fibroblasten bevordert de formatie van een tumormassa. Op MRI veroorzaken 
hemosiderine deposities de lokale veranderingen in signaalopname 
waardoor men de karakteristieke lage signaalintensiteit van tenosynoviale 




reusceltumoren krijgt op T1- en T2-gewogen spin echo of gradiënt echo 
sequenties. Hoewel arthroscopische synovectomie vaak als alternatief voor 
open synovectomie verdedigd wordt is er een aanzienlijk risico op onvolledige 
excisie en lokaal recidief, in het bijzonder in het achterste compartiment van de 
knie. Bovendien bestaat het risico van enten van de tumor rond de artroscopie 
portals. Voor het lokaal type tenosynoviale reusceltumoren en voor minimale 
ziekte in het anterieure knie compartiment kan arthroscopische verwijdering 
afdoende zijn. Voor primaire en recidiverende grote diffuus type tenosynoviale 
reusceltumoren is open synovectomie de aangewezen behandeling. 
Gecombineerde of gefaseerde operaties kunnen worden overwogen. Voor 
tumoren in het posterieure knie compartiment wordt een lazy-S incisie 
gemaakt met elevatie van de origo van de musculus gastrocnemius waardoor 
neurovasculaire structuren beschermd blijven. Dit wordt gevolgd door een 
artrotomie om de achterste kruisband en gewrichtsoppervlakte goed in zicht 
te krijgen en een volledige capsulotomie uit te kunnen voeren. Voor tumoren 
in het anterieure knie compartiment is een mediale parapatellaire artrotomie 
geadviseerd, omdat deze zorg draagt voor een goede visualisatie van de 
synoviale holte, het vetlichaam van Hoffa, de kruisbanden en de collaterale 
ligamenten. Resttumor grenzend aan de gewrichtsspleet kan ook veilig worden 
gereseceerd. In geval van recidiverende en extra-articulair uitbreidende 
tumoren kunnen matige doses radiotherapie of systemische therapie worden 
overwogen. Hoewel er momenteel slechts weinig bewijs is voor de effectiviteit 
van neoadjuvante M-CSFR-gerichte tyrosine kinase remmers (imatinib) voor de 
behandeling van diffuus type tenosynoviale reusceltumoren, kan systemische 
therapie in de toekomst in de behandelstrategie voor uitgebreidere ziekte 
opgenomen worden, in analogie met systemische behandeling voor ossale 
reusceltumoren.
Hoofdstuk 10 is een systematische review van 59 artikelen met in totaal 313 
patiënten met lokaal type en 777 patiënten met diffuus type tenosynoviale 
reusceltumoren. De methodologische kwaliteit (Newcastle-Ottawa Scale voor 
kwaliteitsbeoordeling van cohortstudies) was hoog in 40%, middelmatig 
in 50% en laag in 10% van de geïncludeerde studies. De gerapporteerde 
recidiefkans was 4% na open en 6% na arthroscopische synovectomie van 
lokaal type en 14% na open en 40% na arthroscopische synovectomie van 
diffuus type tenosynoviale reusceltumoren in de knie. Na instillatie van intra-
articulaire radioactieve colloïden was de recidiefkans 15% na open en 22% na 
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arthroscopische synovectomie van intra-articulaire diffuus type tenosynoviale 
reusceltumoren in de knie en heup. Na adjuvante radiotherapie was de 
recidiefkans 12% na open en 13% na arthroscopische synovectomie van extra-
articulaire diffuus type tenosynoviale reusceltumoren. Open synovectomie en 
excisie van extra-articulaire uitbreiding verdient aanbeveling om de relatief 
hoge recidiefkans te minimaliseren.
Hoofdstuk 11 is een retrospectieve studie over de invloed van ziekte-ernst 
en het type operatie op de functionele resultaten en kwaliteit van leven bij 
30 patiënten welke behandeld zijn voor tenosynoviale reusceltumoren in de 
knie tussen 1980 en 2011. Vijftien patiënten werden primair behandeld in 
één topreferent centrum; vijftien andere patiënten werden naar dit centrum 
verwezen voor de behandeling van een lokaal recidief. Ziekte-ernst werd 
vastgesteld aan de hand van preoperatieve MRI beelden of verslagen. Zestien 
patiënten (53%) hadden een milde vorm, gedefinieerd als een solitair gesteelde 
laesie of diffuse betrokkenheid van het voorste of achterste compartiment van 
de knie. Veertien patiënten (47%) hadden een uitgebreidere vorm, gedefinieerd 
als betrokkenheid van zowel het voorste als het achterste compartiment van de 
knie of extra-articulaire uitbreiding. Patiënten met aanvankelijk uitgebreidere 
ziekte hadden vaak al meerdere synovectomieën ondergaan, waaronder in de 
meeste gevallen primaire arthroscopische synovectomie, alvorens verwezen 
te worden. Allen ondergingen als laatste behandeling open synovectomie. Na 
een gemiddelde follow-up duur van 8 jaar (range 2 tot 23) rapporteerden deze 
patiënten significant slechtere functionele en kwaliteit van leven uitkomsten. 
In deze studie leidde primaire open synovectomie an sich niet tot een 
verminderde functie of kwaliteit van leven in vergelijking met herhaaldelijke 
arthroscopische synovectomie.
Conclusies, klinische implicaties en toekomstperspectieven voor de 
behandeling van reusceltumoren van bot en tenosynoviaal weefsel worden 
besproken in Hoofdstuk 13.
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Les patients atteints de tumeurs à cellules géantes osseuses ou ténosynoviales 
posent des problèmes difficiles pour le traitement chirurgical. Pour les tumeurs 
osseuses à cellules géantes, le défi clinique est d´étendre les indications pour 
la résection intralésionnelle, tout en fournissant des résultats oncologiques, 
fonctionnels et de qualité de vie optimaux. Pour les tumeurs ténosynoviales 
à cellules géantes, en particulier celles du type diffus, le défi clinique est 
d´améliorer les résultats oncologiques et de maintenir une articulation 
fonctionnelle et la qualité de vie. Par conséquent, les objectifs de cette thèse de 
doctorat étaient d´améliorer la sélection des patients pour les différents types 
de chirurgie en identifiant les facteurs de risque de récidives et de complications, 
de définir les indications pour la thérapie systémique et d´évaluer les résultats 
cliniques après le traitement chirurgical de l´un des deux types de tumeurs à 
cellules géantes en fournissant une analyse de décision clinique.
Les Tumeurs à cellules géantes osseuses
Le Chapitre 2 donne un aperçu de l´imagerie, de la génétique, de 
l´histopathologie et du traitement multidisciplinaire des tumeurs osseuses 
à cellules géantes. La surexpression de l´activateur du récepteur du facteur 
nucléaire kappa-B ligand (RANKL) par les cellules stromales néoplasiques 
mononucléaires favorise le recrutement de nombreuses cellules géantes 
multi-nucléées réactives. Radiologiquement, les tumeurs osseuses à cellules 
géantes montrent des lésions typiquement lytiques et excentriques. La 
tomodensitométrie peut être effectuée pour évaluer l´amincissement cortical, 
les fractures pathologiques et l´implication attente de l´articulation adjacente. 
L´imagerie par résonance magnétique (IRM) est nécessaire pour évaluer 
l´étendue des tumeurs à cellules géantes dans l´os et dans les tissus mous pour 
la planification chirurgicale. L´IRM montre généralement une faible à moyenne 
intensité sur les pondérations T1 et une intermédiaire à haute intensité sur les 
pondérations T2. Le traitement de choix pour la majorité des tumeurs à cellules 
géantes osseuses est le curetage intralésionnel avec des adjuvants locaux. 
Une grande fenêtre ovale est faite dans le cortex, en créant une exposition 
suffisante de la cavité tumorale. La tumeur est ensuite soigneusement curetée 




avec de différentes tailles de curettes, suivi par l´ébavurage à haute vitesse 
des parois de la cavité. Les adjuvants locaux peuvent être le phénol, l´alcool 
ou l´azote liquide. La cavité restante peut être remplie soit avec des greffes 
osseuses ou avec du polyméthacrylate de méthyle (PMMA). Les avantages 
du PMMA sont le risque de récidive hypothétiquement inférieur à travers des 
propriétés hyperthermiques, le support mécanique immédiate et la détection 
des récidives locales précoce.  Les taux de récidive rapportés sont comparables 
pour les différents adjuvants locaux (27-31%)  ; la plupart des récidives 
surviennent dans les deux ans après la chirurgie initiale. La résection peut être 
effectuée lorsque le sauvetage de l´articulation adjacente n´est pas possible 
et dans les os extensibles. Le dénosumab (RANKL-inhibiteur) bloque et l´acide 
zolédronique (un bisphosphonate) inhibe la résorption des ostéoclastes dérivés 
des tumeurs à cellules géantes. Avec de l´acide zolédronique, la stabilisation de 
la maladie locale et métastatique a été signalé, bien que le niveau de preuve 
ait faible. Le denosumab a été étudié dans une plus large mesure et semble 
être efficace dans le «  down-staging  » de cette maladie avant le traitement 
chirurgicale. Le denosumab a récemment été homologué par la US Food and 
Drug Administration (FDA) pour les tumeurs à cellules géantes non résécables. 
Par conséquent, le rôle de la thérapie systémique dans le traitement standard 
des tumeurs à cellules géantes doit être davantage exploré. La radiothérapie à 
dose modérée devrait être limitée à des rares cas des tumeurs à cellules géantes 
non résécables, récidivantes, résiduelles ou lorsque la chirurgie conduirait à 
une morbidité inacceptable.
Le Chapitre 3 a comparé l´efficacité relative de plusieurs adjuvants locaux dans 
une étude de cohorte rétrospective dans deux centres de référence tertiaires 
qui appliquent des traitements standards différents. L´affectation du traitement 
dépendait uniquement du centre de référence où les patients avaient été 
admis, les deux centres avaient des indications similaires pour la chirurgie 
intralésionnelle et l´expertise chirurgicale était comparable (c´est-à-dire une 
étude pseudo-randomisée). Ainsi, 132 patients atteints d´une tumeur à cellules 
géantes ayant subi un curetage soit avec du phénol et PMMA (P-PMMA ; n=82), 
de l´azote liquide et PMMA (AL-PMMA ; n=26) ou de l´azote liquide et des greffes 
osseuses (AL-GO ; n=24) entre 1990 et 2010 ont été analysés. Le suivi moyen 
était de 8 ans (allant de 2 à 22 ans). Les trois cohortes étaient comparables, 
sauf pour la localisation tumorale  : les greffes osseuses ont été appliquées 
plus couramment au lieu de PMMA dans les os non porteurs dans le centre 
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spécialisé dans la cryochirurgie. Les taux de récidive étaient comparables pour 
P-PMMA (28% ; 23/82), AL-PMMA (31% ; 8/26) et AL-GO (38% ; 9/24 ; p=0,52). Le 
risque de récidive a été augmenté deux fois par la présence d´extension dans 
les tissus mous. À l´égard de l´usage de l´azote liquide, il faut se méfier des 
complications, comme cela a été le cas après AL-GO (33% ; 8/24) et AL-PMMA 
(27% ; 7/26) par rapport à P-PMMA (11% ; 9/82 ; p=0,019). En outre, le risque 
de complication a été augmenté quatre fois par les fractures pathologiques. 
Le résultat fonctionnel était excellent et comparable dans les trois cohortes 
(p=0,52).
Environ 20% des patients atteints de tumeurs à cellules géantes osseuses 
présente avec une fracture pathologique, ce qui peut gêner la chirurgie 
intralésionnelle. Le Chapitre 4 comportait une analyse rétrospective 
multicentrique de 48 patients ayant subi une fracture pathologique, traité 
avec curetage intralésionnel avec adjuvants locaux (n=23) ou résection en bloc 
(n=25) entre 1981 et 2009 dans l´un des trois centres de référence tertiaires. 
Le suivi moyen était de 8,4 ans (allant de 2,3 à 24 ans). Les taux de récidive 
étaient plus élevés après chirurgie intralésionnelle (30% ; 7/23) par rapport à 
la résection en bloc (0%) et a été cinq fois plus élevé en cas d´extension dans 
les tissus mous. Moins de complications ont été rapportées après la chirurgie 
intralésionnelle (4% ; 1/23) par rapport à la résection en bloc (16% ; 4/25). La 
guérison des fractures après le curetage a eu lieu dans tous sauf un patient. Le 
résultat fonctionnel était supérieur après la chirurgie intralésionnelle.
Environ 2-5% des tumeurs à cellules géantes se produisent dans les petits os des 
mains et des pieds. Le Chapitre 5 décrit une revue systématique de la littérature 
avec douze articles comprenant un total de 91 patients avec tumeurs à cellules 
géantes des petits os. Les taux de récidive publiés étaient de 72% après le 
curetage, 13% après le curetage avec adjuvants locaux, 15% après la résection 
en bloc et 10% après l´amputation. Deuxièmement, une analyse rétrospective 
multicentrique a été réalisée sur l´ensemble des 30 patients traités pour les 
tumeurs à cellules géantes des petits os entre 1987 et 2010 dans l´un des cinq 
centres de référence tertiaires. Le suivi moyen était de 7,9 ans (allant de 2 à 26 
ans). Les taux de récidive étaient de 50% après curetage seul (3/6), 22% après 
curetage avec adjuvants locaux (4/18) et 17% après résection en bloc (1/6  ; 
p=0,40). Nous n´avons pas pu identifier des facteurs individuels associés aux 
risques plus élevés de récidive ou de complication. Le résultat fonctionnel était 
supérieur après la chirurgie intralésionnelle par rapport à la résection en bloc. 




Le curetage avec adjuvants locaux répété a finalement abouti à la guérison de 
tous les patients.
Environ 2-8% des tumeurs à cellules géantes étaient localisées dans le sacrum. Le 
Chapitre 6 contient une évaluation rétrospective nationale de l´ensemble des 
26 patients traités chirurgicalement pour une tumeur à cellules géantes dans 
le sacrum entre 1990 et 2010 aux Pays-Bas. La majorité des patients avait une 
destruction corticale, une extension dans les tissus mous et avaient un rapport 
étroit avec les racines nerveuses lors de leur présentation.  L´embolisation 
artérielle sélective a été réalisée dans dix-neuf patients avant le traitement 
chirurgical. Tous les patients ont subi une résection intralésionnelle, dont 
21 avec des adjuvants locaux différents, un traitement systémique ou de  la 
radiothérapie adjuvante. Chez huit patients ayant une vaste destruction 
corticale et masses des tissus mous, pas d´adjuvants chimiques ont été utilisés. 
Les marges chirurgicales ont été étendues en quatre patients par excision de la 
paroi antérieure du sacrum. La stabilisation postérieure avec fixation lombaire 
avec du PMMA ou des greffes osseuses a été indiquée chez trois patients, la 
reconstruction avec des greffes osseuses chez sept patients et avec du PMMA 
en un patient. Tous, sauf un patient avait un suivi minimum de deux ans 
(moyenne 8,3 ans ; allant de 0,5 à 19 ans). Deux patients sont décédés à cause de 
la progression tumorale et des métastases et un patient à cause d´un sarcome 
radio-induit. Le taux de récidive était de 54% (14/26). Le risque de récidive a 
été augmenté trois fois en cas d´extension dans les tissus mous de plus de 
10 cm. Des complications ont été rapportées chez 46% (12/26) des patients 
et comprenaient des hémorragies massives, des infections, des neuropraxies, 
l´échec de l´instrumentation, un sarcome radio-induit, une ménopause radio-
induite, une fracture de dissociation de l´os pubien en raison de l´ostéopénie 
après la radiothérapie et de la cicatrisation retardée. Les résultats fonctionnels 
étaient bons chez les patients sans complications. Chez huit patients, tous 
les symptômes préopératoires ont disparu après la chirurgie. De la douleur 
persistante a été rapportée par huit patients. Les symptômes neurologiques 
ont été transitoires chez huit patients et permanents chez cinq patients. Le 
taux de récidive était plus élevé après curetage sans aucun adjuvant local ou 
systémique (80% ; 4/5), ce qui indique que le traitement adjuvant est nécessaire 
pour obtenir le contrôle local de la tumeur.
Le Chapitre 7 vise à analyser rétrospectivement les facteurs de risque de 
récidive individuels chez 93 patients traités par curetage, phénol et PMMA 
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(n=75) ou curetage avec PMMA (n=18) entre 1981 et 2009 dans un centre de 
référence tertiaire. Le suivi moyen était de 8 ans (allant de 2 à 24 ans). Vingt-cinq 
patients ont développé une récidive (27%). Dix-sept patients étaient indemnes 
de la tumeur après le deuxième curetage avec des adjuvants locaux et chez 
huit patients une résection en bloc a été nécessaire pour obtenir la guérison. 
Nous avons trouvé un risque de récidive cinq fois plus élevé en cas d´extension 
dans les tissus mous, tandis que l´âge, le sexe, la localisation et une fracture 
pathologique associée n´augmentaient pas le risque de récidive.
Le Chapitre 8 rapporte une étude radiologique sur la prévalence et l´impact 
clinique de l´arthrose radiologique (Kellgren et Lawrence grades 3-4) chez 
53 patients qui ont subi un curettage avec PMMA pour une tumeur à cellules 
géantes au niveau du  genou entre 1987 et 2007 dans un centre de référence 
tertiaire. Le suivi moyen était de 7 ans (allant de 5 à 24 ans). L´arthrose 
radiologique a été trouvé chez 17% des patients après un délai médian de 
57 mois après curettage avec PMMA. Aucun des patients n´a été opéré d´une 
arthrose au dernier suivi. Le risque de développer une arthrose du genou 
était neuf fois plus élevé lorsque l´os sous chondral était envahi et quatre fois 
plus élevé pour les tumeurs à cellules géantes en position sous chondrale. Les 
résultats fonctionnels et de qualité de vie étaient comparables pour les patients 
de grades 3-4  et 0-2 de Kellgren et Lawrence, suggérant un impact clinique 
modeste de l´arthrose radiologique avec un recul intermédiaire. Toutefois, cela 
peut augmenter avec le temps et un suivi prolongé est nécessaire.
Les Tumeurs à cellules géantes ténosynoviales
Le Chapitre 9 décrit un aperçu de l´imagerie, de  la génétique, de 
l´histopathologie et du traitement multidisciplinaire des types localisés et des 
types diffus de tumeurs ténosynoviales à cellules géantes. La surexpression du 
macrophage colony-stimulating facteur 1 (M-CSF) et de son récepteur (M-CSFR) 
par des fibroblastes synoviaux favorise la formation d´une masse tumorale. 
Sur l´imagerie par résonance magnétique (IRM), les dépôts d´hémosidérine 
provoquent des changements locaux de l´intensité du signal, ce qui entraîne 
l´apparition du signal de faible intensité caractéristique des tumeurs 
ténosynoviales à cellules géantes sur les pondérations T1 et T2 en séquences 
écho de spin et écho de gradient. Bien que  la synovectomie arthroscopique 




ait été préconisée comme une alternative à la synovectomie à ciel ouvert,  il y 
a des risques de récidive et de résection insuffisante importants, en particulier 
dans le compartiment postérieur du genou. En outre, il existe un risque de 
semer la maladie dans les tissus mous autour des portails arthroscopique. 
Pour le type localisé et pour le type diffus limité au compartiment antérieur du 
genou, la synovectomie arthroscopique peut être suffisante. Pout le type diffus 
initial et récidivant, la synovectomie à ciel ouvert est conseillée. La chirurgie 
combinée ou en deux étapes peut être envisagée. Pour la maladie postérieure, 
une incision «  lazy-S  » est réalisée avec l´élévation de l´origine du muscle 
gastrocnémien permettant la protection des structures neurovasculaires. Il 
est suivi par l´arthrotomie pour visualiser le ligament croisé postérieur et les 
surfaces articulaires et pour faire une capsulotomie complète pour réaliser 
une synovectomie adéquate. Pour la maladie antérieure, une approche 
antérieure médiane est conseillée, car cela permet une bonne visualisation 
de la cavité synoviale, du coussinet adipeux de Hoffa et des ligaments croisés 
et collatéraux. De la tumeur résiduelle adjacente à l´interligne articulaire et à 
gouttières unilatérales peut également être réséquée en toute sécurité. Pour 
les récidives et pour l´extension extra-articulaire, la radiothérapie à dose 
modérée ou la thérapie systémique devraient également être considérées. Bien 
qu´il existe encore peu de preuves scientifiques sur l´efficacité des inhibiteurs 
de la tyrosine kinase M-CSFR (par exemple l´imatinib) pour le traitement des 
tumeurs à cellules géantes ténosynoviales, il pourrait à l´avenir être intégré 
dans la stratégie de traitement pour une maladie plus étendue, par analogie 
avec le traitement systémique pour les tumeurs à cellules géantes des os.
Le Chapitre 10 présente une revue systématique de la littérature sur les 
tumeurs ténosynoviales à cellules géantes avec 59 articles comprenant un 
total de 313 patients avec le type localisé et 777 patients avec le type diffus. La 
qualité méthodologique (Newcastle-Ottawa échelle d´évaluation de la qualité 
des études de cohortes) était bonne dans 40%, intermédiaire dans 50% et 
médiocre dans 10% des articles inclus. Les taux de récidive rapportés étaient de 
4% après synovectomie à ciel ouvert et 3% après synovectomie arthroscopique 
pour le type localisé dans le genou et de 14% après synovectomie à ciel ouvert 
et 40% après synovectomie arthroscopique pour le type diffus dans le genou. 
Avec l´utilisation de colloïdes radioactifs intra-articulaires (synoviorthèses) les 
taux de récidive étaient de 15% après synovectomie à ciel ouvert et de 22% 
après synovectomie arthroscopique pour le type diffus au genou et à la hanche. 
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Avec la radiothérapie adjuvante, les taux de récidive étaient de 12% après 
synovectomie à ciel ouvert et de 13% après synovectomie arthroscopique 
pour le type diffus avec extension extra-articulaire du genou. En général, 
la synovectomie à ciel ouvert ainsi que l´excision des tissus tumoraux extra-
articulaires sont recommandées pour réduire le risque de récidive relativement 
élevé.
Le Chapitre 11 a évalué de manière rétrospective l´influence de la mesure des 
tumeurs et du type de chirurgie sur les résultats fonctionnels et de qualité de 
vie chez 30 patients traités pour une tumeur ténosynoviale à cellules géantes 
du genou entre 1980 et 2011. Quinze patients ont été principalement traités 
dans notre centre de référence tertiaire et 15 patients ont été renvoyés dans 
notre centre pour le traitement d´une récidive. La mesure des tumeurs a été 
évaluée sur l´IRM préopératoire ou sur les rapports d´imagerie. Seize patients 
(53%) avaient une tumeur moins étendue, définie comme une lésion pédiculée 
solitaire ou l´atteinte diffuse du compartiment antérieur ou postérieur de 
genou. Quatorze patients (47%) avaient une tumeur plus étendue, définie 
comme l´atteinte des compartiments antérieurs et postérieurs du genou ou en 
cas d´extension extra-articulaire. Les patients ayant initialement une tumeur 
plus étendue ont souvent subi de multiples interventions chirurgicales, y 
compris une synovectomie arthroscopique initiale et une synovectomie à ciel 
ouvert pour la dernière récidive. Après un suivi moyen de 8 ans (allant de 2 à 
33 ans), ces patients ont rapporté des résultats fonctionnels et de qualité de vie 
nettement inférieurs. Dans cette étude, la synovectomie à ciel ouvert comme 
intervention de première intention n´a pas entraîné de déficits fonctionnels 
ou une diminution de la qualité de vie par rapport à la synovectomie 
arthroscopique.
Les conclusions, les implications cliniques et les perspectives d’avenir pour les 
sujets de cette thèse de doctorat sont discutés dans le Chapitre 13.
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